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ABSTRACT OF DISSERTATION
DISCOVERY OF GZ-793A, A NOVEL VMAT2 INHIBITOR AND POTENTIAL
PHARMACOTHERAPY FOR METHAMPHETAMINE ABUSE

Methamphetamine abuse is a serious public health concern affecting
millions of people worldwide, and there are currently no viable
pharmacotherapies to treat methamphetamine abuse. Methamphetamine
increases extracellular dopamine (DA) concentrations through an interaction with
the DA transporter (DAT) and the vesicular monoamine transporter-2 (VMAT2),
leading to reward and abuse. While numerous studies have focused on DAT as
a target for the discovery of pharmacotherapies to treat psychostimulant abuse,
these efforts have been met with limited success. Taking into account the fact
that methamphetamine interacts with VMAT2 to increase DA extracellular
concentrations; the focus of the current work was to develop novel compounds
that interact with VMAT2 to inhibit the effects of methamphetamine. Lobeline,
the principal alkaloid found in Lobelia inflata, inhibits VMAT2 binding and
function. Inhibition of VMAT2 was hypothesized to be responsible for the
observed lobeline-induced inhibition of methamphetamine-evoked DA release in
striatal slices and decrease in methamphetamine self-administration in rats.
Lobeline has recently completed Phase Ib clinical trials demonstrating safety in
methamphetamine abusers. Lobeline is also a potent inhibitor of nicotinic
acetylcholine receptors (nAChRs), limiting selectivity for VMAT2. Chemical
defunctionalization of the lobeline molecule afforded analogs, meso-transdiene
(MTD) and lobelane, which exhibited decreased affinity for nAChRs. MTD, an

unsaturated analog of lobeline, exhibited similar affinity for VMAT2 and increased
affinity for DAT compared to lobeline. Conformationally-restricted MTD analogs
exhibited decreased affinity for DAT compared to MTD, while retaining affinity at
VMAT2. One analog, UKMH-106 exhibited high affinity and selectivity for
VMAT2 and inhibited METH-evoked DA release from striatal slices.
Unfortunately, the MTD analogs exhibited poor water solubility which limited
further investigation of these promising analogs. Importantly lobelane, a
saturated analog of lobeline, exhibited increased affinity and selectivity for
VMAT2 compared to lobeline. To improve water solubility, a N-1,2dihydroxypropyl (diol) moiety was incorporated into the lobelane molecule. GZ793A, an N-1,2-diol analog, potently and competitively inhibited VMAT2 function,
exhibiting over 50-fold selectivity for VMAT2 over DAT, serotonin transporters
and nAChRs. GZ-793A released DA from preloaded synaptic vesicles, fitting a
two-site model with the high-affinity site inhibited by tetrabenazine and reserpine
(classical VMAT2 inhibitors), suggesting a VMAT2-mediated mechanism of
release. Further, low concentrations of GZ-793A that selectively interact with
high-affinity sites on VMAT2 to evoke DA release, inhibit methamphetamineevoked DA release from synaptic vesicles. Results showed that increasing
concentrations of GZ-793A produced a rightward shift in the METH concentration
response; however, the Schild regression revealed a slope different from unity,
consistent with surmountable allosteric inhibition. In addition, GZ-793A
specifically inhibited methamphetamine-evoked DA release in striatal slices and
methamphetamine self-administration in rats. To examine the possibility that GZ-

793A produced DA depletion, the effect of a behaviorally active dose of GZ-793A
on DA content in striatal tissue and striatal vesicles was determined. GZ-793A
administration did not alter DA content in striatal tissue or vesicles and
pretreatment with GZ-793A prior to methamphetamine administration did not
exacerbate the DA depleting effects of methamphetamine. Importantly, GZ-793A
was shown to protect against methamphetamine-induced striatal DA depletions.
Thus, GZ-793A represents an exciting new lead in the development of
pharmacotherapies to treat methamphetamine abuse.
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Drug Discovery, GZ-793A
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CHAPTER ONE

Introduction
I. Methamphetamine Background

Methamphetamine (METH; N-methyl-1-phenylpropan-2-amine; Fig.1) is a
highly addictive psychostimulant and N-methyl derivative of amphetamine
(AMPH; Fig 1). Structurally METH is characterized by a phenyl ring connected to
a secondary amine by an ethyl side chain with a methyl group on the α-carbon.
METH exists in two stereoisomers with the S(+)-enantiomer being more
biologically active than the D(+)-enantiomer (Cruickshank and Dyer, 2009).

METH was first synthesized from ephedrine in 1893 by Japanese chemist,
Nagai Nagayoshi (Anglin et al., 2000). In 1919, Akira Ogata first synthesized the
crystalline form through a reduction of ephedrine with red phosphorus and iodine
(Anglin et al., 2000). METH use became widespread beginning with soldiers in
World War II for its ability to increase energy, alertness, and appetite suppression
(Gonzales et al., 2009). In the years following World War II, METH and related
stimulant use increased in young adults, particularly students and blue collar
workers for the performance-enhancing benefit (Anglin et al., 2000). The U.S.
Food and Drug Administration approved METH under the trade name “desoxyn”
in 1944 for the treatment of narcolepsy, depression, alcoholism and hay fever
(Berman, et al., 2009; Steinkellner et al., 2011). METH and related stimulants
were available over-the-counter until the late 1950’s, significantly contributing to
its use and abuse (Anglin et al., 2000). The use of prescribed METH increased
1

rapidly, reaching a peak with over 31 million prescriptions in 1967 (Anglin et al.
2000). The medicinal uses of METH were more tightly regulated with the
passage of the Comprehensive Drug Abuse Prevention and Control Act of 1970,
which limited the indications for which METH can be prescribed (Gonzales et al.,
2009). The U.S. government classifies METH as a schedule II controlled
substance with strict regulations governing its use. METH is recognized as a
highly addictive substance which is only available through a prescription that
cannot be refilled. Currently METH is only approved for clinical use in the
treatment of attention-deficit hyperactivity disorder (ADHD), nacrolepsy and
obesity (Sulzer et al., 2005).

As a result of the restricted prescribed use and production of METH, illicit
METH production began in the early 1960’s in clandestine laboratories in the
Western U.S. (Anglin et al., 2000). In the 1970’s and 1980’s, METH use
continued to grow with increased popularity amongst motorcycle gangs with an
influx of crystallized METH (“ice”) into Hawaii and California from Southeast Asia
(Gonzales et al., 2009). METH was easily synthesized with common household
products and precursors found in over-the-counter cold and allergy medicine
(Derlet and Heischober, 1990; Barr et al., 2006). Due to the relative ease of
production of METH and the availability of METH precursors, illicit production
increased rapidly in the 1990’s. Both small clandestine labs and larger “super
labs” began to arise in locations across the U.S., Mexico and Canada (Barr et al.,
2006). In 2000, the U.S. Federal Drug Enforcement Agency seized over 6,300
illegal METH labs in the U.S. and the number of lab seizures increased 25%
2

between 2001 to 2005, with the peak number of reported METH lab seizures
occurring in 2004 (Sulzer et al., 2005; United Nations Office on Drugs and Crime,
2007). Not surprisingly, METH is the most commonly synthesized illegal drug in
the U.S., with an estimated world-wide synthesis of over 2.9 billion doses of
METH (100 mg) in 2005 (United Nations Office on Drugs and Crime, 2007).
More recent figures show that the number of METH lab seizures increased 26%
from 2008 to 2009 (United Nations Office on Drugs and Crime, 2011).

As a result of the rise in METH production, the U.S. government passed
numerous laws and regulations, such as the Combat Methamphetamine
Epidemic Act in 2005. This act limited the consumer availability of precursors
such as pseudoephedrine, which are used in the illicit production of METH
(Gonzales et al., 2009). Despite these efforts to control and limit supplies
needed for METH production, METH use continues to rise in the U.S.. While
METH use was traditionally popular among blue collar adult males, METH abuse
has increased in popularity among women, students and young professionals
(Gettig et al., 2006). Further, METH use has increased in homosexual and
bisexual males, as METH is known to increase sexual performance (Gettig et al.,
2006). METH use is often involved with risky sexual behavior and is highly
prevalent in people with human immunodeficiency virus (HIV; Yamamoto et al.,
2010). Thus, a significant health risk persists in these individuals. According to
a 2008 Drug and Alcohol Services Information System report, AMPHs were the
primary cause of over 170,000 substance abuse emergency room admissions,
with over 80% of these cases involving METH (DASIS, 2008). In 2009, the
3

number of people illicitly using METH in the past month increased 59%
compared to 2008 (NSDUH, 2009).

Currently, METH is the second most abused illicit drug in the world, after
marijuana, with an estimated global usage at 15-16 million users (Krasnova and
Cadet, 2009; Cruickshank and Dyer, 2009). Over half of the world’s METH use
occurs in Asia, while use is increasing in other regions of the world such as Africa
and South America (United Nations Office on Drugs and Crime, 2011). Thus,
METH abuse represents a world-wide health concern.

II. Clinical Pharmacology of METH

METH is a highly addictive psychostimulant with deleterious health risks
associated with its use. METH is commonly referred to as “meth”, “glass”, “go”,
“speed”, “crystal”, or “ice”, and is available in many different forms including
tablet, powder, free base, and crystallized form (Derlet and Heischober, 1990;
Anglin et al, 2000). METH can be taken orally, smoked, snorted (insufflation) or
injected to obtain its stimulatory and euphoric effects (Karila et al., 2010). The
onset of the effects of METH is dependent on the method of administration. The
effects of METH are almost immediate following intravenous injection or
smoking, while effects are seen within 5 and 20 minutes following snorting or oral
ingestion, respectively (Anglin et al., 2000).

4

METH acts as a central nervous system (CNS) stimulant, producing
increased alertness, energy, self-esteem, respiration, hyperthermia, sexuality
and euphoria, as well as decreased appetite (Derlet and Heischober, 1990;
Gonzales et al., 2009). While METH elicits similar effects to that of cocaine, the
half-life of METH is much longer than other stimulants with a range from 8 to 12
hours (Gonzales et al., 2009; Karila et al., 2010).

Acute physical side effects of METH include increased blood pressure,
tachycardia and hyperthermia, while psychological effects include increased
agitation, aggression, anxiety, insomnia, hallucinations and paranoia (Barr et al.,
2006; Cruickshank and Dyer, 2009). Consumption of high doses of METH can
lead to renal and liver failure, cardiac arrhythmias, heart attacks, strokes,
psychosis, delirium, seizures and death (Krasnova and Cadet, 2009). Chronic
METH use leads to serious health risks from impaired cardiovascular function,
e.g., hypertension, coronary heart disease, stroke and sudden cardiac death
(Hanson, 2002; McGee et al., 2004; Kaye et al., 2007). In addition to these
cardiovascular events, chronic use of METH has been associated with
neurological symptoms such as anxiety, depression, social isolation, and
reductions in attention, memory and cognition (Simon et al., 2000; Sekine et al.,
2001; Freese et al., 2002; Salo et al., 2007; Darke et al., 2008; Krasnova and
Cadet, 2009). Disruption of METH use in those abusing the drug repeatedly
leads to METH- related withdrawal symptoms such as depression, anxiety,
disturbed sleep, reduced energy, hyperphagia, and increased METH craving
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(Gossop et al., 1982; Srisurapanont et al., 1999; Zweben et al., 2004; Homer et
al., 2008; McGregor et al., 2008).

III. Dopamine and Reward
a. Dopamine Pathways

Psychostimulants such as METH, cocaine and nicotine elicit their
stimulant and rewarding effects through activation and modulation of the
mesolimbic, mesocortical and nigrostriatal dopamine (DA) pathways (Di Chiara et
al., 2004; Wise, 2009). The mesolimbic DA pathway is characterized by neurons
originating in the ventral tegmental area and innervating the nucleus accumbens
(NAc), ventral palladium and amygdala (Fig 2). The mesocortical DA pathway
originates in the ventral tegmental area (VTA) and projects to the prefrontal
cortex (Fig 2). The mesolimbic and mesocortical DA pathways are involved in
motivation, reward, emotion and cognition (Wise, 1978; Simon et al., 1980; Di
Chiara and Imperato, 1988; Pierce and Kumaresan, 2006). Modulation of DA
neurotransmission in the NAc and medial prefrontal cortex is important in primary
reward, learning and cue-associated reinforcement (Everitt and Robbins, 2005;
Chen et al., 2010). The nigrostriatal DA pathway originates in the substantia
nigra and innervates the striatum (Fig 2). This pathway is involved in movement,
motor control and conditioning (Robertson and Robertson, 1989; Everitt and
Robbins, 2005). While these pathways were originally referenced as being
anatomically and functionally distinct, they actually overlap and often share
functionalities (Bjorklund and Dunnett, 2007; Wise, 2009). Thus, DA
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neurotransmission in the mesolimbic, mesocortical and nigrostriatal pathways
play important roles in the rewarding properties of abused psychostimulant drugs
(Everitt and Robbins, 2005; Wise, 2009).

b. DA

DA (Fig. 1) is a catecholamine neurotransmitter involved in reward,
emotion and movement. The biosynthesis of DA is shown in Fig 3. DA
biosynthesis begins with the hydroxylation of the amino acid L-tyrosine by
tyrosine hydroxylase (TH) to form L-dihydroxylphenylalanine (L-DOPA) in the
axon terminals of DA neurons. TH requires the cofactors, Fe2+, O2 and
tetrahydropteridine and the hydroxylation of L-tyrosine is the rate-limiting step in
the biosynthesis of DA (Cooper et al., 2003). L-DOPA is then decarboxylated by
DOPA-decarboxylase to form DA. The action of DOPA-decarboxylase requires
pyridoxal phosphate (vitamin B6) as a cofactor and also occurs in the cytoplasm
of the axon terminals (Cooper et al., 2003). Following synthesis, DA is stored in
synaptic vesicles in the presynaptic axon terminal until ready to be used. DA
can be stored in large dense core vesicles (LDCV) or small synaptic vesicles
(SSV). LDCVs are located away from the synaptic cleft, while SSVs are located
near the synapse or “active zone” (Ludwig and Leng, 2006). As such, LDCVs
are sometimes referred to as the non-readily releasable pool of vesicles, while
SSVs are referred to as the readily releasable pools. When a DA neuron is
stimulated, an action potential travels into the axon terminal opening voltage
gated Ca2+ ion channels, leading to the influx of Ca2+ into the terminal (Cooper et
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al., 2003). Sensors on SSVs are activated by increases in Ca2+ ion
concentrations, leading to exocytosis (Ludwig and Leng, 2006). In exocytosis,
vesicles fuse with the synaptic plasmalemma membrane and release the
contents (DA) of the vesicles into the synaptic cleft. Exocytosis is a rapid
process, occuring within milliseconds of vesicle fusion (Almers et al., 1991).
Exocytosis is followed by endocytosis where the empty vesicle is internalized and
refilled with DA (Sudhof, 2004). Once in the cytosol, DA can bind to pre and
postsynaptic receptors, undergo metabolism, or be taken back up into the
presynaptic terminal by the DA transporter (DAT).

c. DA Receptors

Following DA release into the synaptic cleft, DA can bind to pre and
postsynaptic DA receptors (Fig 3). There are two types of DA receptors in the
brain, D1- like and D2-like receptors. Both types of DA receptors are
metabotropic G-protein coupled receptors, consisting of 7 transmembrane
domains (TMDs). Activation of D1-like receptors increases production of cyclic
adenosine monophosphate (cAMP) by stimulating adenylate cyclase while
activation of D2-like receptors inhibits adenylate cyclase decreasing cAMP
production. D1-like receptors consist of D1 and D5 receptors, while D2-like
receptors consist of D2, D3 and D4 receptors. D1 and D2 receptors are more
abundant in the brain, being present 10-100 times more than D3, D4, and D5
receptors (Hurley and Jenner, 2006). D1 receptors are located primarily in the
striatum and cortex (more abundant in the striatum than the cortex), while D5
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receptors are located primarily in the hippocampus, thalamus and hypothalamus.
D2 receptors are located in the striatum and cortex, while D3 receptors are
located primarily in the island of Calleja, nucleus accumbens and olfactory
tubercle, and D4 receptors are in cortex (Hurley and Jenner, 2006). Both D3 and
D4 receptors have decreased expression in the striatum. In addition to
postsynaptic localization of D2 receptors, D2 receptors are located on the
presynaptic membrane where they act as autoreceptors modulating DA
neurotransmission through a negative-feedback mechanism. Activation of D2
autoreceptors on midbrain neurons increases K+ conductance through activation
of coupled K+ channels, hyperpolarizing DA neurons and reducing DA
neurotransmission (Lacey et al., 1987; Cass and Zahniser, 1991). Activation of
D2 autoreceptors on presynaptic terminals decreases DA synthesis through an
inhibition of adenylate cyclase activity, subsequently decreasing cAMP-induced
activation of TH (Onali and Olianas, 1989; Onali et al., 1992).

d. DA metabolism

DA is inactivated by undergoing metabolism in both the synaptic cleft and
presynaptic terminal. DA is metabolized by two main enzymes, catechol-Omethyl transferase (COMT) and monoamine oxidase (MAO). DA is metabolized
into 3-methoxy-4-hydroxyphenylacetaldehyde by COMT in the synaptic cleft. 3methoxy-4-hydroxyphenylacetaldehyde can then be further metabolized into
homovanillic acid by MAO. An alternate metabolic pathway is the metabolism of
DA into dihydroxyphenylacetic acid (DOPAC) by MAO in the presynaptic terminal
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(Fig 3). Additionally, DOPAC can then be metabolized into homovanillic acid by
COMT.

e. DA Transporter

In addition to metabolism, DA is inactivated by being transported back into
the presynaptic terminal through DAT (Fig 3). As such, DAT regulates DA
neurotransmission by determining DA concentrations in the synaptic cleft
available for postsynaptic receptor stimulation. While DAT exhibits affinity for DA,
DAT also transports other substrates into DA nerve terminals such as AMPH,
METH, methylenedioxymethamphetamine, tyramine, 5-HT, norepinephrine, and
1-methyl-4-phenylpyridinium (MPP+). Numerous DAT inhibitors have been
synthesized including cocaine, methylphenidate, GBR-12909, GBR-12935, WIN
35,428, nomifensine, buproprion, and mazindol (Cooper et al., 2003; Torres et
al., 2003).

DAT consists of 620 amino acid residues arranged in 12 hydrophobic
TMDs spanning the plasma membrane (Torres et al., 2003). The N and C
termini of DAT are both located in the cytoplasm on the interior side of the
plasma membrane. Additionally, a large extracellular loop exists between TMDs
3 and 4, possessing multiple glycosolation sites available for post-translational
modification (Torres et al., 2003). The structural regions involved in substrate
translocation are controversial. Using chimeric constructs of DAT and the
norepinephrine transporter (NET), Giros and colleagues discovered that the first
five TMDs were involved in substrate translocation (Giros et al., 1994). Using
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similar techniques, Amara and colleagues concluded that TMD4 through TMD8
were important for substrate translocation (Buck and Amara, 1995). Studies
using chimeras made from human and bovine DAT found that TMD3 was
involved in determining DA affinity (Lee et al., 1998). Specifically, site-directed
mutagenesis studies showed that the phenylalanine residue in TMD3 is crucial
for the binding of DA (Chen et al., 2001). Recently, utilizing the crystal structure
of the leucine transporter, a related sodium dependent transporter, a 3-D model
of DAT was constructed as a structural template (Indarte et al., 2008). Using this
model and performing docking studies, Indarte and colleagues determined that
TMDs 1 and 6 combine with TMDs 3 and 8 to form the binding pocket for DA
(Indarte et al., 2008). DAT inhibitors and substrates are proposed to bind to
different regions of DAT protein. Cocaine and related phenyltropane analogs
inhibit DA uptake through a proposed interaction with TMDs 5-8, while GBR
inhibitors (GBR-12909 and 12935) are proposed to interact with TMDs 1 and 2
(Giros, et al., 1994; Vaughan and Kuhar, 1996; Vaughan et al., 1999).

DAT is localized on DA neurons, at the cell bodies, on axonal membranes
and perisynaptically at nerve terminals (Pickel et al., 1996; Hersch et al., 1997;
Torres et al., 2003; Mengual and Pickel, 2004). In the brain, DAT is found in
striatum, nucleus accumbens, olfactory tubercle, cingulated cortex, frontal cortex,
lateral habenula and on cell bodies in the VTA and substantia nigra (Ciliax et al.,
1995; Torres et al., 2003). In regions where DAT is present in low levels such as
the prefrontal cortex, DA is transported out of the synapse through the NET
(Moron et al., 2002). DAT is also found outside the brain in the body periphery.
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DAT has been found in the stomach, pancreas and kidney, and in these
locations, DAT inactivates peripheral DA involved in paracrine and autocrine
signaling (Eisenhofer, 2001).
DAT is a member of the SLC6 family of Na+/Cl- dependent transporters,
which also includes NET and serotonin transporter (SERT). Transport of DA
through DAT is driven by the Na+ gradient from the Na+/K+ transporting ATPase
and accompanied by the co-transport of Na+ and Cl- ions (Cooper et al., 2003;
Torres et al., 2003). The stoichiometry of substrate transport is the co-transport
of two Na+ ions and one Cl- ion for each DA molecule (Krueger, 1990).
Traditionally, DA transport was thought to occur through an “alternating access
model” of transport (Jardetzky, 1966). In this model, DA and co-substrates (ions)
bound to the outward facing binding site of the transporter. Then, the transporter
underwent a conformational change in which the binding site with the bound DA
and ions face the cytosol, where DA and ions were released into the cytosol.
Transport of DA generates an electrochemical current which can be measured
using voltage clamp and can be blocked by transporter inhibitors (Sonders et al.,
1997; Torres et al., 2003). The existence of transport-mediated currents and the
reliance on electrochemical gradients provides evidence for a transportermediated channel-like mechanism of substrate and ion transport (Sonders and
Amara, 1996). In this model of transport, DAT undergoes a conformational
change in which DAT protein acts as a single channel opening, allowing the
passage of DA and ions through the plasma membrane. The probability of these
openings is increased by the presence of substrates and ions (Sonders and
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Amara, 1996). Additionally, DAT transporter currents may play a role in
membrane depolarization and regulation of DA release. Utilizing patch clamp
recordings, DA transport through DAT was shown to be accompanied by an
inward current (mediated by Cl- ion flow) that elicited an excitatory response,
leading to an increase in DA neuron firing rate (Ingram et al., 2002). Thus, the
ion channel-like current flow through DAT protein modulates membrane potential
and DA release from DA neurons.

Numerous studies utilizing DAT knock-out (KO) mice have been
performed demonstrating the importance of DAT in DA neurotransmission and
the mechanism of action of psychostimulants (Gainetdinov, 2008). DAT KO mice
exhibit decreased weight gain and long term survival rates compared to wild-type
(WT) mice, due to the decreased food intake in DAT deficient mice (Giros, et al.,
1996). As expected, the lack of DA clearance by DAT in DAT KO mice resulted
in an increased extracellular DA. In DAT KO mice, DA persists in the extracellular
compartment 100-300 times longer compared to WT mice (Giros, et al., 1996;
Jones et al., 1998a). Further, DAT KO mice exhibited a 5-fold increase in
extracellular DA levels and 20-fold decrease in tissue DA concentrations due to
the disruption of the DA reuptake and recycling (Gainetdinov et al., 1998; Jones
et al., 1998a). As expected, DAT KO mice exhibit increased locomotor activity
compared to WT mice, presumably due to the increased concentration and
action of extracellular DA (Giros et al., 1996). In addition to disrupting DA
clearance, DA synthesis rates were doubled in DAT KO mice compared to WT
mice (Jones et al., 1998a). Interestingly, TH levels were 90% lower in DAT KO
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mice compared to WT, suggesting an increase in efficiency to synthesize DA in
DAT KO mice (Jones et al., 1998a). Consistent with these results, D2 receptor
expression was decreased by 45% in DAT KO mice compared to WT mice,
which could further explain the increase in DA synthesis as D2 autoreceptors
inhibit DA synthesis by decreasing TH activity (Giros et al., 1996; Jones et al.,
1999). DAT KO also altered DA metabolism by COMT which was increased by
400% in DAT KO mice compared to WT mice (Jones et al., 1998a).

Studies utilizing DAT KO mice have contributed also to the understanding
of the mechanism of action of psychostimulants. Unlike in WT mice, AMPH or
cocaine treatment did not increase locomotor activity in DAT KO mice,
suggesting a role for DAT in the mechanism of action of these drugs (Giros et al.,
1996). Consistent with these results, AMPH or cocaine treatment did not
increase extracellular DA in the striatum of DAT KO mice, and behavioral studies
demonstrated that DAT KO mice exhibit decreased cocaine self-administration
rates compared to WT mice (Jones et al., 1998b; Gainetdinov, 2008; Thomsen et
al., 2009). In contrast, microdialysis experiments show that AMPH and cocaine
increase extracellular DA in the NAc in DAT KO mice (Carboni et al., 2001).
Further, DAT KO mice self-administer cocaine and exhibit conditioned place
preference for AMPH, despite lacking the presumed pharmacological target of
cocaine and AMPH (Rocha et al., 1998, Budygin et al., 2004). Thus, even though
DAT is one of the pharmacological targets of AMPH and cocaine, evidence exists
for the role of other neurotransmitter transporters such as SERT, NET and the
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vesicular monoamine transporter (VMAT) in the rewarding effects of these drugs
(Budygin et al., 2004; Gainetdinov, 2008).

DAT function is regulated by multiple post-translational modifications and
protein-protein interactions. Analysis of the amino acid sequence of DAT reveals
multiple sites of phosphorylation and other post-translational modifications such
as glycosylation and ubiquitination (Torres et al., 2003; Jayanthi et al., 2007).
Phosphorylation by kinases such as protein kinase C (PKC), cAMP-dependent
protein kinases, mitogen-activated protein kinases, and tyrosine kinases
modulate DAT activity. Studies utilizing phorbol 12-myristate 13-acetate, which
activates PKC, have demonstrated that phosphorylation by PKC reduces DAT
transport activity by altering DA surface levels (Vaughan et al., 1997; Zhang et
al., 1997; Zhu et al., 1997). PKC-dependent endocytosis of DAT is also
mediated by ubiquitination of DAT on the amino terminus of DAT (Miranda et al.,
2007; Miranda and Sorkin, 2007). Further, PKC-mediated DAT trafficking is
characterized by internalization through a clathrin-associated endocytosis
mechanism that is dynamin dependent (Daniels and Amara, 1999). Constitutive
internalization and recycling of DAT, which is important for membrane
homeostasis, is also mediated by a clathrin-dependent mechanism (Sorkina et
al., 2005). Furthermore, recent research illustrates that residues 60-65 on the Nterminal domain are important for the prevention of clathrin-dependent
constitutive internalization of DAT (Sorkina et al., 2009). In addition, other
kinases such as protein kinase A (PKA), Ca2+/calmodulin-dependent kinases and
tyrosine kinases have been shown to upregulate DAT surface expression
15

(Zahniser and Doolen, 2001). Substrates such as DA, AMPH and METH, as well
as reactive oxygen species and nitric oxide have been shown to decrease DAT
surface expression through a PKC-mediated mechanism; while D2 receptor
agonists and DAT inhibitors, such as cocaine, increase DAT cell-surface
expression (Zahniser and Doolen, 2001; Cervinski et al., 2005). Further, DAT has
been shown to interact with other proteins such as the D2 receptor, syntaxin 1A,
synaptogyrin-3, and α-synuclein, which can further modulate DAT trafficking and
function (Lee et al., 2001, 2004, 2007; Egana et al., 2009, Eriksen et al., 2010).

f. Vesicular Monoamine Transporter

Once transported back into the presynaptic nerve terminal, DA is
metabolized into DOPAC by MAO. However, DA that is not metabolized by MAO
is repackaged into synaptic vesicles by the vesicular monoamine transporter
(VMAT; Fig 3). VMAT belongs to the major facilitator and solute carrier
superfamily of transporters (Pao et al., 1998; Eiden et al., 2004). VMAT exists in
humans in two isoforms, VMAT1 and VMAT2, encoded by separate genes
SLC18A1 and SLC18A2, respectively (Eiden and Weihe, 2011). VMAT1 is
located primarily in endocrine cells found in adrenal medulla chromaffin cells and
absent in adult neuronal cells. Conversely, VMAT2 is located in neuronal cells of
the CNS as well as in sympathetic adrenal chromaffin cells and neurons in the
intestine and stomach (Peter et al., 1995). VMAT2 is expressed in all
monoamine neurons primarily localized to cell bodies and axon terminals, and is
responsible for packaging DA, serotonin (5-HT), norepinephrine (NE),
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epinephrine (E) and histamine into small synaptic vesicles. Thus, VMAT2
represents a vital protein in regulating neuronal monoamine transmission.

VMAT2 KO mice have been generated to elucidate the importance of
VMAT2 function in neurotransmission. Homozygous VMAT2 KO mice were born
without complication, suggesting that VMAT2 was not important in gestation and
birth (Takahashi et al., 1997). However, most of the homozygous KO mice died
on the first day due to a lack of feeding, with 100% mortality by postnatal day 14
(Takahashi et al., 1997; Fon et al., 1997). Heterzygous VMAT2 KO mice
survived, exhibiting ~50% less VMAT2 binding compared to WT mice (Takahashi
et al., 1997). Monoamine levels in VMAT2 KO mice were significantly decreased
compared to WT mice, while no differences in brain structure and DA neuronal
projections were found (Fon et al., 1997). Interestingly, DA synthesis was
increased in VMAT2 KO mice; however DA metabolite levels were similar to
those found in WT mice, demonstrating the importance of VMAT2 in
sequestering newly synthesized DA into vesicles to prevent degradation (Fon et
al., 1997; Wang et al., 1997).

VMAT2 transports monoamines from the cytosol into vesicles against a
high concentration gradient (>105; Wimasalena, 2010). To accomplish this,
VMAT2-mediated transport utilizes electrochemical and transmembrane pH
gradients (~1.5 units) generated by a V-type ATPase (Kirschner, 1962;
Schuldiner, 1994). ATPases, found in virtually all eukaryotic cells and
organelles, utilize the hydrolysis of ATP to drive the transport of protons across a
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membrane (Nelson et al., 2000). In VMAT2, the ATPase generates a H+
electrochemical gradient, acidifying the interior lumen of the synaptic vesicle
(Yelin and Schuldiner, 2000). VMAT2, utilizing an antiport transport mechanism,
couples the efflux of two protons out of the vesicle to the transport of one
substrate molecule into the vesicular lumen (Knoth et al., 1981; Schuldiner, 1994;
Schuldiner et al., 1995; Parsons, 2000). Specifically, the efflux of the first proton
from the vesicular lumen elicits a conformational change in the transporter, which
exhibits high affinity monoamine binding sites on the cytosolic face. Following
monoamine binding, the efflux of the second proton generates a conformational
change in the transporter, in which the monoamine-bound face of the transporter
is toward the vesicular lumen. In this orientation, monoamine-binding affinity is
now reduced, allowing the release of the monoamine into the vesicle. In addition
to the proton gradient, VMAT2-mediated transport in synaptic vesicles is also
dependent upon cytosolic amine concentrations, extra vesicular media and the
number of transporters in the vesicular membrane (Wimalasena, 2011).

Studies examining VMAT2 kinetic uptake parameters determined that the
order of substrate uptake efficiency was 5-HT>DA>E>NE (Wimalasena, 2011).
Similar to DAT, VMAT2 transports MPP+, sequestering MPP+ from the cytosol
into synaptic vesicles which protects the neuron from MPP+-induced toxicity (Liu
et al., 1992). In addition, AMPH and related compounds are also transported by
VMAT, which plays a critical role in their mechanism of action (Sulzer et al.,
2005). Numerous studies have focused on the ability of two well known inhibitors
of VMAT2, reserpine and tetrabenazine (TBZ). Reserpine (Fig. 1) is an indole
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alkaloid historically used to treat high blood pressure. Reserpine inhibits
monoamine uptake at VMAT2 with high affinity and can be surmounted by
increasing concentrations of substrate, indicative of competitive inhibition
(Schuldiner et al., 1995). Further, reserpine binding is modulated by the
transmembrane pH gradient (Yelin and Schuldiner, 2000; Wimalasena, 2011).
Reserpine binds to the high affinity substrate binding site inhibiting the efflux of
H+ thereby preventing the conformational change necessary to transport the
ligand into the vesicular lumen. Reserpine becomes trapped in the active site
and is not readily dissociated. With reserpine in the active site, VMAT2 cannot
efflux another proton to return the transporter to its active, high affinity state
(Schuldiner et al., 1995). Therefore, reserpine has been classified as an
irreversible inhibitor of VMAT function.

TBZ (Fig. 1) is a benzoquinolizine derivative, marketed as Xenazine, and
currently FDA approved to treat Huntington’s chorea. TBZ inhibits monoamine
uptake with high affinity, however unlike reserpine, TBZ is proposed to interact
with a site distinct from the substrate site (Pletscher, 1977; Scherman and Henry,
1984; Schuldiner, 1994). This conclusion is based upon studies showing that
TBZ binding is 1) not dependent on the pH gradient, 2) not inhibited by reserpine
binding at reserpine concentrations that inhibit substrate transport and 3)
substrates (5-HT, DA, NE) displace TBZ only at concentrations 100-fold higher
than their affinity for the substrate site (Scherman and Henry, 1984). Unlike
reserpine, TBZ is relatively short acting with respect to inhibition of VMAT2
function. Radiolabeled TBZ and its derivative dihydrotetrabenazine (DTBZ) have
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been used extensively to study VMAT2 binding, regulation, distribution and
expression (Yelin and Schuldiner, 2000).

In addition to exhibiting different tissue distribution, VMAT1 and VMAT2
also display different affinities for substrates and inhibitors. VMAT2 has been
shown in cell expression systems to exhibit 4-5-fold higher affinity for DA, 5-HT,
NE, and E compared to VMAT1 (Peter et al., 1994). Despite the difference in
affinities for monoamines between the two isoforms of VMAT, the rank order of
affinities is similar for both transporters (Yelin and Schuldiner, 2000).
Interestingly, both isoforms exhibit affinity not different from one another for
MPP+ and AMPH, but VMAT2 exhibits over two orders of magnitude higher
affinity for histamine compared to VMAT1 (Peter et al., 1994). In regards to
inhibitors, both VMAT1 and VMAT2 exhibit similar affinity for reserpine (Ki =
0.034 and 0.012 µM, respectively). Conversely, VMAT2 exhibits high affinity for
TBZ; Ki = 0.097 µM), while VMAT1 exhibits low affinity for TBZ (Ki = > 20 µM;
Wimalasena, 2011).

Similar to DAT, VMAT2 consists of 12 TMDs. Despite this similarity and
the fact that both proteins transport common substrates, VMAT2 and DAT share
little structural homology (Hoffman et al., 1998). VMAT is a 70 kDa glycoprotein
located within the membrane of synaptic vesicles. While both VMAT1 and
VMAT2 are derived from different genes, they exhibit high structural homology
(~60%; Adam et al., 2008; Wimalasena, 2011). Sequence analysis of VMAT2
reveals a 521 amino acid protein, with both the N and C termini facing outward
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towards the cytoplasm (Liu et al., 1992; Yelin and Schuldiner, 2000). A large
hydrophilic loop occurs between TMDs 1 and 2 facing the interior lumen of the
vesicle, which is presumed to be involved in post-translational modification and
regulation, as this loop contains multiple sites for glycosylation (Yelin and
Schuldiner, 2000). Further, four aspartic residues in TMDs 1, 6, 10 and 11 (Asp
34, Asp 267, Asp 404, and Asp 431), as well as a lysine residue in TMD 2 (Lys
139), are important in transporter function and substrate and reserpine binding
(Yelin and Schuldiner, 2000). His419 (between TMD 10 and 11) has also been
shown to play an important role in monoamine transport, possibly through H+
translocation and energy coupling required for transport (Wimasalena, 2010).
Studies using chimeras have shown that regions encompassing TMDs 5-8 and
TMDs 9-12 are important for the high affinity interaction with monoamines and
TBZ (Peter et al., 1996).

Similar to DAT, VMAT2 can undergo post-translational modifications
regulating VMAT2 function, expression and localization. Studies utilizing
pheochromocytoma cells of the rat adrenal medulla (PC12) showed that
treatment with cAMP down regulated vesicular monoamine transport, suggesting
a role of phosphorylation in the modulation of VMAT activity (Nakanishi et al.
1995). In Chinese hamster ovary, PC12 and COS cells, casein kinase I and II
phosphorylated the carboxyl-terminus of VMAT2, but not VMAT1, suggesting a
difference in the regulation of the two isoforms (Krantz et al., 1997). Further
phosphorylation in VMAT2 affected the subcellular localization and membrane
trafficking of VMAT (Krantz et al., 1997). Using PC12 cells, Hersh and
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colleagues found that in the presence of PKA, VMAT2 is preferentially sorted to
LDCVs and not to SSVs (Yao et al., 2004). Interestingly, the effect of PKA on
VMAT2 sorting is not due to phosphorylation of the protein, but rather
glycosylation of the C terminus (Yao et al., 2004). In addition to action by
kinases, G-proteins have been shown to regulate VMAT2 activity. Guanosinetriphosphate-bound G-proteins inhibited both monoamine uptake and reserpine
binding in PC12 cells (Ahnert-Hilger et al., 1998; Holtje et al., 2000). This
inhibition of uptake is attenuated by increasing monoamine concentrations,
suggesting that G-protein mediated inhibition is through an effect on monoamine
affinity for the transporter (Ahnert-Hilger et al., 2000). Similar to results seen in
the phosphorylation studies, VMAT2 was more susceptible to regulation by Gproteins compared to VMAT1 (Holtje et al., 2000). More recent studies utilizing
site-directed mutagenesis have shown that the first intracellular loop is
responsible for G-protein-mediated regulation of VMAT activity (Brunk et al.,
2006). Collectively, these studies demonstrate that intravesicular monoamine
concentration can modulate VMAT activity, regulating vesicular filling and
subsequently affecting neurotransmission.

IV. METH mechanism of action

As discussed previously, METH is an N-methyl derivative of AMPH.
METH and AMPH exhibit similar rewarding effects, pharmacokinetic properties,
and mechanism of action to release DA in brain (Sulzer et al., 2005). Many initial
studies concerning the rewarding effects and mechanism of action of AMPH-like

22

stimulants utilized AMPH, while studies examining DA neurotoxicity were
performed using METH (Sulzer et al., 2005). In the subsequent discussion of the
mechanism of action of METH, early mechanistic studies using AMPH will be
discussed, in addition to studies using METH, as both drugs employ the same
mechanism of action to increase extracellular DA and elicit reward.

a. METH action at plasma membrane transporters

Experiments utilizing DAT KO mice provide evidence for a role of other
monoamine transporters such as SERT and NET in addition to DAT in the
mechanism of action of AMPH and METH (Budygin et al., 2004; Gainetdinov,
2008). Similar to DAT, SERT is a plasma membrane transporter belonging to the
Na+/Cl- dependent transporter SLC6 family (Rothman et al., 2003). Unlike DA
transport through DAT, one molecule of 5-HT is transported with only one Na+
ion and one Cl- ion (Gu et al., 1998). Structurally, SERT is composed of 630
amino acid residues arranged into 12 hydrophobic TMDs, with both N and C
termini located in the cytoplasm and characterized by a large extracellular loop
between TMDs 3 and 4 (Rudnick, 2006). Substrate binding and translocation is
believed to occur through an interaction with TMDs 1, 3, 6 and 8, while inhibitors
are proposed to interact with same domains (Rudnick, 2006). SERT is located
primarily on serotoninergic neurons, as well as peripheral locations such as the
lung, placenta and platelets (Jayanthi et al., 2007). In the brain, SERT is located
on 5-HT nerve cell bodies originating primarily from the dorsal and medial raphe
nucleus, SN, VTA and hypothalamus (Hoffman et al., 1998). 5-HT and DA
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containing neurons co-innervate many brain regions. Thus SERT is found in
striatum, cortex and hippocampus (Hoffman et al., 1998). In brain, SERT
functions to terminate the action of 5-HT through the transport of 5-HT from the
extracellular space into the presynaptic terminal, where it is metabolized or
repackaged into vesicles by VMAT2. 5-HT functions in the CNS as a regulator of
mood, sleep, memory, appetite, thyroid function, gastrointestinal function, and
sexual drive (Jacobs and Azmitia, 1992). Dysfunction of 5-HT signaling is linked
to numerous psychiatric disorders such as depression, suicide, alcoholism, and
violence (Jayanthi et al., 2007). Numerous inhibitors of SERT function have
been used in the treatment of depression and mood stabilization, such as
fluoxetine, paroxetine, sertraline, and citalopram (Rudnick, 2006).

Similar to DAT and SERT, NET is a plasma membrane transporter
belonging to the SLC6 family of Na+/Cl- dependent transporters. The
stoichiometry of NE transport is similar to SERT in that one Na+ ion and one Clion is co-transported with one molecule of NE (Gu et al., 1998). NET is
structurally homologous to DAT and SERT, and is composed of 617 amino acid
residues arranged into 12 TMDs (Torres et al., 2003).

Similar to DAT and

SERT, the N and C termini of NET are located in the cytoplasm and a large
extracellular loop exists between TMDs 3 and 4 (Torres et al., 2003). Studies
utilizing chimeric DAT and NET proteins showed that TMDs 1-5 and 9-12 are
important for substrate translocation, and TMDs 6-8 are important for interaction
with uptake inhibitors such as cocaine, desipramine and nortryptiline (Giros et al.,
1994). NET is located on cell bodies and axon terminals of noradrenergic
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neurons originating from the locus coeruleus and innervating the hippocampus
and cortex (Torres et al., 2003). NET also has been found in peripheral
locations, such as placenta, lung, adrenal glands and vas deferens (Torres et al.,
2003; Jayanthi et al., 2007). NET functions primarily to terminate the action of
NE through the transport of NE from the extracellular space into presynaptic
terminals. NE acts as a regulator of attention, arousal, learning, memory, and
mood as well as being involved in depression, aggression, thermal regulation
and autonomic functioning (Jayanthi et al., 2007). Thus, modulation of NET
plays an important role in many diseases and pharmacotherapies. NET
inhibitors such as atomoxetine, reboxetine, desipramine, and mazindol have
been used in the treatment of depression, attention-deficit hyperactivity disorder,
drug abuse and other mental illnesses (Zhou, 2004).

The rewarding effects of AMPH-like compounds are a result of the ability
of these compounds to increase extracellular monoamine levels. The first
evidence that AMPH elicits its effects through a release of catecholamines from
the presynaptic terminal was introduced by Burn and Rand in 1958. These
studies demonstrated that AMPH increased blood pressure in animals, but this
effect was blocked by the treatment of reserpine, a catecholamine-depleting
agent, suggesting that AMPH acts by increasing catecholamine concentrations
(Burn and Rand, 1958). Additional results from this study demonstrated that
cocaine blocked AMPH-induced release of catecholamines, providing the first
evidence that AMPH-induced monoamine release involves plasma membrane
transporters (Burn and Rand, 1958). Early studies demonstrated that AMPH
25

inhibited [3H]monoamine uptake into rat synaptosomes and slices, further
demonstrating an interaction of AMPH with plasma membrane transporters
(Ross and Renyi, 1964, 1966; Coyle and Snyder, 1969). Initial evidence that
AMPH is a substrate for monoamine transporters in the brain was found in
studies utilizing PC12 rat chromaffin cells. Using radiolabled AMPH, Bonisch
demonstrated that AMPH was transported in a manner similar to that of NE,
dependent upon Na+ and Cl- gradient and blocked by plasma membrane
transporter inhibitors cocaine and desipramine (Bonisch, 1984). Follow-up
studies using rat striatal synaptosomes demonstrated that AMPH uptake was
saturable with a Km of 97 nM and a Vmax of 3.0 fmol/mg/min (Zaczek et al., 1991).
Therefore, one mechanism by which AMPH increases monoamine
concentrations is by inhibiting uptake of monoamines into presynaptic terminals
by acting as a substrate. These early studies examining AMPH uptake through
monoamine transporters were complicated by the physiochemical properties of
AMPH (Sulzer et al., 2005). Due to the lipophilicity of AMPH, AMPH and related
compounds also enter presynaptic terminals through passive diffusion (Fig 4;
Fischer and Cho, 1979; Sieden et al., 1993).

In addition to inhibiting monoamine uptake through plasma membrane
transporters as a substrate, AMPH also elicits a non-exocytotic release of
monoamines from monoaminergic neurons (Fig 4). Early studies using
radiolabeled monoamines demonstrated that AMPH released monoamines in rat
brain tissue (Glowinski and Axelrod, 1966; Brodie et al., 1969). The ability of
AMPH to release DA from neurons is dependent on both a plasmalemmal and
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vesicular component. Pifl and colleagues performed [3H]DA release studies
utilizing cell lines that expressed DAT only, VMAT2 only and both DAT and
VMAT2 (Pifl et al., 1995). Results from this study showed that DAT expression
was essential for DA release, as the cell expressing VMAT2 alone did not
release DA and the extent of DA release was larger in the cell expressing both
DAT and VMAT2. Further evidence for the importance of DAT in the mechanism
of action of AMPH was provided by Jones and colleagues in 1998. Using DAT
KO mice and fast scan cyclic voltammetry, it was shown that AMPH-mediated
DA release was DAT dependent, as AMPH-mediated DA release was not seen in
DAT KO mice (Jones et al., 1998). Thus, DAT plays an important role in the
effects of AMPH.

AMPH-induced release of DA via DAT has been hypothesized to follow a
facilitated exchange diffusion mechanism (Paton, 1973; Arnold et al., 1977;
Fischer and Cho, 1979). Based upon a glucose-mediated transport mechanism,
AMPH is translocated into the cytosol from the extracellular space as a substrate
for DAT (Stein, 1968). As AMPH is released in the cytosol, high affinity DA
binding sites on DAT are exposed, enabling the high concentrations of cytosolic
DA to bind. One molecule of DA is expected to bind and be released in the
extracellular space when the transporter returns to the external face. Reverse
transport by this mechanism is dependent upon Na+ concentrations and follows a
one-to-one AMPH molecule to DA molecule ratio. While support for this
mechanism is widely found in the literature, results from some studies cannot be
explained by this hypothesis. Sulzer and colleagues found that AMPH directly
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injected into neurons of the pond snail, Planorbis corneus, induced reverse
transport of DA into the extracellular space (Sulzer et al., 1995). In this
experiment, AMPH was not transported into the neuron through DAT, but DA
was still released in a non-exocytotic, reverse transport mechanism. Additionally,
increasing cytosolic Na+ concentrations reversed transport of DA through DAT in
the absence of AMPH (Khoshboeui et al., 2003). Further, why DA preferentially
binds to the cytosolic face of the transporter and not AMPH, is not explained, as
AMPH is not reverse transported out of the neuron, despite interacting with the
same site on DAT. Thus, evidence exists for an alternative mechanism of
AMPH-induced DA release through DAT.

Recent studies have provided evidence for AMPH-evoked DA release
through DAT by a channel-like mechanism. Utilizing patch clamp recordings of
Xenopus oocytes expressing DAT, it was demonstrated that DAT exhibits
transport and leak-associated currents derived from the conductance of
monoamine transport (Sonders et al., 1997). Other monoamine transporters,
such as NET and SERT have been shown to exhibit similar ion conductance with
associated monoamine transport (Galli et al., 1998). Channel-like DA release in
the presence of AMPH was demonstrated by Galli and colleagues in 2005
(Kahlig et al., 2005). In this study, AMPH-induced ionic currents were measured
using patch clamp and amperometric recordings from human embryonic kidney
cell lines expressing DAT. Results from this study showed that AMPH releases
DA from neurons through DAT in two ways, a slow, exchange mediated
mechanism and a fast, channel-like mechanism. Release of DA through the
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channel-like mechanism is characterized by fast bursts of DA efflux containing a
large number of DA molecules in each channel-like event. Interestingly, unlike
AMPH, the endogenous substrate DA, could not evoke these channel-like
events. Thus, AMPH could be evoking DA release through DAT in a facilitated
exchange diffusion or channel-like mechanism to increase extracellular DA
concentrations.

In addition to evoking DA release through DAT, AMPH and METH also
modulate DAT uptake and expression. Synaptosomal DA uptake in striatum was
significantly reduced 1 hr following an acute high dose of METH (15 mg/kg;
Fleckenstein et al., 1997). This reduction in DAT function is characterized by a
decrease in maximal uptake (Vmax), with no effect on affinity for DA (Km).
However, total DAT binding was not altered, suggesting that METH altered cell
surface localization of DAT through a trafficking mediated mechanism. Others
have shown that METH-induced DAT internalization is PKC-dependent and
similar to substrate-mediated internalization through clathrin-coated vesicles
(Saunders et al., 2000; Cervinski et al., 2005; Schmitt and Reith, 2010).
Interestingly, the effect of METH to internalize DAT was not seen in the
synaptosomes prepared from the nucleus accumbens, suggesting regional
modulation of DAT expression and potentially activity (Kokoshka et al., 1998). In
addition to the differential regional regulation, the observed changes are also
dependent on time following METH treatment. Results from the Gnegy and
colleagues showed that exposure to 3 µM AMPH increased DAT cell surface
expression levels 70% within 30 sec of exposure and expression remained
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elevated for 1 min (Johnson et al., 2005). Thus, AMPH and METH rapidly
increase DAT activity immediately following exposure, but decrease DAT
expression after 20 min, suggesting that AMPH and METH regulate DAT activity
in a complex manner dependent upon time and brain region.

Utilizing fluorescence resonance energy transfer microscopy, DAT was
shown to oligomerize in the endoplasmic reticulum and remain oligomerized
while trafficking to the plasma membrane (Sorkina et al., 2003). Interestingly,
substrates such as AMPH and METH dissociate the DAT oligomers suggesting a
possible role in AMPH-mediated DAT trafficking (Chen and Reith, 2008). Results
from this study suggest that DAT in the plasma membrane is present in oligomer
and monomer forms, and AMPH promotes the formation of monomers resulting
in increased DAT internalization.

In summary, DAT plays an important role in the stimulant effects of
abused drugs, specifically METH. Through the reversal of DAT function, METH
releases DA into the extracellular space leading to its abuse. Furthermore,
METH can modulate DAT activity through various mechanisms, such as
phosphorylation or altered formation of DAT oligomers. The extensive research
on METH and DAT has provided a greater understanding of the mechanism of
action of METH and will hopefully contribute to the development of a successful
pharmacotherapy for METH abuse.

b. METH at VMAT2
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In addition to the effect of METH on DAT, METH interacts with VMAT2 to
increase extracellular DA levels (Fig 4). As discussed previously, results from
Pifl and colleagues showed that while DAT was necessary for AMPH-induced DA
release, cells expressing both DAT and VMAT2 exhibited greater and more
sustained release compared to cell expressing just DAT (Pifl et al., 1995). Using
neuronal cultures from VMAT2 KO mice, neurons lacking VMAT2 exhibited
significantly decreased AMPH-evoked DA release compared to WT neurons (Fon
et al., 1997). Thus, the effect of AMPH on vesicular DA stores is critical in the
mechanism of AMPH-induced DA release.

AMPH acts to redistribute DA from presynaptic vesicular stores to the
cytosol, where it can be reverse transported into the extracellular space through
DAT (Sulzer et al., 2005). Low concentrations of AMPH (doses less than 1
mg/kg) are hypothesized to release DA available in the cytosol, while higher
concentrations of AMPH (doses greater than 5 mg/kg) are hypothesized to
interact with vesicular pools and VMAT2 to redistribute DA to cytosolic pools to
then be released into the extracellular space (Seiden et al., 1993). Evidence for
a redistribution of DA from vesicles to the cytosol was provided by Sulzer and
colleagues in 1995. Direct injection of AMPH into DA neurons of Planorbis
corneus increased cytosolic DA and decreased vesicular DA concentrations
(Sulzer et al., 1995). Further, quantal DA release following injection of AMPH
was reduced by >50%, supporting AMPH-induced decreases in vesicular DA
storage. Elevated cytosolic DA induces reverse transport leading to DA release
into the extracellular space,
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One mechanism of AMPH-induced increases in cytosolic DA is the
inhibitory effect of AMPH on DA uptake into vesicles. AMPH inhibits the uptake
of monoamines into synaptic vesicles (Knepper et al., 1988). AMPH is a
substrate for VMAT2, competing with reserpine for the VMAT2 substrate uptake
site (Peter et al., 1994; Erickson et al., 1996). In addition to displacing reserpine
binding, AMPH also displaces TBZ binding to VMAT2, providing a mechanism for
AMPH-induced inhibition of vesicular monoamine uptake (Gonzalez et al., 1994).
Thus, one mechanism by which AMPH increases cytosolic DA concentrations is
through an inhibition of DA uptake at VMAT2.

In addition to inhibiting DA uptake at VMAT2, AMPH evokes DA release
from vesicular stores to increase cytosolic DA concentrations (Sulzer et al.,
2005). As a substrate for VMAT2, AMPH acts to release DA from vesicles
through an interaction with VMAT2. Similar to the facilitated exchange diffusion
model hypothesized for AMPH-induced DA release through DAT, AMPH evokes
DA efflux through VMAT2 and may do so via a similar mechanism. Under this
proposed mechanism, transport of AMPH into vesicles would increase
accessibility to DA binding sites on the inner-facing surface of the transporter.
Subsequently, the bound DA will then be reverse transported out of the vesicle
and into the cytosol (Sulzer et al., 2005).

Several studies have shown that

vesicles “leak” monoamines into the cytosol (Floor et al., 1995). Further, this
efflux of DA from synaptic vesicles is independent of uptake blockade, as TBZ
did not inhibit this DA efflux (Floor et al., 1995). In addition, low concentrations of
AMPH evoke DA release from synaptic vesicles that is not dependent on the
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electrochemical H+ gradient (Floor and Meng, 1996). Thus, in addition to
inhibiting DA uptake through VMAT2, AMPH simultaneously evokes the efflux of
DA from vesicles, increasing cytosolic DA.

In addition to a VMAT2-mediated mechanism, AMPH is also proposed to
release DA from vesicles through a “weak base” effect (Sulzer et al., 2005). As
discussed previously, uptake of monoamines through VMAT2 is coupled to a H +
electrochemical gradient. Intravesicular monoamine concentration is estimated
to be around 500 mM, while cytosolic concentrations are only 25 µM (Johnson,
1988). Thus, VMAT2 uses an H+ gradient to transport monoamines against a
140,000 to 1 concentration gradient. The H+ gradient is produced and
maintained by the activity of the ATPase proton pump. Consequently, the interior
lumen of synaptic vesicles is acidic with an interior pH around 5.5 (Johnson,
1988; Fleckenstein et al., 2007). AMPH is a lipophilic weak base, exhibiting a
pKA of 9.88 (Mack and Bonisch, 1979). In addition to active transport through
VMAT2, AMPH also diffuses across the synaptic membrane due to its lipophilicity
(Peter et al., 1995; Sulzer et al., 2005). In the vesicular lumen, AMPH becomes
protonated, causing the vesicular lumen to become more alkaline, which disrupts
the pH gradient needed to provide the energy for monoamine transport. The first
evidence for this mechanism was provided using the fluorescent weak base
quinacrine in real-time estimation of internal pH of isolated chromaffin vesicles. In
this study, AMPH was shown to alkalinize vesicular pH, leading to decreased DA
uptake and increased DA release from vesicles (Sulzer and Rayport, 1990).
Further evidence for the weak base effect was seen with other weak bases, such
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as ammonium chloride, chloroquine, and bafilomycin, which are known to disrupt
pH gradients in neuronal cells. Incubation with these compounds increased
vesicular DA release and decreased vesicular DA content as a result of the
alkanization of the vesicular lumen and disruption in the pH gradient (Sulzer et
al., 1993; Mundorf et al., 1999; Sulzer and Pothos, 2000).

Despite considerable evidence for the weak base effect of AMPH to
release vesicular DA, several arguments to this proposed mechanism exist.
Lower concentrations of AMPH have been shown to release DA from synaptic
vesicles, independently of the electrochemical pH gradient (Floor and Meng,
1996). Specifically, synaptic vesicles loaded with [3H]DA exposed to 3 µM AMPH
rapidly released over 70% of DA, while the pH gradient was only decreased by
12% (Floor and Meng, 1996). Further evidence arises from the fact that
bafilomycin A1, an ATPase inhibitor, decreased the pH gradient 2-fold more than
AMPH, but only released DA half as fast as AMPH (Floor and Meng, 1996).
Another important caveat to the weak base mechanism is that the S(+)
stereoisomer of AMPH is more effective in promoting DA release than the R(-)
stereoisomer, despite having the same effect on vesicular pH (Peter et al., 1994).
Interestingly, the S(+) isomer of AMPH binds with higher affinity to VMAT2 which
could account for the ability of the S(+) isomer to preferentially release DA,
further supporting a VMAT2-mediated mechanism of vesicular DA release
(Erickson et al., 1996; Sulzer et al., 2005). Taken together, these results suggest
that the alkalization of vesicles alone cannot fully explain AMPH-induced DA
release from synaptic vesicles.
34

Similar to the effect on DAT, AMPH and METH treatment can modulate
VMAT2 activity. Multiple high doses of METH (10 mg/kg, s.c. x 4) significantly
decreased DA uptake at VMAT2 at both 1 hr or 24 hrs following treatment
(Brown et al., 2000; Hogan et al., 2000). Further, DTBZ binding to VMAT2 was
also reduced in striatal vesicles, but not in total striatal homogenates, suggesting
a redistribution of VMAT2 protein within the presynaptic terminal (Hogan et al.,
2000; Fleckenstein et al., 2007). Western blot analysis revealed that multiple
high doses of METH (10 mg/kg x 4) decreased by 80%VMAT2 immunoreactivity
in cytoplasmic striatal vesicles (Riddle et al., 2002). Further, redistribution of
VMAT2 was not retained in the synaptosomal fraction, suggesting that METH
decreases VMAT2 function by trafficking VMAT2 containing vesicles out of
presynaptic terminal. METH-induced decreases in VMAT2 immunoreactivity in
the striatum were also found by Yamamoto and colleagues further supporting
METH-induced VMAT2 redistribution (Eyerman and Yamamoto, 2005). Thus,
METH modulates VMAT2 function by altering the subcellular distribution of
VMAT2 protein in the presynaptic terminal.

c. METH at MAO

Under physiological conditions, cytosolic DA is rapidly metabolized into
DOPAC by MAO. In addition to the redistribution of DA into the cytosol from
vesicular stores, AMPH inhibits the enzymatic activity of MAO in the cytosol (Fig
4; Mantle et al., 1976). AMPH is a competitive and reversible low affinity inhibitor
of MAO (Sulzer et al., 2005). Thus, in the presence of AMPH, DA is not
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metabolized into DOPAC in the cytosol. The increased DA in the cytosol is
available for reverse transport through DAT. AMPH itself is not a substrate for
MAO oxidation (Sulzer et al., 2005).

d. METH on DA synthesis

In addition to the ability of AMPH to increase cytosolic DA concentrations
by redistributing DA from vesicles and inhibiting MAO, AMPH also increases
synaptosomal DA synthesis (Sulzer et al., 2005). Using radiolabeled tyrosine,
AMPH was demonstrated to exacerbate TH enzymatic activity to increase DA
biosynthesis (Kuczenski, 1975). Interestingly, the AMPH-induced increase in DA
biosynthesis was found in striatum, but not in the nucleus accumbens or olfactory
tubercle, suggesting regional specific modulation of TH activity (Demarest et al.,
1983). In addition to inhibiting DA uptake into vesicles, releasing DA from
vesicles and inhibiting DA metabolism by MAO, AMPH increases DA synthesis to
increase cytosolic DA concentrations available for reverse transport, which can
lead to AMPH-induced neurotoxicity.

V. METH-induced neurotoxicity

Acute and repeated METH use is characterized by a decrease in
behavioral and cognitive functions, as well as deficits in attention, memory and
decision making (Krasnova and Cadet, 2009). These neurological changes are
thought to be mediated in part through the neurotoxic effect of METH on
monoamine signaling.
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Utilizing neuroimaging techniques as well as other assays, the neurotoxic
effects of METH have been shown in numerous animal models (monkeys, rats,
and mice) and in humans studies. Both acute and high doses of METH have
been shown to decrease DA, 5-HT and NE levels in the striatum, cortex, nucleus
accumbens, and hippocampus in monkeys and rodents (Seiden et al., 1976,
Kogan et al., 1976; Ricaurte et al., 1980; Bakhit et al., 1981; Fumagalli et al.,
1998; Graham et al., 2008). A similar decrease in monoamine levels was
observed in autopsied brains of human METH users (Wilson et al., 1996;
Moxzczynska et al., 2004). Decreases in DAT and SERT levels following METH
administration were also observed in both animal models and humans (Wagner
et al., 1980; Fumagalli et al., 1999; Melega et al., 2000; Armstrong and Noguchi,
2004; Volkow et al., 2001; Sekine et al., 2003). In addition to changes in plasma
membrane transporters, decreases in VMAT2 function and immunoreactivity
were observed following METH administration (Riddle et al., 2002; Guilarte et al.,
2003; Segal et al., 2005; Eyerman and Yamamoto 2005, 2007). METH also
decreases DA and 5-HT synthesis, as evidenced by decreases in TH and
tryptophan hydroxylase activity in rodents and humans (Seiden et al., 1976;
Hotchkiss et al., 1979; Wilson et al., 1996). Thus, METH mediates numerous
changes in monoamine neuron function, significantly altering neuronal signaling.

DA and oxidative stress plays an important role in METH-induced
neurotoxicity (Cadet and Krasnova, 2009). The importance of DA in METHinduced neurotoxicity is demonstrated by experimental results showing that αmethyl-p-tyrosine (AMPT), which decreases DA synthesis, protects against
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METH-neurotoxicity (Krasnova and Cadet, 2009). Further, heterozygous VMAT2
KO mice exhibit exacerbated METH-induced neurotoxicity compared to WT mice,
as evidenced by prolific DA neurodegeneration and significant decreases in DA,
DOPAC, and DAT levels in the brain (Fumagalli et al., 1999; Guillot et al., 2008).
These studies provide support for the importance of DA in METH-induced
neurotoxicity and the important role VMAT2 plays to prevent the neurotoxic
effects of METH by sequestering DA into vesicles.

METH acts to increase cytosolic and extracellular DA concentrations, as
previously discussed above. Cytosolic DA is rapidly auto-oxidized to form DA
quinones, leading to the production of superoxide radicals and hydrogen
peroxides (Krasnova and Cadet, 2009). Further, DA metabolism into DOPAC by
MAO also produces hydrogen peroxides which can lead to the generation of
reactive oxygen species (ROS) causing oxidative stress in the neuron. Due to
the lack of free electrons, hydrogen peroxide does not have an oxygen radical,
but readily interacts with metal ions such as iron, leading to the production of
highly toxic hydroxyl radicals (Cadet and Brannock, 1998). Hydroxyl radicals are
very reactive and can cause damage to nucleic acids, amino acids in proteins
and phospholipids, damaging lipid membranes (Cadet and Brannock, 1998).
Moreover, METH has been shown to decrease levels of antioxidants and free
radical scavengers in DA neurons, limiting the ability of DA neurons to decrease
oxidative stress (Yamamoto et al., 2010).
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In addition to oxidative stress, METH has also been shown to induce
neuronal damage through an excitotoxic mechanism. METH administration
increases glutamate release in the striatum (Nash and Yamamoto, 1992).
Increased glutamate signaling increases intracellular calcium, which stimulates
the activity of calcium-dependent enzymes to produce free radicals and nitric
oxide (Yamamoto et al, 2010). Nitric oxide reacts with superoxide radicals to form
peroxynitrite, which damages DNA and proteins (Krasnova and Cadet, 2009).
Nitric oxide and peroxynitrite have also been shown to activate apoptotic
pathways leading to neuronal death and impairment of mitochondrial and
endoplasmic reticulum function (Yamamoto et al., 2010).

An important aspect of METH-induced neurotoxicity is the effect of METH
on body and brain temperature. High doses of METH induce hyperthermia and
this increase in temperature is associated with an increase in striatal DA content
depletion (Bowyer et al., 1994). Support for the role of hyperthermia is provided
by results showing that high doses of METH administered in a cold environment
did not decrease striatal DA levels, while METH treatment at normal room
temperatures significantly decreased DA levels (Ali et al., 1994). Hyperthermia is
proposed to increase ROS formation and glutamate neurotransmission, both
leading to oxidative stress and neuronal damage (Yamamoto et al., 2010).
Drugs such as AMPT, MK-801, and 2-deoxyglucose attenuate the neurotoxic
effects of METH through the ability to attenuate METH-induced hyperthermia
(McCann and Ricaurte, 2004). Further, hyperthermia plays a role in METHinduced increases in blood-brain barrier (BBB) damage (Bowyer and Ali, 2006).
39

METH-induced BBB damage then can lead to neuronal damage and
degeneration as well as enhanced vulnerability to environmental toxins and
infections (Krasnova and Cadet, 2009; Cadet and Krasnova, 2009; Yamamoto et
al., 2010)

VI. Treatment Options for METH abuse
a. Cognitive and Behavioral Therapy

Currently there are no approved medications to treat METH abuse. Thus,
cognitive and behavioral therapy is vital for the treatment of METH abuse.
Cognitive and behavioral therapy (CBT) employs learning and conditioning in
aiding METH abstinence (Lee and Rawson, 2008). While different forms of CBT
exists, CBT employs self- and group-help that integrate several intervention
techniques such as providing information and assistance on use cessation as
well as withdrawal and depression symptoms in an effort to prevent relapse
(Rawson et al., 2002; Baker et al., 2005; Lee and Rawson, 2008). Contingency
management (CM) is a behavioral therapy aimed at reducing METH use by
providing positive reinforcement in exchange for drug abstinence (Prendergast et
al., 2006; Roll et al., 2006). This behavioral technique is similar to operant
conditioning in that performance of a behavioral task (drug abstinence in this
situation) results in the delivery of a reward. Positive reinforcement is usually in
the form of a monetary reward. CM has exhibited moderate effectiveness in
reducing METH use (Shoptaw et al., 2006; Roll, 2007). In addition to METH, CM
therapies have been used in promoting abstinence from multiple drugs such as
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cocaine, nicotine, alcohol, opiates and marijuana (Prendergast et al., 2006).
Despite the limited success of CBT and CM, behavioral therapies are not
efficacious universally (Vocci and Appel, 2007). Thus, the development of
pharmacological treatment strategies would be highly beneficial in the treatment
of METH abuse.

b. Plasma Membrane Transporters as a Therapeutic Target

METH elicits its rewarding effects, in part, through an interaction with DAT,
as previously discussed above. As such, numerous studies have focused on
monoamine transporters in the development of pharmacotherapies to treat
METH abuse. The antidepressant, buproprion inhibits DA and NE uptake
through DAT and NET, and represents an effective therapy in nicotine cessation
(Richmond and Zwar, 2003). By increasing monoamine levels, buproprion is
hypothesized to alleviate withdrawal symptoms associated with METH
abstinence (Karila et al., 2010). Initial clinical studies showed that buproprion
attenuates cue-induced cravings for METH (Newton et al., 2006). Despite this
decrease in METH cravings, buproprion was not effective in reducing METH use
following a 12-week treatment program (Shoptaw et al., 2008; Karila et al., 2010).

In a manner similar to buproprion, methylphenidate (MPD) was
hypothesized to be efficacious in treating METH abuse. MPD is a “goldstandard” treatment for childhood attention deficit hyperactivity disorder (ADHD;
Patrick et al., 2005). MPD inhibits DA and NE uptake through DAT and NET
inhibition to increase extracellular monoamine concentrations. While the effect of
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MPD is similar to that of cocaine, MPD exhibits decreased abuse liability due to
different pharmacokinetic properties (Volkow et al., 1999; Yano and Steiner,
2007). Initial clinical trials examining the effect of MPD on AMPH abuse showed
that MPD was efficacious in reducing intravenous AMPH use in patients with
severe AMPH dependence (Tiihonen et al., 2007).

In addition to DAT and NET inhibitors, selective serotonin reuptake
inhibitors (SSRIs) have been proposed as treatments for METH abuse. As
discussed previously, METH interacts with SERT to increase extracellular 5-HT
concentrations. Considering the role that SSRIs play in mood stabilization and
the treatment of depression, the use of SSRIs in the treatment of withdrawalassociated depression is warranted (Karila et al., 2010). SSRIs have also been
shown to alter DA signaling. Studies measuring the electrical activity of DA
neurons showed that SSRIs such as sertaline, paroxetine and fluvoxamine
inhibited DA firing rates and dopaminergic function (Di Mascio et al. 1998).
Further, studies utilizing KO mice showed that SERT is involved in the rewarding
effects of psychostimulants. Psychostimulants produced rewarding effects in
DAT KO mice, but did not produce reward in mice deficient in both DAT and
SERT, suggesting a role of SERT in the rewarding effects of psychostimulants
(Rocha et al., 1998; Sora et al., 2001). Consistent with this hypothesis,
fluoxetine, a SSRI, attenuated METH conditioned place preference and METHinduced locomotor sensitization (Takamatsu et al., 2006). Clinical trials
determining the ability of fluoxetine to treat METH abuse revealed that fluoxetine
failed to demonstrate efficacy in attenuating METH use (Karila et al., 2010).
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Preliminary clinical studies with paroxetine found that paroxetine treatment
reduced METH-associated cravings (Piasecki et al., 2002). Future studies will be
needed to determine the efficacy of SSRIs in the treatment of METH
dependence.

c. DA receptors as therapeutic targets

Modulation of DA receptors has been proposed as a potential treatment
strategy for METH abuse (Karilla et al., 2010). Risperidone, an atypical
antipsychotic, acts as a D2 and 5-HT2a receptor antagonist and has been shown
to improve cognitive function (Meredith et al., 2009). Clinical trials examining the
efficacy of risperidone in the treatment of METH dependence were recently
conducted and results indicated that risperidone was well tolerated and
associated with a decrease in METH use and an increase in cognition and
memory in METH users (Meredith et al., 2009). These results are promising but
further studies are needed to determine the efficacy of risperidone in the
treatment of METH abuse.

In addition to D2 receptor antagonists, D2 receptor partial agonists are
proposed to be efficacious in the treatment of METH abuse. The idea behind the
use of D2 partial agonism in METH dependence focuses on the dual use of
partial agonists to increase DA signaling during METH abstinence (when
withdrawal symptoms are present) and to act as an antagonist on D2 receptors
when METH is used (relapse; Lile et al., 2005). Initial clinical trials determining
the efficacy of aripiprazole, a D2 and 5-HT1a partial agonist, in AMPH
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dependence showed that ariprazole decreased the subjective effects of AMPH
(Lile et al., 2005; Stoops et al., 2006). Results from more recent clinical trials
with aripiprazole in the treatment of METH and AMPH dependence have shown
that aripiprazole exacerbated METH-related cravings and increased AMPH use
compared to placebo groups (Tiihonen et al., 2007; Newton et al., 2008). In
contrast to ealier studies, the recent results suggest that aripiprazole increases
METH cravings leading to increased use. While the subjective effects play an
important role in predicting drug use, many other factors are involved in the
manifestation of drug abuse. Thus, future studies to determine the utility of
apiprazole as a pharmacotherapy for METH abuse are needed.

d. 5-HT receptors as therapeutic targets

5-HT increases DA release in NAc, prefrontal cortex, striatum and VTA
through an interaction with 5-HT1 and 5-HT3 receptors (Guan and McBride, 1989;
Arborelius et al., 1993; Benloucif et al., 1993; Parsons and Justice, 1993; Prisco
et al., 1994). Thus, modulation of 5-HT signaling through 5-HT receptor
antagonism could inhibit the effects of METH by decreasing DA release (Vocci
and Appel, 2007; Karilla et al., 2010). Consistent with this hypothesis,
mirtazapine, a 5-HT3 and 5-HT2a receptor antagonist, decreased METH-induced
conditioned place preference, METH behavioral sensitization and cue-induced
responding for METH in rats (McDaid et al., 2007; Herrold et al., 2009; Graves
and Napier, 2011). However, clinical trials determining the effect of mirtazapine
for the treatment of METH withdrawal symptoms failed to show efficacy

44

compared to placebo (Cruickshank et al., 2008). Even though mirtazapine did
not affect METH withdrawal symptoms, future studies determining the effect of
mirtazapine and other modulators of 5-HT neurotransmission on METH use
should be investigated. In addition to importance of 5-HT in depression and
mood balance as part of potential withdrawal symptoms, 5-HT also modulates
DA signaling and could be a viable target for the development for treatments of
METH abuse.

Ondansetron, a 5-HT3 receptor antagonist has also been hypothesized to
inhibit the rewarding effects of METH. Ondansetron, co-administered with DA
agonist, pergolide inhibited METH-induced behavioral sensitization and METHinduced reinstatement in rats (Davidson et al., 2007). Moreover, ondansetron
was shown to attenuate METH-induced reductions in food intake in mice (Ginawi
et al., 2005). Clinical trials determining the efficacy of ondansetron in the
treatment of METH dependence failed to reveal a significant effect of
ondansetron to attenuate METH use or withdrawal symptoms (Johnson et al.,
2008).

e. GABA neurotransmitter system as a therapeutic target

gamma-Aminobutyric acid (GABA) is an inhibitory neurotransmitter in the
brain primarily functioning to modulate neuronal excitability (Cooper et al., 2003).
GABA interacts with GABA receptors in the brain which are comprised of GABA A
receptors that act as ligand gated ion channels, and GABAB receptors, which act
as metabotrophic G-protein coupled receptors. GABAA receptor activation leads
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to the opening of Cl- channels, while GABAB receptor activation leads to the
opening of K+ channels, resulting in hyperpolarization of the cell membrane and a
decrease in neuronal firing (Cooper et al., 2003). DA neurons in the ventral
palladium receive GABA inputs from the NAc which play an important role drug
reward and abuse (Zahm et al., 1985; Koob, 1992; Bardo, 1998). Specifically,
activation of GABA receptors in the ventral palladium decreases DA release and
signaling (Gong et al., 1998). Thus, by decreasing DA neurotransmission,
modulation of GABA neurotransmission could attenuate the reinforcing effects of
abused drugs. Consistent with this hypothesis, GABA receptor agonists have
been used in the treatment of cocaine, heroin, nicotine, METH, and alcohol
(Cousins et al., 2000; Vocci and Appel, 2007; Karila et al., 2010). Baclofen, a
GABAB receptor agonist, decreased AMPH-induced increases in extracellular DA
in the NAc and decreased AMPH self-administration in rats (Brebner et al.,
2005). Further, baclofen improved METH-induced decreases in memory and
cognition (Arai et al., 2008, 2009). Gabapentin, a nonselective GABA receptor
agonist, attenuated METH-induced hyperlocomotion, conditioned place
preference and behavioral sensitization (Itzhak and Martin, 2000; Kurokawa et
al., 2011). Clinical trials however, revealed that baclofen and gabapentin were
not effacious in decreasing METH use (Heinzerling et al., 2006). Vigabatrin
(gamma-vinyl-GABA) increases GABA transmission through inhibition of GABA
metabolism by GABA transaminase (Gerasimov et al., 1999). Vigabatrin
pretreatment inhibited METH-induced increases in NAc DA release and
reinstatement of METH-induced conditioned place preference (Gerasimov et al.,
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1999; DeMarco et al., 2008). Results from clinical trials revealed that vigabatrin
decreased METH use in METH-dependent users (Brodie et al., 2004). Thus,
GABA neurotransmission may represent a useful therapeutic target in developing
pharmacotherapies for METH abuse.

f. Acetylcholine neurotransmitter system as a therapeutic target

Acetylcholine (ACh) is a neurotransmitter involved in both the central and
peripheral nervous systems (Cooper et al., 2003). In the peripheral nervous
system, ACh functions to regulate the autonomic nervous system activity and
skeletal muscle contraction. In the central nervous system, ACh is important in
reward, learning, and memory (Miwa et al., 2011). Removal of cholinergic
neurons in NAc by immunotoxin treatment decreased ACh signaling in the NAc,
leading to an increase in the rewarding effects of cocaine (Hikida et al., 2001).
Thus, an increase in ACh signaling is hypothesized to decrease the rewarding
effects of psychostimulants (Karila et al., 2010). Cholinesterase inhibitors such
as donepezil and rivastigmine inhibit acetylcholinesterase, the enzyme
responsible for the degradation of acetylcholine, to increase the action of
acetylcholine. Donepezil treatment attenuated cue- and drug-induced METH
reinstatement in rats (Hiranita et al., 2006). Preliminary clinical trials examining
the effects of rivastigmine on METH users revealed that rivastigmine reduced
METH-induced increases in blood pressure as well as METH-induced cravings in
METH users (De la Garza et al., 2008). Additional clinical trials are needed to
determine the effectiveness of cholinesterase inhibitors for the treatment of
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METH, but preliminary reports suggest a possible clinical benefit in the treatment
of METH abuse (Karila et al. 2010).

g. Opioid receptors as therapeutic targets

Opioid receptors are G-protein coupled receptors found in the CNS and
gastrointestinal tract, consisting of three main receptor subtypes (µ, δ, κ; Dhawan
et al., 1996). Opioid receptors are involved in pain and interact with endogenous
peptides such as enkephalins, dynorphins and endorphins, as well as other
agonists such as morphine, sufentanil, and fentanyl (Dhawan et al., 1996).
Antagonists such as naltrexone and naloxene inhibit the action of opioid peptides
and stimulation by opioid receptor agonists (Dhawan et al., 1996). Morphine and
endogenous opiates interact with opioid receptors to increase extracellular DA
release in the NAc, leading to reward and abuse (Koob et al., 1998). Opioid
receptors are also involved in psychostimulant reward and reinforcement (Chiu et
al., 2006). Naltrexone pretreatment attenuated AMPH-induced increases in
locomotor activity, and naloxone pretreatment decreased AMPH conditioned
place preference (Trujillo et al., 1991; Balcells-Olivero and Vezina, 1997).
Further, naltrexone treatment inhibited METH-induced behavioral sensitization in
mice and cue-induced METH reinstatement in rats trained to self-administer
METH (Chiu et al., 2005; Anggardiredja et al., 2004). Clinical trials report that
naltrexone decreased the subjective effects of AMPH (Jayaram-Lindstrom et al.,
2004). More recent results revealed that naltrexone decreased AMPH use and
cravings in AMPH users (Jayaram-Lindstrom et al., 2008). Thus, antagonism of
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opioid receptors may represent an effective therapeutic target in the treatment of
METH abuse.

h. VMAT2 as therapeutic target

VMAT2 represents a primary target in the mechanism of action of METH
(Sulzer et al., 2005). METH inhibits DA uptake at VMAT2 and promotes DA
release from vesicles to increase cytosolic DA. Thus, pharmacological agents
that modulate VMAT2 function or act to redistribute DA from presynaptic
vesicles, thereby limiting vesicular and cytosolic DA available for METH-induced
reverse transport, may be efficacious for the treatment of METH. Consistent with
this hypothesis, VMAT2 heterzygous KO mice showed decreased AMPHinduced conditioned place preference (Takahashi et al., 1997). Further, VMAT2
inhibition by TBZ pretreatment decreased METH-induced hyperactivity (Kuribara,
1997). However, additional studies examining the effects of TBZ on METH have
shown that high doses of TBZ nonspecifically inhibited METH self-administration
in rats, while low doses increased METH self-administration (Meyer et al., 2011).
Nevertheless, VMAT2 inhibition may represent a novel therapeutic target for the
development of pharmacotherapies to treat METH abuse.

VII.

Lobeline
a. Background and Historical Uses

(-)-Lobeline (2R,6S,10S-lobeline; Fig. 1) is the principal alkaloid found in
Lobelia inflata, a biannual or annual flowering plant grown primarily in Eastern
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North America. The herb was named after famous French botanist, Matthias de
Lobel (Felpin and Lebreton, 2004). While the entire plant is harvested and used
in the extraction of alkaloids, the seeds contain the highest percent of the
alkaloid, lobeline (Krochmal and Krochmal, 1973; Dwoskin and Crooks, 2002).
Lobelia has also been called “Indian tobacco” because Native Americans used to
chew and smoke the dried leaves of lobelia to obtain the CNS effects of the
alkaloids (Millspaugh et al., 1974) Lobelia is also known as “puke weed”,
“gagroot”, and “vomit wort” presumably from its emetic side effects. While the
species of plant was identified by Linneaus in 1741, Lobelia was not used
medicinally until its introduction in 1813 for its use in the treatment of asthma by
the botanic physician, Reverend D. Cutler (Millspaugh, 1974). In addition to the
respiratory stimulant effects used for the treatment of asthma, Lobelia extracts
have historically been used as an expectorant, emetic, anti-spamodic, diuretic
and muscle relaxant (Dwoskin and Crooks, 2002).

Lobeline is the most biologically active alkaloid of more than 20 alkaloids
found in Lobelia (Felpin and Lebreton, 2004). Structurally, lobeline is
characterized by a central piperdine ring with two phenylethyl side chains
attached at the 2- and 6-positions of the piperdine ring. Lobeline possesses a
hydroxyl moiety on the 8-position and a keto moiety on the 10-position of the
phenylethyl side chains. Lobeline has three chiral centers, at the 8-position on
the side chain and the 2- and 6-positions of the piperdine ring.
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The first known therapeutic use of lobeline was the treatment of asthma
due to the powerful respiratory stimulant effect of lobeline (King et al., 1928). In
addition to the respiratory stimulant effects, lobeline has been shown to offer
expectorant benefits (Felpin and Lebreton, 2004). Due to these effects, lobeline
has been used in treatment of pneumonia, whooping cough, bronchitis, and
asphyxsia from narcotic, morphine, and alcohol poisoning (Dwoskin and Crooks,
2002). In addition, lobeline has also been tested for potential benefits as a
smoking cessation agent. The earliest use of lobeline as a smoking cessation
agent was shown in 1936 (Dorsey, 1936). Numerous pharmacological agents
containing lobeline, such as CigArest, Nicoban, NicFit, Bantron and Smoker’s
Choice have been used as smoking cessation aids, but were deemed ineffective
by the FDA (Felpin and Lebreton, 2004). Results from numerous clinical trials
have shown that lobeline is not effective as a smoking cessation agent (Stead
and Hughes, 2000). One potential reason for the ineffectiveness of lobeline as a
smoking cessation agent is its poor bioavailability (Schneider and Olsson, 1996).
As such, sublingual formulations of lobeline have been tested for their efficacy in
attenuating nicotine use (Glover et al., 2010). Results from these studies
however, demonstrated that lobeline is ineffective as a smoking cessation agent.

b. Pharmacology

While lobeline and nicotine are not structurally similar, they exhibit many
similar effects. Lobeline interacts with the autonomic ganglia, producing various
sympathetic and parasympathetic effects. Lobeline induces tachycardia and
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hypertension, as well as increased salivation and gastric mobility (Dwoskin and
Crooks, 2002). Lobeline acts at the emetic center in the CNS and directly
irritates the gastrointestinal tract causing nausea and vomiting (Felpin and
Lebreton, 2004). In addition, lobeline has been shown to improve learning and
memory in rats, as well as improve performance in sustained attention tasks
(Decker et al., 1993; Brioni et al., 1993; Terry et al., 1996).

Lobeline exhibits its nicotine-like effects through interactions with nicotinic
acetylcholine receptors (nAChRs). Lobeline exhibits high affinity (Ki = 4 nM) at
α4β2* nAChRs (* indicates putative nAChR assignment), as probed by
[3H]nicotine binding studies (Damaj et al., 1997). Unlike nicotine, repeated
exposure to lobeline does not result in an upregulation of α4β2* nAChRs (Bhat et
al., 1991). Further, studies have shown that lobeline acts as an antagonist at
α4β2* nAChRs as lobeline inhibits nicotine-evoked Rb+ efflux from rat thalamic
synaptosomes (Miller et al., 2000). Lobeline also displaces
[3H]methyllycaconitine (MLA) binding (Ki = 11.6 µM), suggesting an interaction
with α7* nAChRs (Miller et al., 2004). Further, functional studies utilizing
Xenopus oocytes demonstrated that lobeline was an antagonist at α7* nAChRs
(Briggs and McKenna, 1998). In addition to antagonism at α4β2* and α7*
nAChRs, lobeline also inhibits nicotine-evoked [3H]NE release from cultured fetal
rat locus coeruleus cells, suggesting antagonism at α3β4* nAChRs. Lobeline has
also been shown to antagonize nAChRs mediating nicotine-evoked DA release,
as lobeline inhibits nicotine-evoked [3H]DA release from striatal slices (Miller et
al., 2000). While the exact nAChR subunits responsible for nicotine-evoked DA
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release are controversial, several nAChR subtypes are proposed to be involved
including α4β2*, α6β2*, α4α6β2*, and α6β3β2* (Champtiaux et al., 2003;
Salminen et al., 2004). Lobeline also evokes [3H]DA and [3H]NE release from
striatal and hippocampal slices, respectively; however release was not mediated
by nAChRs, as release was not sensitive to the noncompetitive nAChR
antagonist, mecamylamine (Clarke and Reuben, 1996; Kiss et al., 2001).

In addition to an interaction at nAChRs, lobeline also interacts with VMAT2
(Fig 5). Lobeline inhibits [3H]DTBZ binding in whole brain homogenates and
[3H]DA uptake in striatal vesicles with similar potency (IC50 ~ 0.9 µM; Teng et al.,
1997, 1998). Lobeline also inhibits [3H]DA uptake at DAT (IC50 = 80 µM),
exhibiting 90-fold higher potency at VMAT2 compared to DAT (Teng et al.,1997).
In addition to the inhibition of DA uptake at VMAT2, lobeline also releases [3H]DA
from preloaded synaptic vesicles (Nickell et al., 2011). Similar to METH, lobeline
interacts with VMAT2 to redistribute DA from vesicles, increasing cytosolic DA
concentrations. Unlike METH, however, lobeline does not inhibit MAO, as high
concentrations of lobeline evoked DOPAC overflow, rather than DA (Teng et al.,
1997). Lobeline redistributes DA from synaptic vesicles into the cytosol where it
can then be metabolized by MAO into DOPAC, limiting the DA available for
METH-induced reverse transport. Thus, due to the interaction with VMAT2,
lobeline has been proposed to inhibit the neurochemical effects of METH
(Dwoskin and Crooks, 2002). Consistent with this hypothesis, lobeline inhibited
AMPH-evoked DA release from striatal slices in the same concentration range
that lobeline interacted with VMAT2 (0.1 -1 µM; Miller et al., 2001). In respect to
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behavioral experiments, lobeline pretreatment attenuated AMPH- and METHinduced hyperlocomotor activity and the discriminative stimulus effects of METH
in rats (Miller et al., 2001). Further, lobeline decreased METH self-administration
in rats and this inhibition was not surmounted by increasing concentrations of
METH (Harrod et al., 2001). Importantly, lobeline is predicted to have low abuse
liability, as lobeline is not self-administered and does not produce conditioned
place preference in rats (Fudala and Iwamoto, 1986; Harrod et al., 2003). Based
upon these preclinical findings, lobeline is currently undergoing clinical trials to
determine effectiveness as a pharmacotherapy for METH abuse. Results from
recently completed Phase Ib clinical trials demonstrated that sublingual lobeline
was safe in METH addicted individuals (Jones et al, 2007). Despite these
encouraging results, some problems with lobeline exist. The half-life of lobeline
is relatively short however (~50 min), requiring multiple dosings (Miller et al.,
2003). Further, lobeline interacts with multiple targets in the CNS such as
nAChRs. Thus, recent focus has been on the development of lobeline analogs
with better pharmacokinetic profiles and increased selectivity for VMAT2.

c. meso-Transdiene

meso-Transdiene (MTD) is a defunctionalized (i.e. keto and hydroxyl
moieties removed), unsaturated analog of lobeline (Fig 1; Zheng et al., 2005a).
MTD exhibited low affinity for α4β2* and α7* nAChRs, as probed by [ 3H]nicotine
and [3H]MLA binding (Ki >100 µM for both subtypes; Miller et al., 2004). These
results suggest that the hydroxyl and keto groups on the phenyethyl side chains
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are important for potent nAChR binding affinity. Compared with lobeline, MTD
was found to exhibit similar affinity for the [3H]DTBZ binding site and [3H]DA
uptake site on VMAT2 (Ki = 9.88 and 0.54 µM, respectively; Zheng et al., 2005a;
Nickell et al., 2010). Unfortunately, MTD exhibited high affinity for DAT (Ki = 0.58
µM), which has been associated with a potential for abuse liability (Miller et al.,
2004). MTD inhibited METH-evoked DA overflow from rat striatal slices with
potency not different from lobeline (IC50 = 0.44 and 0.42 µM, respectively; Nickell
et al., 2010). Interestingly, MTD exhibited ~20% greater inhibitory activity
compared to lobeline in inhibiting METH-evoked DA release (Imax = 76.3 and
56.1%, respectively; Nickell et al., 2010). The ability of MTD to decrease METH
self-administration is unknown. Unfortunately, chemical defunctionalization
decreased the water solubility of MTD compared to lobeline.

d. Lobelane

Lobelane is a defunctionalized, saturated analog of lobeline (Fig 1; Zheng
et al., 2005a). Similar to MTD, lobelane exhibits low affinity for α4β2* and α7*
nAChRs, as probed by [3H]nicotine and [3H]MLA binding (Ki = 77.3 and 43.1 µM,
respectively; Miller et al., 2004). Lobelane exhibits affinity for [3H]DTBZ binding
(Ki = 0.97 µM) not different from lobeline (Zheng et al., 2005a). Interestingly,
lobelane exhibits increased potency to inhibit [3H]DA uptake at VMAT2 (Ki =
0.045 µM) compared to lobeline (Nickell et al., 2010). Compared to lobeline,
lobelane exhibited higher affinity for DAT (Ki = 1.57 µM; Nickell et al., 2010).
Lobelane inhibited METH-evoked DA release with potency not different from
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lobeline (IC50 = 0.65; Nickell et al., 2010). Similar to MTD, lobelane exhibited
~20% greater inhibitory activity compared to lobeline in inhibiting METH-evoked
DA release (Imax = 76.3 and 56.1%, respectively; Nickell et al., 2010). Further,
lobelane pretreatment dose-dependently decreased METH self-administration in
rats; however tolerance developed to this behavioral effect after repeated
dosings (Neugebauer et al., 2007). Similar to MTD, chemical defunctionalization
resulted in decreased water solubility compared to lobeline.

VIII.

Hypothesis and Specific Aims

The purpose of the current research is to identify analogs of MTD and
lobelane with improved selectivity for inhibition of VMAT2 function, in an effort to
develop pharmacotherapies for METH abuse. This thesis describes the results
from an iterative drug discovery effort consisting of two sets of analogs, 3,5disubstituted MTD analogs and N-1,2-dihydroxypropyl (diol) lobelane analogs.
Results from initial structure activity relationships (SAR) determining the ability of
these analogs to interact with VMAT2, DAT, SERT, and nAChRs are reported.
The ability of the most VMAT2 selective analogs to inhibit METH-evoked DA
release was determined to select the lead analogs from each series (UKMH-106
and GZ-793A). In addition, mechanistic studies were conducted to further
identify the effect of GZ-793A on VMAT2 and METH-evoked DA release. Finally,
initial DA neurotoxicity evaluations were conducted with GZ-793A to determine
the effect of GZ-793A on DA content.
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The hypothesis of this thesis is that selective VMAT2 inhibition by lobeline
analogs will inhibit the effects of METH. The specific hypotheses and aims for
this project were:

Hypothesis 1: 3,5-Disubstituted MTD analogs inhibit VMAT2 function,
and VMAT2-selective MTD analogs inhibit METH-evoked DA release from
striatal slices.

Specific Aims:

1) Determine the ability of MTD to decrease METH self-administration in
rats.
2) Determine the selectivity of MTD analogs to inhibit VMAT2 function in
vitro.
3) Determine the ability of MTD analogs to inhibit METH-evoked DA
release in striatal slices in vitro.

Hypothesis 2: N-1,2-Diol analogs of lobelane inhibit VMAT2 function,
and VMAT2 selective analogs inhibit METH-evoked DA release from striatal
slices.

Specific Aims:

1) Determine the selectivity of N-1,2-diol analogs to inhibit VMAT2
function in vitro.
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2) Determine N-1,2-diol lobelane analogs to inhibit METH-evoked DA
release in striatal slices in vitro.

Hypothesis 3: GZ-793A interacts with VMAT2 to release DA from striatal
vesicles and inhibits METH-evoked DA release from striatal vesicles.

Specific Aims:

1) Determine the ability of GZ-793A to release DA from striatal vesicles in
vitro.
2) Determine the ability of GZ-793A to inhibit METH-evoked DA release
from striatal vesicles in vitro.

Hypothesis 4: VMAT2 inhibition by GZ-793A does not alter striatal DA
content and GZ-793A protects against METH-induced DA depletions in striatal
tissue and vesicles.

Specific Aims:

1) Determine the effect of acute and repeated GZ-793A on DA content in
striatal tissue and vesicle preparations.
2) Determine the effect of acute and repeated GZ-793A pretreatment on
acute and repeated METH-induced DA content depletion in striatal
tissue and vesicle preparations.
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Fig. 1. Chemical Structures (Chapter 1)
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Fig. 2. Sagittal view of rodent brain showing DA pathways (as indicated by solid
lines).
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Fig. 3. Schematic diagram of DA nerve terminal.
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Fig. 4. Schematic diagram of DA nerve terminal in the presence of
methamphetamine (METH).
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Fig. 5. Schematic diagram of DA nerve terminal in the presence of lobeline
(LOB).

Copyright © David B. Horton 2012
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CHAPTER TWO

MTD Analogs Inhibit VMAT2 Function and METH-evoked DA Release
Portions of this chapter have been published in the manuscript:
Horton DB, Siripurapu KB, Norrholm SD, Deaciuc AG, Hojahmat M, Culver JP,
Crooks PA, Dwoskin LP. Lobeline and meso-transdiene analogs:
interaction at neurotransmitter transporters and nicotinic receptors. J
Pharm Exp Ther, 336:940-951, 2011.

Chapter reprinted with permission of the American Society for Pharmacology and
Experimental Therapeutics. All rights reserved.

I.

Introduction
METH abuse is a serious public health concern (NSDUH, 2008).
Pharmacotherapies are not available to treat METH abuse. Efforts have focused
on the DAT as a therapeutic target (Dar et al., 2005; Howell et al., 2007; Tanda
et al., 2009), because METH interacts with DAT to increase extracellular DA
concentrations, leading to its reinforcing properties (Wise and Bozarth, 1987; Di
Chiara and Imperato, 1988; Di Chiara et al., 2004). DAT translocates DA from
the extracellular space into presynaptic terminals, whereas METH reverses DAT
translocation to increase DA extracellularly (Fischer and Cho, 1979; Liang and
Rutledge, 1982; Sulzer et al., 1995). This approach has not led to therapeutic
agents for METH abuse, although several DAT inhibitors currently are
undergoing clinical trials.
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A largely unexplored target of METH action is VMAT2. By interacting with
VMAT2, METH increases cytosolic DA concentrations available for translocation
by DAT to the extracellular compartment (Sulzer and Rayport, 1990; Sulzer et al.,
1995; Pifl et al., 1995). The current research focuses on the discovery of novel
compounds which interact with VMAT2 and inhibit the pharmacological effects of
METH. Lobeline, the major alkaloid of Lobelia inflata, inhibits VMAT2 function
(Teng et al., 1997, 1998), has high affinity for [3H]DTBZ binding sites on VMAT2
(Kilbourn et al., 1995; Miller et al., 2004) and decreases AMPH-evoked DA
release from rat striatal slices (Miller et al., 2001). However, lobeline is not
selective for VMAT2, acting as a nAChR antagonist with low affinity for DAT and
SERT (Damaj et al., 1997; Flammia et al., 1999; Miller et al., 2000, 2004).
Lobeline also decreases METH-induced hyperactivity, behavioral sensitization
and self-administration in rats (Harrod et al., 2001; Miller et al., 2001).
Importantly, lobeline is not self-administered, indicating lack of abuse liability
(Harrod et al., 2003). Based on these preclinical findings, lobeline is being
evaluated as a treatment for METH abuse. Initial Phase Ib clinical trials report
that lobeline is safe in METH addicts (Jones et al., 2007).
Lobeline has a central piperidine ring with phenyl rings attached at C-2
and C-6 of the piperidine ring by ethylene linkers containing hydroxyl and keto
functionalities at the C8 and C10 positions on the linkers, respectively (Fig. 6).
Potency and selectivity for VMAT2 were improved based on SARs, with the
emergence of two new lead compounds, i.e., lobelane and MTD (Zheng et al.,
2005a; Nickell et al., 2010). Lobelane is a lobeline analog with defunctionalized
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(hydroxyl and keto groups of lobeline eliminated from the linkers) and saturated
linkers. Subsequent reports described the preclinical evaluation of lobelane as
well as analogs based on the lobelane structural scaffold (Beckmann et al., 2010;
Nickell et al., 2011). MTD is a lobeline analog with defunctionalized and
unsaturated (double bonds) linkers (Fig. 6). Compared with lobeline, MTD was
found to exhibit similar affinity for the [3H]DTBZ binding site on VMAT2 and
decreased affinity for nAChRs, thus revealing increased selectivity for VMAT2
(Zheng et al., 2005a). Also, MTD inhibited METH-evoked DA overflow from rat
striatal slices (Nickell et al., 2010). However, MTD exhibited high affinity for DAT
(Miller et al., 2004), which has been associated with potential for abuse liability.
Furthermore, MTD has limited solubility, diminishing its potential for development
as a pharmacotherapy for METH abuse.
To extend the previous work, the current study determined if MTD
decreases METH self-administration in rats. The current SAR also identified
analogs based on the MTD scaffold that potently and selectively inhibit VMAT2
function, and had both low affinity for DAT and increased water solubility
compared to MTD. These analogs were designed as more rigid,
conformationally-restricted analogs of MTD, in which the phenylethylene
substituents in the MTD structure were incorporated into the piperidine ring
system (Fig. 7). This structural change reduces the molecular weight and the
number of rotational carbon bonds from four in MTD to two in the current
analogs. Other changes included: 1) altering the geometry of the C5 double
bond from E to Z; 2) lengthening the linker units at C3 and C5 of the piperidine
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ring; 3) adding aromatic substituents to the phenyl moieties; and 4) replacing the
phenyl rings with heteroaromatic rings, such as thiophene or furan. Affinity for
VMAT2 was retained despite these structural alterations, and importantly,
selectivity for VMAT2 was improved. These novel analogs were evaluated further
for their ability to inhibit METH-evoked DA release from superfused rat striatal
slices, and constitute new leads in the discovery of novel treatments for METH
abuse.
The hypothesis of this chapter is that 3,5-disubstituted MTD analogs will
inhibit VMAT2 function and VMAT2 selective MTD analogs will inhibit METHevoked DA release from striatal slices.
II.

Methods
IIa.

Animals. Male Sprague-Dawley rats (200–250 g, Harlan,

Indianapolis, IN) were housed two per cage with ad libitum access to food and
water in the Division of Laboratory Animal Resources at the University of
Kentucky (Lexington, KY). Experimental protocols involving the animals were in
accord with the 1996 NIH Guide for the Care and Use of Laboratory Animals and
were approved by the Institutional Animal Care and Use Committee at the
University of Kentucky.
IIb.

Chemicals. [3H]Nicotine (L-(-)-[N-methyl-3H]; specific activity, 66.9

Ci/mmol), [3H]dopamine ([3H]DA; dihydroxyphenylethylamine, 3,4-[7-3H]; specific
activity, 28 Ci/mmol), and [3H]5-hydroxytryptamine ([3H]5-HT; hydroxytryptamine
creatinine sulfate 5-[1,2-3H(N)]; specific activity, 30 Ci/mmol) and Microscint 20
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LSC-cocktail were purchased from PerkinElmer, Inc. (Boston, MA).
[3H]Dihydrotetrabenazine ([3H]DTBZ; (±)alpha-[O-methyl3

H]dihydrotetrabenazine; specific activity, 20 Ci/mmol) and [3H]methyllycaconitine

([3H]MLA; ([1,4(S),6β,14,16β]-20-ethyl-1,6,14,16-tetramethoxy-4-[[[2-([3-3H]methyl-2,5-dioxo-1-pyrrolidinyl)benzoyl]oxy]-methyl]aconitane-7,8-diol; specific
activity, 100 Ci/mmol) were obtained from American Radiolabled Chemicals, Inc.
(St. Louis, MO). Diazepam and ketamine were purchased from N.L.S. Animal
Health (Pittsburgh, PA). Acetonitrile, ATP-Mg2+, benzaldehyde, 2,4dichlorobenzaldehyde, 4-methoxybenzaldehyde, 4-methylbenzaldehyde, furan-2carbaldehyde, furan-3-carbaldehyde, trans-cinnamaldehyde, catechol, DA,
DOPAC, disodium ethylenediamine tetraacetate (EDTA), ethylene glycol
tetraacetate (EGTA), ethyl acetate, fluoxetine HCl, 1-(2-(bis-(4fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine (GBR 12909), α-Dglucose, N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES),
hexane, MgSO4, methanol, methylene chloride, 1-methyl-4-piperidone, pargyline
HCl, polyethyleneimine (PEI), KOH, potassium tartrate, sodium borohydride,
NaOH, Na2SO4, sucrose, silica gel (240-400 mesh), and trifluoroacetic acid were
purchased from Sigma-Aldrich, Inc. (St. Louis, MO). L-Ascorbic acid and
NaHCO3 were purchased from Aldrich Chemical Co. (Milwaukee, WI). CaCl2,
KCl, K2PO4, MgCl2, NaCl, and NaH2PO4 were purchased from Fisher Scientific
Co. (Pittsburgh, PA). Thiophene-2-carbaldehyde and thiophene-3-carbaldehyde
were purchased from Acros Organics USA (Morris Plains, NJ). Preparative TLC
plates (250 µM silica layer, organic binder, no indicator) were purchased from

68

Dynamic Adsorbents Inc. (Atlanta, GA). Chloroform-D was purchased from
Cambridge Isotope Laboratories, Inc. (Andover, MA). Complete counting cocktail
3a70B was purchased from Research Products International Corp. (Mount
Prospect, IL). (2R,3S,11bS)-2-Ethyl-3-isobutyl-9,10-dimethoxy-2,2,4,6,7,11bhexahydro-1H-pyrido[2,1-a]isoquinolin-2-ol (Ro-4-1284) was a generous gift from
Hoffman-LaRoche Inc. (Nutley, NJ).
IIc.

General Synthetic Methodology for the UKMH Analogs. A

mixture of 1-methyl-4-piperidone (1.0 eq, 10.2 mmol), the appropriately
substituted aromatic aldehyde (2.1 eq, 21.42 mmol), and potassium hydroxide
(2.1 eq, 21.42 mmol) were stirred in methanol (20 ml) at ambient temperature for
4 h. The resulting yellow precipitate was collected by filtration and washed with
cold methanol to yield the crude 3,5-disubstituted-1-methylpiperidin-4-one (9.179.83 mmol; 89.9-96.4% yield). Without further purification, the crude 3,5disubstituted-1-methylpiperidin-4-one product was added to a pre-equilibrated
mixture of sodium borohydride (4 eq.) and trifluoroacetic acid (16 eq.) in a 1:1
mixture of dichloromethane and acetonitrile. The mixture was stirred at ambient
temperature for 4-8 h until TLC and GC-MS analysis revealed that all of the
starting material was consumed. The reaction mixture was then diluted with
dichloromethane, and 2 M aqueous sodium hydroxide solution was added dropwise with stirring to afford a pH of 10. The organic layer was then separated,
dried over anhydrous sodium sulfate, filtered, and the filtrate evaporated to
dryness under vacuum. The reaction yielded a mixture of mainly the 3Z,5Z- and
3Z,5E-geometrical isomers of the 3,5-disubstituted-1-methylpiperidines, as well
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as other minor geometric double bond combinations; both these isomers could
be separated by silica gel column chromatography or by preparative TLC,
utilizing a 10:1 hexane:ethyl acetate solvent mixture. Utilizing this general
procedure, the UKMH series of analogs shown in Fig. 6 were prepared and fully
characterized for structural identity and purity, as determined by TLC, GC-MS, 1H
NMR and 13C NMR analysis.
IId.

METH Self-administration. Behavioral experiments were

conducted using previously described methods (Neugebauer et al., 2007).
Operant conditioning chambers (ENV-008, MED Assoc., St. Albans, VT) were
enclosed within sound-attenuating compartments (ENV-018M, MED Assoc.).
Each chamber was connected to a personal computer interface (SG-502, MED
Assoc.), and chambers were operated using MED-PC software. A 5  4.2 cm
recessed food tray was located on the response panel of each chamber. Two
retractable response levers were mounted on either side of the recessed food
tray (7.3 cm above metal rod floor). A 28V, 3-cm diameter, white cue light was
mounted 6 cm above each response lever.
Rats were trained briefly to respond on a lever for food reinforcement.
Immediately after food training, rats were allowed free access to food for 3 days.
Rats were anesthetized (100 mg/kg ketamine and 5 mg/kg diazepam, i.p.) and
catheters were implanted into the right jugular vein, exiting through a dental
acrylic head mount affixed to the skull via jeweler screws. Drug infusions were
administered i.v. (0.1 ml over 5.9 sec) via a syringe pump (PHM-100, MED
Assoc.) through a water-tight swivel attached to a 10 ml syringe via catheter
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tubing, which was attached to the cannulae mounted to the head of the rat.
Following a one-week recovery period from surgery, rats were trained to press
one of two levers for an infusion of METH (0.05 mg/kg/infusion). Each infusion
was followed by a 20-sec time out signaled by illumination of both lever lights.
The response requirement was gradually increased to a terminal fixed ratio 5 (FR
5) schedule of reinforcement. Each session was 60 min in duration. Training
continued until responding stabilized across sessions. Stable responding was
defined as less than 20% variability in the number of infusions earned across 3
successive sessions, a minimum of a 2:1 ratio of active (drug) lever responses to
inactive (no drug) lever responses, and at least 10 infusions per session. Once
stability was reached, an acute dose (0, 3.0, 5.6, 10 or 17 mg/kg) of MTD was
administered (s.c.) 15 min prior to the session according to a within-subject Latin
square design. Two maintenance sessions (i.e., no pretreatment) were included
between each test session to ensure stable responding throughout the
experiment.
IIe.

Food-Maintained Responding. Briefly, rats were trained to

respond on one lever (active lever) for food pellet reinforcement (45 mg pellets,
BIO-SERV, #F0021, Frenchtown, NJ), while responses on the other lever
(inactive lever) had no programmed consequence. Location (left or right) of the
active and inactive levers was counterbalanced across rats. The response
requirement was gradually increased, terminating at an FR 5. Following lever
training, a 20-sec signaled time out (illumination of both lever lights) was included
following each pellet delivery. Time out following each pellet delivery was
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instituted to be consistent with the METH self-administration procedure. Each
food-reinforced session lasted 60 min. Training continued until responding
stabilized across sessions. Stable responding was defined as less than 20%
variability in the number of pellets earned across 3 successive sessions, and a
minimum of a 2:1 ratio of active lever responses to inactive lever responses.
After the stability criteria were reached, an acute dose of MTD (17 mg/kg) was
administered (s.c.) 15 min prior to the 60-min session. Two maintenance
sessions (i.e., no pretreatment) were included between test sessions to ensure
stable responding throughout the experiment.
IIf.

[3H]Nicotine and [3H]MLA Binding Assays. Analog-induced

inhibition of [3H]nicotine and [3H]MLA binding was determined using published
methods (Miller et al., 2004). Whole brain, excluding cortex and cerebellum, was
homogenized using a Tekmar polytron (Tekmar-Dohrmann, Mason, OH) in 20
volume of ice-cold modified Krebs’-HEPES buffer, containing: 2 mM HEPES,
14.4 mM NaCl, 0.15 mM KCl, 0.2 mM CaCl2·2H2O and 0.1 mM MgSO4·7H2O, pH
7.5. Homogenates were centrifuged at 31,000 g for 17 min at 4 oC (Avanti J-301
centrifuge, Beckman Coulter, Fullerton, CA). Pellets were resuspended by
sonication (Vibra Cell, Sonics & Materials Inc, Danbury, CT) in 20 volumes of
Krebs’-HEPES buffer and incubated at 37 oC for 10 min (Reciprocal Shaking
Bath Model 50, Precision Scientific, Chicago, IL). Suspensions were centrifuged
using the above conditions. Resulting pellets were resuspended by sonication in
20 volumes buffer and centrifuged at 31,000 g for 17 min at 4 oC. Final pellets
were stored in incubation buffer, containing: 40 mM HEPES, 288 mM NaCl, 3.0
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mM KCl, 4.0 mM CaCl2·2H2O, and 2.0 mM MgSO4·7H2O, pH 7.5. Membrane
suspensions (100-140 µg protein/100 µl) were added to duplicate wells
containing 50 µl analog (7-9 concentrations, 1 nM – 0.1 mM, final concentration
in assay buffer), 50 µl of buffer, and 50 µl of [3H]nicotine or [3H]MLA (3 nM; final
concentration) for a final volume of 250 µl, and incubated for 1 h at room
temperature. Nonspecific binding was determined in the presence of 10 µM
cytisine or 10 µM nicotine for the [3H]nicotine and [3H]MLA assays, respectively.
Reactions were terminated by harvesting samples on Unifilter-96 GF/B filter
plates presoaked in 0.5% PEI using a Packard Filter Mate Harvester (Perkin
Elmer, Inc.). Samples were washed 3 times with 350 l of ice-cold buffer. Filter
plates were dried for 60 min at 45 oC, bottom-sealed and each well filled with 40
l of Microscint 20 cocktail. Bound radioactivity was determined via liquid
scintillation spectmometry (TopCount NXT scintillation counter; PerkinElmer,
Inc.).
IIg.

Synaptosomal [3H]DA and [3H]5-HT Uptake Assays. Analog-

induced inhibition of [3H]DA and [3H]5-HT uptake into rat striatal and hippocampal
synaptosomes, respectively, was determined using modifications of a previously
described method (Teng et al., 1997). Brain regions were homogenized in 20 ml
of ice-cold 0.32 M sucrose solution containing 5 mM NaHCO3 (pH 7.4) with 16
up-and-down strokes of a Teflon pestle homogenizer (clearance ~ 0.005”).
Homogenates were centrifuged at 2,000 g for 10 min at 4 °C, and resulting
supernatants centrifuged at 20,000 g for 17 min at 4 °C. Pellets were
resuspended in 1.5 ml of Krebs’ buffer, containing: 125 mM NaCl, 5 mM KCl, 1.5
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mM MgSO4, 1.25 mM CaCl2, 1.5 mM KH2PO4, 10 mM α-D-glucose, 25 mM
HEPES, 0.1 mM EDTA, with 0.1 mM pargyline and 0.1 mM ascorbic acid
saturated with 95% O2 /5% CO2, pH 7.4). Synaptosomal suspensions (20 µg
protein/50 µl) were added to duplicate tubes containing 50 µl analog (7-9
concentrations, 0.1 nM – 1 mM, final concentration in assay buffer) and 350 µl of
buffer and incubated at 34 °C for 5 min in a total volume of 450 µl. Samples were
placed on ice and 50 µl of [3H]DA or [3H]5-HT (10 nM; final concentration), was
added to each tube for a final volume of 500 µl. Reactions proceeded for 10 min
at 34°C and were terminated by the addition of 3 ml of ice-cold Krebs’ buffer.
Nonspecific [3H]DA and [3H]5-HT uptake were determined in the presence of 10
µM GBR 12909 and 10 µM fluoxetine, respectively. Samples were rapidly
filtered through Whatman GF/B filters using a cell harvester (MP-43RS; Brandel
Inc.). Filters were washed 3 times with 4 ml of ice-cold Krebs’ buffer containing
catechol (1 μM). Complete counting cocktail was added to the filters and
radioactivity determined by liquid scintillation spectrometry (B1600 TR scintillation
counter; PerkinElmer, Inc.).
IIh.

[3H]DTBZ Vesicular Binding Assays. Analog-induced inhibition

of [3H]DTBZ binding, a high affinity ligand for VMAT2, was determined using
modifications of a previously published method (Teng et al., 1998). Rat whole
brain (excluding cerebellum) was homogenized in 20 ml of ice-cold 0.32 M
sucrose solution with 10 up-and-down strokes of a Teflon pestle homogenizer
(clearance ~ 0.008”). Homogenates were centrifuged at 1,000g for 12 min at 4 °C
and resulting supernatants were centrifuged at 22,000g for 10 min at 4 °C.
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Resulting pellets were osmotically shocked by incubation in 18 ml of cold water
for 5 min. Osmolarity was restored by adding 2 ml of 25 mM HEPES and 100
mM potassium tartrate solution. Samples were centrifuged (20,000g for 20 min at
4°C), and then 1 mM MgSO4 solution was added to the supernatants. Samples
were centrifuged at 100,000g for 45 min at 4°C. Pellets were resuspended in
cold assay buffer, containing: 25 mM HEPES, 100 mM potassium tartrate, 5 mM
MgSO4, 0.1 mM EDTA, and 0.05 mM EGTA, pH 7.5. Assays were performed in
duplicate in 96-well plates. Vesicular suspensions (15 µg protein/100 µl) were
added to wells containing 50 µl analog (7-9 concentrations, 0.01 nM – 0.1 mM,
final concentration in assay buffer), 50 µl of buffer, and 50 µl of [3H]DTBZ (3 nM;
final concentration) for a final volume of 250 µl and incubated for 1 hr at room
temperature. Nonspecific uptake was determined in the presence of 50 µl of 20
µM Ro-4-1284. Reactions were terminated by filtration onto Unifilter-96 GF/B
filter plates (presoaked in 0.5% PEI). Filters were washed 3 times with 350 µl of
ice-cold buffer, containing: 25 mM HEPES, 100 mM potassium-tartrate, 5 mM
MgSO4, and 10 mM NaCl, pH 7.5. Filter plates were dried, bottom-sealed and
each well filled with 40 µl of scintillation cocktail (MicroScint 20; PerkinElmer,
Inc.). Radioactivity on the filters was determined by liquid scintillation
spectrometry.
IIi.

Vesicular [3H]DA Uptake Assay. Analog-induced inhibition of

[3H]DA uptake into rat striatal vesicles was determined using modifications of a
previously published method (Teng et al., 1997). Previous reports from our
laboratory show that this vesicle preparation contains <1% contaminating
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membrane fragments (Teng et al., 1997). Striata were homogenized in 14 ml of
ice-cold 0.32 M sucrose solution containing 5 mM NaHCO3 (pH 7.4) with 10 upand-down strokes of a Teflon pestle homogenizer (clearance ~ 0.008”).
Homogenates were centrifuged at 2,000 g for 10 min at 4 °C and resulting
supernatants centrifuged at 10,000 g for 30 min at 4 °C. Pellets were
resuspended in 2.0 ml of 0.32 M sucrose and were transferred to tubes
containing 7 ml of milliQ water and homogenized with 5 up-and-down strokes.
Homogenates were transferred to tubes containing 900 μl of 0.25 M HEPES and
900 μl of 1.0 M potassium tartrate solution and centrifuged at 20,000 g for 20 min
at 4 ºC. Resulting supernatants were centrifuged at 55,000 g for 60 min at 4 ºC.
Subsequently, 100 μl of 1 mM MgSO4, 100 μl of 0.25 M HEPES and 100 μl of 1.0
M potassium tartrate were added to the supernatant and centrifuged at 100,000 g
for 45 min at 4 ºC. Final pellets were resuspended in assay buffer, containing: 25
mM HEPES, 100 mM potassium tartrate, 50 μM EGTA, 100 μM EDTA, and 1.7
mM ascorbic acid, 2 mM ATP-Mg2+, pH 7.4. Vesicular suspensions (10 µg
protein/100 µl) were added to duplicate tubes containing 50 µl analog (7-9
concentrations, 1 nM – 0.1 mM, final concentration in assay buffer), 300 µl of
buffer, and 50 µl of [3H]DA (0.1 µM; final concentration) for a final volume of 500
µl and incubated for 8 min at 34 °C. Nonspecific [3H]DA uptake was determined
in the presence of 10 µM Ro-4-1284. Samples were filtered rapidly through
Whatman GF/B filters using the cell harvester and washed 3 times with assay
buffer containing 2 mM MgSO4 in the absence of ATP. Radioactivity retained by
the filters was determined as previously described.
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IIj.

Kinetics of Vesicular [3H]DA Uptake. Vesicle suspensions were

prepared as described above; striata were pooled from 2 rats. Vesicular
suspensions (20 µg protein/50 µl) were added to duplicate tubes containing 25 µl
analog (final concentration approximating the Ki), 150 µl of buffer, and 25 µl of
[3H]DA (1 nM – 5 μM; final concentration) for a final volume of 250 µl, and
incubated for 8 min at 34 °C. Nonspecific [3H]DA uptake was determined in
samples containing 10 µM Ro4-1284. Samples were processed as previously
described.
IIk.

Endogenous DA Release Assay. HPLC-EC determination of DA

release was performed by Kiran Siripurapu, Ph.D.. Rat coronal striatal slices (0.5
mm thick) were prepared and incubated in Krebs’ buffer, containing: 118 mM
NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 1.0 mM NaH2PO4, 1.3 mM CaCl2, 11.1 mM D-glucose, 25 mM NaHCO3, 0.11 mM L-ascorbic acid and 0.004 mM EDTA, pH
7.4, saturated with 95% O2/5% CO2 at 34 ºC in a metabolic shaker for 60 min
(Teng et al., 1997). Each slice was transferred to a glass superfusion chamber
and superfused at 1 ml/min for 60 min with Krebs’ buffer before sample
collection. Two basal samples (1 ml) were collected at 5-min and 10-min time
points. Each slice was superfused for 30 min in the absence or presence of a
single concentration of analog (0.1 -10 M) to determine analog-evoked DA and
DOPAC overflow, and remained in the buffer until the end of the experiment.
METH (5 M) was added to the buffer after 30 min of superfusion, and slices
were superfused for 15 min, followed by 20 min of superfusion in the absence of
METH. In each experiment, a striatal slice was superfused for 90 min in the
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absence of both analog and METH, serving as the buffer control condition. In
each experiment, duplicate slices were superfused with METH in the absence of
analog, serving as the METH control condition. The concentration of METH was
selected based on pilot concentration-response data showing a reliable response
of sufficient magnitude to allow evaluation of analog-induced inhibition. Each
superfusate sample (1 ml) was collected into tubes containing 100 l of 0.1 M
perchloric acid. Prior to HPLC-EC analysis, ascorbate oxidase (20 µl, 168 U/mg
reconstituted to 81 U /ml) was added to 500 µl of each sample and vortexed for
30 s, and 100 µl of the resulting solution injected onto the HPLC-EC.
The HPLC-EC consisted of a pump (model 126 Beckman Coulter, Inc,
Fullerton, CA) and autosampler (model 508 Beckman Coulter, Inc), an ODS
Ultrasphere C18 reverse-phase 80 × 4.6 mm, 3-µm column and a Coulometric-II
detector with guard cell (model 5020) maintained at +0.60 V and analytical cell
(model 5011) maintained at potentials E1 = -0.05 V and E2 = +0.32 V (ESA Inc.,
Chelmsford, MA). HPLC mobile phase (flow rate, 1.5 ml/min) was 0.07 M
citrate/0.1 M acetate buffer pH 4, containing: 175 mg/l octylsulfonic acid sodium
salt, 650 mg/l NaCl and 7% methanol. Separations were performed at room
temperature, and 5-6 min was required to process each sample. Retention times
of DA or DOPAC standards were used to identify respective peaks. Peak
heights were used to quantify the detected amounts of analyte based on
standard curves. Detection limit for DA and DOPAC was 1-2 pg/100 µl.
IIl.

Data Analysis. For the behavioral experiments, one-way ANOVA

with dose as a within-subject factor was used to determine if MTD altered METH
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self-administration. Dunnett’s post-hoc tests were used to compare each MTD
dose to the saline control. A single paired-sample t-test was used to determine
the effects of MTD on food-maintained behavior.
For the neurochemical experiments, specific [3H]nicotine, [3H]MLA and
[3H]DTBZ binding and specific [3H]DA and [3H]5-HT uptake were determined by
subtracting the nonspecific binding or uptake from the total binding or uptake.
Analog concentrations producing 50% inhibition of specific binding or uptake
(IC50 values) were determined from concentration effect curves via an iterative
curve-fitting program (Prism 5.0; GraphPad Software Inc., San Diego, CA).
Inhibition constants (Ki values) were determined using the Cheng-Prusoff
equation (Cheng and Prusoff, 1973). For kinetic analyses, Km and Vmax were
determined using one-site binding curves. Paired two-tailed t-tests were
performed on the arithmetic Vmax and the log Km values to determine significant
differences between analog and control conditions. Pearson’s correlation
analysis determined the relationship between affinity for the [3H]DTBZ binding
site and vesicular [3H]DA uptake.
For endogenous neurotransmitter release assays, fractional release was
defined as the DA or DOPAC concentration in each sample divided by the slice
weight. Basal DA or DOPAC outflow was calculated as the average fractional
release of the two basal samples collected 10 min prior to addition of analog to
the buffer. Analog-evoked DA or DOPAC overflow was calculated as the
average fractional release during the 30 min period of analog exposure prior to
METH addition to the buffer. Analog-evoked DA or DOPAC overflow was
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analyzed by one-way repeated-measures ANOVA. Time course for analoginduced inhibition of METH-evoked fractional DA or DOPAC release was
analyzed by two-way ANOVA with concentration and time as repeated-measures
factors. If a concentration x time interaction was found, one-way ANOVAs were
performed at each time point at which METH-evoked DA release above basal
outflow. When appropriate, one-way ANOVAs were followed by Dunnett’s post
hoc test to determine concentrations of analog that decreased METH-evoked DA
fractional release. Furthermore, one-way ANOVA was performed on the peak
response of METH-evoked fractional release at each analog concentration. The
log IC50 value was generated using an iterative nonlinear least squares curvefitting program (PRISM version 5.0). Statistical significance was defined as p <
0.05.
III.

Results
IIIa.

MTD decreases METH self-administration without altering

food-maintained responding. The effect of MTD on METH self-administration
is illustrated in Fig. 8 (top panel). One-way ANOVA revealed a dose-related
effect of MTD on the number of METH infusions earned (F4,16 = 4.86, p < 0.05).
Dunnett’s test revealed that the high dose of MTD (17 mg/kg) decreased the
number of METH infusions earned compared to control. Tolerance developed to
the ability of MTD to decrease METH self-administration on the second day of
treatment. The effect of the acute high dose of MTD (17 mg/kg) on foodmaintained responding is illustrated in Fig. 8 (bottom panel). MTD did not
decrease responding for food (p = 0.414). Thus, the high dose of MTD
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specifically decreased METH self-administration; however, tolerance developed
to this effect.
IIIb.

MTD analogs do not inhibit [3H]nicotine and [3H]MLA binding.

Concentration-response curves and Ki values for lobeline, MTD, and the series of
MTD analogs to inhibit [3H]nicotine and [3H]MLA binding to whole brain
membranes, compared with nicotine (positive control), are provided in Fig 9 (top
and bottom panels, respecitively) and Table 1. Ki values for nicotine were 3 nM
and 370 nM at the [3H]nicotine and [3H]MLA binding sites, respectively,
consistent with previous reports (Flammia et al., 1999). Ki values for lobeline
were 4 nM and 6.26 µM at the [3H]nicotine and [3H]MLA binding sites,
respectively, also consistent with previous reports (Zheng et al., 2005a). Ki
values for MTD were >100 µM at both [3H]nicotine and [3H]MLA binding sites, as
previously observed (Miller et al., 2004). None of the MTD analogs in this series
inhibited [3H]nicotine or [3H]MLA binding.
IIIc.

MTD analogs inhibit synaptosomal [3H]DA uptake.

Concentration-response curves and Ki values for lobeline, MTD, and the series of
MTD analogs to inhibit [3H]DA uptake into striatal synaptosomes, compared with
GBR 12909 (positive control), are provided in Fig. 10 and Table 1. The Ki value
for GBR 12909 to inhibit [3H]DA uptake was 0.97 nM, consistent with previous
reports (Reith et al., 1994). The Ki value for lobeline to inhibit [3H]DA uptake was
28.2 µM, whereas the defunctionalized unsaturated compound MTD exhibited a
200-fold higher potency (Ki = 100 nM) compared to lobeline, in agreement with
previous observations (Miller et al., 2004). MTD analogs in the current series
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exhibited 50-1000-fold lower potency (Ki > 5 µM) than MTD at DAT. Of note, the
2,4-dichlorophenyl analogs, UKMH-105 and UKMH-106, exhibited 60-fold lower
potency (Ki = 6.27 and 6.90 μM, respectively) than MTD. Thus, this series of
MTD analogs exhibited lower affinities for DAT compared to the parent
compound.

IIId.

MTD analogs inhibit synaptosomal [3H]5-HT uptake.

Concentration-response curves and Ki values for lobeline, MTD, and the series of
MTD analogs to inhibit [3H]5-HT uptake into hippocampal synaptosomes,
compared with fluoxetine (positive control), are provided in Fig. 11 and Table 1.
The Ki value for fluoxetine to inhibit [3H]5-HT uptake was 6.5 nM, consistent with
previous reports (Owens, 2001). The Ki value for lobeline to inhibit [3H]5-HT
uptake was 46.8 µM, whereas MTD exhibited 6-fold higher potency (Ki = 7 µM)
compared to lobeline, in agreement with previous observations (Miller et al.,
2004). The majority of the MTD analogs had Ki values not different from MTD; of
note, the 2,4-dichlorophenyl analogs, UKMH-105 and UKMH-106, exhibited low
potency at SERT (Ki = 18.3 and 20.7 μM, respectively). Exceptions include
UKMH-101 (no phenyl substituents), UKMH-107 (a 4-methoxyphenyl analog),
UKMH-108 (a 4-methylphenyl analog), and UKMH-112 (a 3-furanyl analog),
which exhibited 10-fold higher potency at SERT compared to MTD.
IIIe.

MTD analogs inhibit [3H]DTBZ binding at VMAT2.

Concentration-response curves and Ki values for lobeline, MTD, and the series of
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MTD analogs to inhibit [3H]DTBZ binding to whole brain membranes, compared
with Ro-4-1284 (positive control), are provided in Fig. 12 and Table 1. The Ki
value for Ro-4-1284 to inhibit [3H]DTBZ binding was 28 nM, consistent with a
previous report (Cesura et al., 1990). The Ki value for lobeline to inhibit
[3H]DTBZ binding was 2.04 µM, whereas MTD exhibited a 5-fold lower potency
(Ki = 9.88 nM) compared to lobeline, consistent with previous observations
(Zheng et al., 2005a). The majority of analogs in the series were equipotent
inhibiting [3H]DTBZ binding compared with MTD (Table 1). An exception was
UKMH-109 (2-thiophenyl analog), which exhibited 10-fold lower potency at the
[3H]DTBZ binding site compared to MTD. Of note, UKMH-105 and UKMH-106,
the 2,4-dichlorophenyl double bond isomers, exhibited geometrically specific
inhibition of [3H]DTBZ binding (Ki = 4.60 and 41.3 μM, respectively).
IIIf.

MTD analogs inhibit [3H]DA uptake by VMAT2. Concentration-

response curves and Ki values for lobeline, MTD, and the series of MTD analogs
to inhibit [3H]DA uptake into striatal vesicles, compared with Ro-4-1284 (positive
control), are provided in Fig. 13 and Table 1. The Ki value for Ro-4-1284 to
inhibit [3H]DA uptake was 18 nM, consistent with a previous report (Nickell et al.,
2011). The Ki value for lobeline to inhibit [3H]DA uptake by VMAT2 was 1.27 µM,
which was not different from that for MTD (Ki = 0.46 µM), consistent with previous
observations (Nickell et al., 2010). The majority of the analogs in this series were
equipotent with MTD inhibiting [3H]DA uptake at VMAT2 (Table 1). Of note, the
2,4-dichlorophenyl isomers, UKMH-105 and UKMH-106, were two of the most
potent analogs in the series, with Ki values of 0.22 and 0.32 µM, respectively.
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Fig. 14 illustrates Ki values for inhibition of vesicular [3H]DA uptake as a
function of Ki for inhibition of [3H]DTBZ binding for lobeline, MTD and the series
of MTD analogs. Correlation analysis revealed no relationship between these
parameters probing VMAT2 (Pearson’s correlation coefficient r = 0.42, p = 0.13).
IIIg.

UKMH-105 and UKMH-106 competitively inhibit [3H]DA uptake

at VMAT2. UKMH-105 and UKMH-106 were 20- to 450-fold selective for VMAT2
over DAT, SERT and 4β2* and 7* nAChRs. UKMH-105 and UKMH-106 had
10- to 100-fold higher affinity in the VMAT2 functional assay compared with the
VMAT2 binding assay. To further evaluate these two analogs, kinetic analyses of
[3H]DA uptake at VMAT2 were conducted to determine the mechanism of
inhibition, i.e., competitive or noncompetitive, compared with parent compounds
(MTD and lobeline). Kinetic assays revealed an increased Km value and no
change in Vmax for each compound (Fig. 15) compared to control, indicating a
competitive mechanism of action.
IIIh.

UKMH-106 inhibits METH-evoked endogenous DA release,

while UKMH-105 does not. The ability of UKMH-105 and UKMH-106 to evoke
DA release from superfused striatal slices is illustrated in Figs. 16 and 17.
Analysis of the effect of UKMH-105 on DA release prior to the addition of METH
to the buffer (20-40 min of sample collection) showed no main effects of
concentration (F5,29 = 0.47, p > 0.05) and time (F4,29 = 1.01, p > 0.05), and no
concentration x time interaction (F20,29 = 0.67, p > 0.05). Thus, UKMH-105 alone
did not evoke DA release. Similarly, UKMH-106 did not alter DA release (no
main effect of concentration (F4,43 = 0.12, p > 0.05) and showed no time x
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concentration interaction (F16,43 = 1.57, p > 0.05)). A main effect of time was
found (F4,43 = 6.78, p < 0.05), revealing that fractional release increased slightly
across the 20 min exposure period in both the absence and presence of UKMH106. Both UKMH-105 and UKMH-106 also had no effect on DOPAC fractional
release across the time period (Fig. 18).
The ability of UKMH-105 and UKMH-106 to decrease METH-evoked DA
release is illustrated also in Figs. 16 and 17. A two-way repeated measures
ANOVA on fractional DA release during exposure to UKMH-105 and METH
revealed no main effect of concentration (F5,29 = 0.65, p > 0.05) and no
concentration x time interaction (F25,29 = 0.45, p > 0.05); however, a main effect
of time (F5,29 = 15.4, p < 0.0001) was observed, which reflects the increase in
fractional release evoked by METH in the absence and presence of UKMH-105.
Similar results were obtained with DOPAC, although in the absence and
presence of UKMH-105, DOPAC fractional release was decreased in response
to METH (Fig. 18). Thus, UKMH-105 did not alter the effect of METH on DA or
DOPAC fractional release.
In a concentration-dependent manner, UKMH-106 decreased METHevoked DA release (Fig. 17). Two-way repeated-measures ANOVA on fractional
DA release during exposure to UKMH-106 and METH revealed a main effect of
concentration (F4,43 = 7.61, p < 0.0001) and time (F5,43 = 23.0, p < 0.0001), and a
concentration x time interaction (F20,43 = 1.68, p < 0.05). Post hoc analysis
revealed that, UKMH-106 (1.0 and 3.0 µM) decreased METH-evoked DA release
compared to control at 50-55 min and 50-60 min, respectively. The
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concentration response for UKMH-106 to inhibit METH-evoked DA release at
peak response is illustrated also in Fig 17. IC50 and Imax values were 0.38 ±
0.13 µM and 50.2 ± 15.5%, respectively. One-way ANOVA on peak response
data revealed a concentration-dependent effect of UKMH-106 (F4,43 = 3.11, p <
0.05). Post hoc analysis revealed that 3 µM UKMH-106 inhibited the DA peak
response. In contrast to the ability of UKMH-106 to decrease METH-evoked
fractional DA release, fractional DOPAC release was not altered (Fig. 18).

IV.

Discussion
In the current study, MTD was shown to decrease METH self-

administration specifically, but only at the highest dose evaluated, and tolerance
developed rapidly to this effect. Taking into account this encouraging finding, but
tempered by the limitations associated with the development of tolerance,
modifications to the MTD molecule were evaluated in search of preclinical
candidates for the treatment of METH abuse. SAR identified several
conformationally-restricted MTD analogs with high affinity and selectivity for
VMAT2. Structural modifications included lengthening the linker units,
introduction of 4-methoxy, 4-methyl, or 2,4-dichloro substituents into the phenyl
rings, or replacement of the phenyl rings with thiophene or furan rings. Effects of
altering the geometry of the double bond at the C5-position of the piperidine ring
were evaluated in analogs with either a lengthened linker unit or an aromatic 2,4dichloro substituted phenyl ring. Affinity for VMAT2 was retained, and increases
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in selectivity for VMAT2 over DAT were found. The most selective analogs
inhibited METH-evoked DA release in a geometrically specific manner.
Conformational restriction in combination with both E and Z geometries at
the C5 position of the piperidine ring (UKMH-101 and UKMH-102, respectively)
did not alter affinity for VMAT2 binding and uptake sites. Lengthening the linker
units, regardless of E or Z geometry (UKMH-103 and UKMH-104, respectively),
or adding aromatic 4-methoxy or 4-methyl substituents (UKMH-107 and UKMH108, respectively), did not alter VMAT2 binding and function. Adding aromatic
electron-withdrawing 2,4-dichloro groups in combination with E or Z geometries
at the C5-postion on the piperidine ring (UKMH-105 and UKMH-106,
respectively) afforded equipotent inhibition of uptake compared to MTD. In
kinetic analyses, UKMH-105 and UKMH-106 increased Km, and did not alter
Vmax, indicating competitive inhibition of DA uptake. Although no differences in
affinity for VMAT2 uptake sites were observed, geometrically-specific inhibition of
[3H]DTBZ binding was observed. Specifically, UKMH-106 (3Z, 5Z geometry)
had 10-fold lower affinity than UKMH-105 (3Z, 5E geometry) at the [3H]DTBZ
binding site. In contrast, double bond geometry was not a contributing factor to
affinity for VMAT2 binding or uptake in analogs (UKMH-101 and UKMH-102) with
no phenyl ring substituents, or analogs (UKMH-103 and UKMH-104) with
lengthened linker units and no phenyl ring substituents. While E geometry was
better tolerated than Z geometry at the VMAT2 binding site, double bond
geometry was not a factor for affinity at the VMAT2 uptake site.
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Substitution of the phenyl rings with thiophene or furan moieties afforded
analogs with equipotent or 10-fold lower affinity for VMAT2 binding and uptake
sites, compared with MTD. Position of the heteroaromatic ring was a factor
influencing affinity. Specifically, 3-substituted analogs were equipotent at VMAT2
binding and uptake sites compared with MTD, whereas 2-substituted analogs
exhibited 10-fold lower potency. These results suggest that VMAT2 can
accommodate analogs in which furanyl and thiophenyl rings have been
substituted for phenyl rings, with the 3-position better tolerated than the 2position.
The current results provide examples of structural modifications that
dissociate affinity for the VMAT2 binding site from that for the VMAT2 substrate
site and support previous observations showing a lack of correlation between
affinities for these sites (Nickell et al., 2011). The best examples from the current
series of analogs are the 2,4-dichlorophenyl analogs (UKMH-105 and UKMH106) which were equipotent at the VMAT2 uptake site, yet exhibited a 10-fold
difference in affinity at the binding site. Thus, these findings support an
interaction at two alternate sites on VMAT2 associated with distinct
pharmacophores.
One goal was to discover MTD analogs with greater selectivity for VMAT2
over DAT. MTD had low affinity (Ki>100 μM) at α4β2* and α7* nAChRs, and
inhibited DA uptake by DAT (Ki=500 nM) and 5-HT uptake by SERT (Ki=8.9 µM;
Miller et al., 2004). Psychostimulant-induced inhibition of DAT function resulted
in increases in extracellular DA, leading to reward and abuse (Ritz et al., 1987;
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Williams and Galli, 2006). Affinity of MTD for DAT (Ki=100 nM; current study) is
similar to that for cocaine and methylphenidate (Ki=300 and 100 nM,
respectively; Han and Gu, 2006), suggesting that MTD may have abuse liability.
Reducing affinity for DAT is imperative to avoiding abuse liability. Analogs in the
current series had reduced affinity (50-1000-fold) at DAT compared to MTD.
Substitution of the phenyl rings with 3-thiophenyl and 3-furanyl rings resulted in
the greatest decreases in DAT affinity. Thus, the current analogs have increased
selectivity for VMAT2 over DAT, compared to MTD, and would be predicted to
have reduced abuse liability.
Since MTD had moderate affinity for SERT (Miller et al., 2004), affinity of
the MTD analogs for SERT also was evaluated. Introduction of aromatic 4methoxy or 4-methyl substituents into the phenyl rings of MTD resulted in a 5-10fold increased affinity for SERT compared with MTD. The remaining structural
changes to MTD did not alter affinity at SERT compared with MTD.
Since the 2,4-dichlorophenyl analogs, UKMH-105 and UKMH-106,
exhibited high affinity and selectivity for inhibiting VMAT2 function, these
compounds were evaluated for their ability to decrease METH-evoked DA
release. Alone, these analogs did not evoke DA release. UKMH-106, but not
UKMH-105, inhibited METH-evoked DA release. Inhibition of DA uptake by the
analogs at the VMAT2 substrate site does not explain the C5 Z-selective
inhibition of the effect of METH on VMAT2. UKMH-105 and UKMH-106
equipotently inhibited DA uptake by VMAT2, but exhibited C5 Z-selective
inhibition of METH-evoked DA release, suggesting that these two geometrical
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isomers interact with different sites on VMAT2 to inhibit DA uptake and METHevoked DA release. Only, the Z double bond geometry at the C5 position of the
piperidine ring (UKMH-106) was tolerated by the DA release site, whereas the
DA uptake site also tolerated the C5 E geometry (UKMH-105). Thus, the VMAT2
site mediating METH-evoked DA release is restricted in its ability to
accommodate both geometrical isomers compared to the VMAT2 uptake site.
While the mechanism by which METH releases DA from synaptic vesicles
is not understood fully, potential mechanisms include weak base effects of
METH, which disrupt vesicular proton gradients and METH effects at the VMAT2
substrate site (Sulzer et al., 2005). Although having different double bond
geometries, UKMH-105 and UKMH-106 are expected to have comparable pKa’s,
inconsistent with the weak base hypothesis as an explanation for differential
effects in decreasing METH-evoked DA release. However, current observations
are consistent with a previous report showing differential effects of the AMPH
optical isomers (Arnold et al., 1977; Fisher and Cho, 1979), despite having the
identical pKa’s, which again does not support the weak base hypothesis (Sulzer
et al., 2005). Thus, UKMH-106 may inhibit METH-evoked DA release through an
interaction with VMAT2 and not via a weak-base mechanism.
One caveat of the current study is that inhibitory effects of the analogs on
DA uptake and METH-evoked DA release were evaluated using different
preparations, isolated vesicles and more intact slices, respectively. One
alternative is that the analogs may inhibit METH-evoked DA release by
interacting with DAT in the slice. Cytosolic DA is transported to the extracellular
90

compartment through a METH-induced reversal of DAT (Fischer and Cho, 1979).
However, UKMH-106 inhibited METH-evoked DA release 18-fold more potently
than inhibition of DAT function, making it unlikely that inhibition of DAT is
responsible for the decrease in METH-evoked DA release. If inhibition of DAT
was responsible, then both UKMH-105 and UKMH-106 would be expected to
decrease METH-evoked DA release, since they are equipotent inhibiting DAT.
A concern regarding the approach of developing VMAT2 inhibitors as
treatments for METH abuse is the potential for neurotoxicity, as increased
cytosolic DA levels can lead to oxidative stress. METH, inhibits DA uptake at
VMAT2, promotes DA release from vesicles, inhibits monoamine oxidase, and
produces DA deficits due to increased formation of reactive oxygen species
(Fleckenstein et al., 2007). To the contrary, lobeline protects against METHinduced neurotoxicity (Eyerman and Yamamoto, 2005). Further, METH-addicted
individuals given lobeline in phase II clinical trials exhibited no adverse effects
(Jones, 2007), and TBZ (a classical VMAT2 inhibitor) is FDA-approved for the
treatment of Huntington’s chorea (Frank, 2010). Thus, precedent for the clinical
use of VMAT2 inhibitors exists. Nevertheless, evaluation of the potential
neurotoxicity of these analogs using animal models will be an integral component
of the drug development process for these candidate treatments for METH
abuse.
In summary, the current results extend our previous research by showing
that MTD decreases METH self-administration without altering food-maintained
responding, demonstrating that inhibition of VMAT2 function translates to a
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promising behavioral result. However, MTD has relatively low water solubility,
diminishing drug-likeness, and has high affinity (100 nM) for DAT, which may
result in abuse liability. Current results show that incorporation of the
phenylethylene moiety of MTD into the piperidine ring system, and the addition of
aromatic dichloro substituents, results in a novel candidate compound, UKMH106, which has improved water-solubility and reduced affinity for DAT, SERT,
and nAChRs, thereby increasing selectivity for VMAT2. Moreover UKMH-106
decreased the effect of METH to evoke DA release. Thus, the current research
utilizing a classical pharmacological approach has identified a novel lead
compound that shows promise as a pharmacotherapy to treat METH abuse, a
devastating problem for which there are no available treatments.
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Table 1. Affinity values (Ki) of MTD analogs, lobeline, MTD and standard
compounds for nicotinic receptors, DAT, SERT, and VMAT2 binding and

Compound

[3H]Nicotine
Binding
Ki ± SEM
(μM)

[3H]MLA
Binding
Ki ± SEM
(μM)

DAT
[3H]DA
Uptake
Ki ± SEM
(μM)

SERT
[3H]5-HT
Uptake
Ki ± SEM
(μM)

VMAT2
[3H]DTBZ
Binding
Ki ± SEM
(μM)

VMAT2
[3H]DA
Uptake
Ki ± SEM
(μM)

Nicotine

0.003 ±
0.0002 a

0.37 ± 0.08
a

NDb

NDb

NDb

NDb

GBR 12909

NDb

NDb

0.00097 ±
0.0001 a

ND

ND

ND

Fluoxetine

ND

ND

ND

0.0065 ±
0.0001 a

ND

ND

Ro-4-1284

ND

ND

ND

ND

0.028 ±
0.003 a

0.018 ±
0.002 a

6.26 ± 1.30

28.2 ± 6.73

46.8 ± 3.70

2.04 ± 0.26c

1.27 ± 0.46

>100d

0.10 ± 0.01

7.00 ± 1.30

9.88 ± 2.22c

0.46 ± 0.11

MTD

0.004 ±
0.0001
>100d

UKMH-101

>100

>100

11.5 ± 1.90

0.71 ± 0.09

31.8 ± 5.84

0.88 ± 0.19

UKMH-102

>100

>100

25.1 ± 2.93

1.37 ± 0.09

12.3 ± 4.70

0.22 ± 0.05

UKMH-103

>100

>100

16.2 ± 1.20

2.10 ± 0.51

20.3 ± 3.73

0.79 ± 0.18

UKMH-104

>100

>100

5.25 ± 0.46

2.67 ± 0.51

15.0 ± 5.22

0.88 ± 0.26

UKMH-105

>100

>100

6.27 ± 0.60

18.3 ± 7.50

4.60 ± 1.70

0.22 ± 0.01

UKMH-106

>100

>100

6.90 ± 1.10

20.7 ± 4.90

41.3 ± 14.3

0.32 ± 0.12

UKMH-107

>100

>100

68.2 ± 6.93

0.51 ± 0.05

7.27 ± 2.28

1.03 ± 0.19

UKMH-108

>100

>100

39.0 ± 16.3

0.61 ± 0.08

3.42 ± 0.26

0.33 ± 0.08

UKMH-109

>100

>100

>100

16.3 ± 4.10

91.3 ± 26.2

2.27 ± 1.13

UKMH-110

>100

>100

58.1 ± 18.7

13.4 ± 4.10

10.4 ± 2.62

0.36 ± 0.12

UKMH-111

>100

>100

>100

16.1 ± 2.91

32.6 ± 6.79

3.82 ± 1.99

UKMH-112

>100

>100

5.50 ± 0.26

0.71 ± 0.19

15.5 ± 1.61

0.58 ± 0.08

Lobeline

function.
a

b

c

d

n = 3-4 rats; ND, not determined; data taken from Zheng et al., 2005a; data taken from Miller et al.,
2001; (3Z,5E)-3,5-dibenzylidene-1-methylpiperidine (UKMH-101); (3Z,5Z)-3,5-dibenzylidene-1methylpiperidine (UKMH-102); [(3Z,5E)-1-methyl-3,5-bis((E)-3-phenylallylidene)piperidine (UKMH-103);
(3Z,5Z)-1-methyl-3,5-bis((E)-3-phenylallylidene)piperidine (UKMH-104); (3Z,5E)-3,5-bis(2,4dichlorobenzylidene)-1-methylpiperidine (UKMH-105); (3Z,5Z)-3,5-bis(2,4-dichlorobenzylidene)-1methylpiperidine (UKMH-106); (3Z,5Z)-3,5-bis(4-methoxybenzylidene)-1-methylpiperidine (UKMH-107);
(3Z,5Z)-1-methyl-3,5-bis(4-methylbenzylidene)-piperidine (UKMH-108); (3Z,5Z)-1-methyl-3,5-bis(thiophen-2ylmethylene)piperidine (UKMH-109); (3Z,5Z)-1-methyl-3,5-bis(thiophen-3-ylmethylene)piperidine (UKMH110); (3Z,5Z)-3,5-bis(furan-2-ylmethylene)-1-methylpiperidine (UKMH-111); (3Z,5Z)-3,5-bis(furan-3ylmethylene)-1-methylpiperidine (UKMH-112)

93

Fig. 6. Chemical structures of lobeline, MTD, and MTD analogs
incorporating the phenyethylene moiety of MTD into the piperidine ring
system with the addition of various phenyl ring substituents. For clarity of
presentation, compounds are grouped according to structural similarity. (top)
Lobeline, MTD and MTD analogs with no phenyl ring additions; (middle) MTD
analogs with dichloro, methoxy, or methyl additions; (bottom) MTD analogs with
heteroaromatic phenyl ring substitutions.
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Lobeline, meso-transdiene, and MTD analogs with no phenyl ring substituents
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Fig 7. Incorporating the phenylethylene moiety of MTD into the piperdine
ring of the analogs affords a novel more rigid molecule. For all analogs in
the series, the phenyethylene substituents in the MTD structure (left) were
incorporated into the piperidine ring system to afford analogs (right) with a similar
number of carbons between the piperidine nitrogen and the phenyl rings. This
structural change reduces the molecular weight and the number of rotational
carbon bonds (curved arrows) from four in MTD to two in the MTD analogs,
affording a novel, more conformationally-restricted structure.

N
N
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Fig 8. MTD decreases METH self-administration, however tolerance
develops to this effect. MTD does not alter food-maintained responding.
Effect of acute MTD (closed circles) and repeated MTD (open circles) on METH
self-administration (top panel). Effect of the high dose of MTD (17.0 mg/kg) on
food-maintained responding (bottom panel). Data are expressed as mean ±
S.E.M. number of METH infusions (0.05 mg/kg/infusion) or number of pellets
earned during 60-min sessions (n = 5-6). *indicates p < 0.05 compared to
control.
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Fig 9. MTD analogs do not inhibit [3H]nicotine binding and [3H]MLA binding
to whole brain membranes. Data represent the ability of analogs to displace
[3H]nicotine and [3H]MLA binding (top and bottom panel, respectively).
Nonspecific [3H]nicotine binding and nonspecific [3H]MLA binding were
determined in the presence of 10 μM cytisine and 10 μM nicotine, respectively.
Control represents [3H]nicotine and [3H]MLA binding in the absence of analog
(56.8 ± 4.22 and 69.7 ± 2.67 fmol/mg protein, respectively). n = 3-4 rats/analog.

Specific [3H]nicotine Binding
(% control)

125

100

75

50

25

0

Nicotine
Lobeline
MTD
UKMH-101
UKMH-102
UKMH-103
UKMH-104
UKMH-105
UKMH-106

CON

-10

UKMH-107
UKMH-108
UKMH-109
UKMH-110
UKMH-111
UKMH-112

-9

-8

-7

-6

log [Analog] (M)

99

-5

-4

-3

Specific [3H]MLA Binding
(% Control)

125

100

75

50

25

0

Nicotine
Lobeline
MTD
UKMH-101
UKMH-102
UKMH-103
UKMH-104
UKMH-105
UKMH-106

CON

UKMH-107
UKMH-108
UKMH-109
UKMH-110
UKMH-112
UKMH-112

-9

-8

-7

-6

log [Analog] (M)

100

-5

-4

-3

Fig. 10. Structural modifications to MTD afford analogs with decreased
affinity for DAT. Analogs are grouped according to structural similarity of the
aromatic rings. (top) Lobeline, MTD and MTD analogs with no aromatic ring
substituents; (middle) MTD analogs with dichloro, methoxy, or methyl aromatic
substituents; (bottom) MTD analogs containing heteroaromatic rings. MTD is
repeated in all 3 panels for purpose of comparison. Nonspecific [3H]DA uptake
was determined in the presence of 10 μM GBR 12909. Control (CON)
represents specific [3H]DA uptake in the absence of analog (35.0 ± 1.55
pmol/mg/min). Legend provides analogs in order from highest to lowest affinity.
n = 4 rats/analog.
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Fig. 11. MTD analogs inhibit [3H]5-HT uptake into rat hippocampal
synaptosomes. Analogs are grouped according to structural similarity of the
aromatic rings. (top) Lobeline, MTD and MTD analogs with no aromatic ring
substituents; (middle) MTD analogs with dichloro, methoxy, or methyl aromatic
substituents; (bottom) MTD analogs containing heteroaromatic rings. MTD is
repeated in all 3 panels for purpose of comparison. Nonspecific [3H]5-HT uptake
was determined in the presence of 10 μM fluoxetine. Control (CON) represents
specific [3H]5-HT uptake in the absence of analog (1.67 ± 0.09 pmol/mg/min).
Legend provides compounds in order from highest to lowest affinity. n = 4
rats/analog.
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Fig 12. MTD analogs inhibit [3H]DTBZ binding to vesicle membranes from
rat whole brain preparations. Analogs are grouped according to structural
similarity of the aromatic rings. (top) Lobeline, MTD and MTD analogs with no
aromatic ring substituents; (middle) MTD analogs with dichloro, methoxy, or
methyl aromatic substituents; (bottom) MTD analogs containing heteroaromatic
rings. MTD is repeated in all 3 panels for purpose of comparison. Nonspecific
[3H]DTBZ binding was determined in the presence of 10 μM Ro-4-1284. Control
(CON) represents specific [3H]DTBZ binding in the absence of analog (5.01 ±
0.10 pmol/mg protein). Analogs are arranged in order from greatest potency to
least potency. n = 4 rats/analog.
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Fig 13. MTD analogs inhibit [3H]DA uptake into rat striatal vesicles. Analogs
are grouped according to structural similarity of the aromatic rings. (top)
Lobeline, MTD and MTD analogs with no aromatic ring substituents; (middle)
MTD analogs with dichloro, methoxy, or methyl aromatic substituents; (bottom)
MTD analogs containing heteroaromatic rings. MTD is repeated in all 3 panels for
purpose of comparison. Nonspecific [3H]DA uptake was determined in the
presence of 10 μM Ro-4-1284. Control (CON) represents specific vesicular
[3H]DA uptake in the absence of analog (29.3 ± 1.38 pmol/mg/min). Legend
provides compounds in order from highest to lowest affinity. n = 4 rats/analog.
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Fig 14. Inhibition of [3H]DTBZ binding does not predict inhibition of [3H]DA
uptake at VMAT2. Data presented are Ki values from analog-induced inhibition
of [3H]DTBZ binding and [3H]DA uptake at VMAT2 (Figs. 12 and 13,
respectively). Pearson’s correlation analysis of these data revealed a lack of
correlation (Pearson’s r = 0.42; p = 0.13) between the ability of analogs to inhibit
[3H]DTBZ binding and [3H]DA uptake at VMAT2.
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Fig 15. Lobeline, MTD and MTD analogs competitively inhibit [3H]DA
uptake into vesicles prepared from rat striatum. Concentrations of lobeline
(0.25 µM), MTD (0.23 µM), UKMH-105 (0.11 µM), and UKMH-106 (0.16 µM)
approximated the Ki values for inhibiting [3H]DA uptake into isolated synaptic
vesicles obtained from the data shown in Fig. 13. Km (top panel) and Vmax
(bottom panel) values are mean ± S.E.M. (* p < 0.05 different from control; ** p <
0.01 different from control; n = 4-7 rats/analog)
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Fig 16. UKMH-105 does not inhibit METH-evoked endogenous DA release
from striatal slices. Fractional DA release represents the amount of DA in each
5-min sample. Slices were superfused with UKMH-105 after 10 min collection of
basal samples, as indicated by the arrow and analog remained in the buffer until
the end of the experiment. METH (5 µM) was added to the buffer for 15 min as
indicated by the horizontal bar. Fractional release data are expressed as mean ±
S.E.M. pg/ml/mg of the slice weight. n = 5 rats.
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Fig 17. In a concentration-dependent manner, UKMH-106 inhibits METHevoked DA release in striatal slices. Fractional DA release (top panel)
represents the amount of DA in each 5-min sample. Slices were superfused with
UKMH-106 after 10 min collection of basal samples, as indicated by the arrow
and analog remained in the buffer until the end of the experiment. METH (5 µM)
was added to the buffer for 15 min as indicated by the horizontal bar.
Concentration-response curve (bottom panel) was derived from peak response
data for each concentration of UKMH-106. Fractional release and peak
response data are expressed as mean ± S.E.M. pg/ml/mg of the slice weight.
For fractional release: *p < 0.05 different from METH alone. For peak response:
*p < 0.05 different from peak response of METH alone (CON). n = 8 rats
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Fig 18. UKMH-105 and UKMH-106 do not alter DOPAC release. Fractional
DOPAC release represents the amount of DOPAC in each 5-min sample. Slices
were superfused with UKMH-105 (top panel) or UKMH-106 (bottom panel) after
10 min collection of basal samples, as indicated by the arrow and analog
remained in the buffer until the end of the experiment. METH (5 µM) was added
to the buffer for 15 min as indicated by the horizontal bar. Fractional release
data is expressed as mean ± S.E.M. pg/ml/mg of the slice weight. n = 8 rats
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CHAPTER THREE

Novel N-1,2-Dihydroxypropyl Analogs of Lobelane Inhibit VMAT2 Function
and METH-evoked DA Release
Portions of this chapter have been published in the manuscript:
Horton DB, Zheng G, Siripurapu KB, Deaciuc AG, Crooks PA, Dwoskin
LP. N-1,2 dihydroxylpropyl analogs of lobelane as novel vesicular
monoamine transporter (VMAT2) inhibitors and potential treatments for
methamphetamine abuse. J Pharm Exp Ther, 339: 286-297, 2011.
Chapter reprinted with permission of the American Society for Pharmacology and
Experimental Therapeutics. All rights reserved.
I.

Introduction
METH is a highly addictive stimulant with robust rewarding properties
leading to its abuse. METH use continues to be a major health concern in the
United States, with 100,000 new users in the United States every year (NSDUH,
2008). To date, there are no approved therapeutics for METH abuse. METH acts
at both the DAT and VMAT2 to increase extracellular DA concentrations (Sulzer
et al., 2005). Specifically, METH reverses DA translocation by DAT to increase
extracellular DA concentrations leading to reward (Fischer and Cho, 1979, Liang
and Rutledge, 1982; Wise and Bozarth, 1987; Di Chiara and Imperato, 1988).
Numerous studies have focused on DAT as a therapeutic target for the
development of treatments for psychostimulant abuse (Grabowski et al., 1997,
Dar et al., 2005; Howell et al., 2007; Tanda et al., 2009). However, this approach
to drug discovery has thus far not resulted in viable efficacious therapeutics for
METH abuse.
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METH inhibits DA uptake at VMAT2 and stimulates DA release from
presynaptic vesicles, which presumably increases cytosolic DA concentrations
(Sulzer and Rayport, 1990; Sulzer et al., 1995; Pifl et al., 1995). Taking into
account VMAT2 as a component of the mechanism of action of METH, our
research focus has been the discovery of novel therapeutic agents that target
VMAT2. SARs have been generated to elucidate novel pharmacophores that
modify VMAT2 function with the aim of developing effective treatments for METH
abuse (Zheng et al., 2005a,b; Nickell et al., 2010a,b; Horton et al., 2010; Crooks
et al., 2010).
Lobeline (Fig. 19), the principal alkaloid in Lobelia inflata, inhibits the
neurochemical and behavioral effects of METH through its interaction with
VMAT2 (Teng et al., 1997, 1998; Miller et al., 2001, Harrod et al., 2001; Dwoskin
and Crooks, 2002; Nickell et al., 2010). Lobeline inhibits [ 3H]DTBZ binding to
VMAT2 (Ki = 0.90 μM), [3H]DA uptake at VMAT2 (Ki = 0.88 μM; Teng et al.,
1997, 1998) and METH-evoked DA release (IC50 = 0.42 μM), supporting the
tenet that VMAT2 is a viable therapeutic target for the development of treatments
for METH abuse. In further support of this hypothesis, lobeline decreases METH
self-administration in rats (Harrod et al., 2001). Importantly, lobeline is not selfadministered (Harrod et al., 2003), suggesting that it will not have abuse liability.
Recently, lobeline has completed Phase Ib clinical trials demonstrating safety in
METH abusers (Jones, 2007).
Initial SAR around the lobeline pharmacophore revealed that lobelane
(Fig. 19), a chemically defunctionalized, saturated analog of lobeline,
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competitively inhibited DA uptake at VMAT2 and exhibited increased affinity and
selectivity for VMAT2 compared with lobeline (Miller et al., 2001; Nickell et al.,
2010). Lobelane inhibited METH-evoked DA release and decreased METH selfadministration; however, tolerance developed to the latter behavior effects
(Neugebauer et al., 2007; Nickell et al., 2010). Unfortunately, lobelane exhibits
decreased water solubility and diminished drug likeness properties due to its
decreased polarity resulting from removal of the keto and hydroxyl functionalities
of lobeline.
In the current study, the N-methyl moiety of the central piperidine ring of
lobelane was replaced with a chiral N-1,2-dihydroxypropyl (N-1,2-diol) moiety to
improve water solubility and enhance drug-likeness properties. Based on
computational modeling, this structural modification was predicted to enhance
water solubility. VMAT2 binding and function was determined following 1)
replacement of the N-methyl moiety with a chiral N-1,2-diol moiety, 2) alteration
of the configuration of the N-1,2-diol moiety, and 3) incorporation of phenyl ring
substituents into the analogs. Specifically, incorporation of 2-methoxy, 3methoxy, 4-methoxy, 3-flouro, 2,4-dichloro, and 3,4-methylenedioxy substituents
into both phenyl rings, or replacement of the phenyl rings with naphthalene or
biphenyl rings, were evaluated. To assess VMAT2 selectivity, SAR was
generated for inhibition of DAT and SERT function. Analogs with highest
potency for inhibiting DA uptake at VMAT2 and with at least 10-fold selectivity
were evaluated for inhibition of METH-evoked DA release from superfused
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striatal slices. GZ-793A emerged as a potent, selective and drug-like VMAT2
inhibitor to be further developed as a treatment for METH abuse.
The hypothesis of this chapter is that N-1,2-diol analogs of lobelane will
inhibit VMAT2 function and VMAT2 selective lobelane analogs will inhibit METHevoked DA release from striatal slices.
II.

Methods
IIa.

Animals. Male Sprague-Dawley rats (200–250g, Harlan,

Indianapolis, IN) were housed two per cage with ad libitum access to food and
water in the Division of Laboratory Animal Resources at the University of
Kentucky (Lexington, KY). Experimental protocols involving the animals were in
accord with the 1996 NIH Guide for the Care and Use of Laboratory Animals and
were approved by the Institutional Animal Care and Use Committee at the
University of Kentucky.
IIb.

Chemicals. [3H]Dopamine ([3H]DA; dihydroxyphenylethylamine,

3,4-[7-3H]; specific activity, 28 Ci/mmol), and [3H]5-hydroxytryptamine ([3H]5-HT;
hydroxytryptamine creatinine sulfate 5-[1,2-3H(N)]; specific activity, 30 Ci/mmol)
and Microscint 20 LSC-cocktail were purchased from PerkinElmer, Inc. (Boston,
MA). [3H]Dihydrotetrabenazine ([3H]DTBZ; (±)alpha-[O-methyl3

H]dihydrotetrabenazine; specific activity, 20 Ci/mmol) was obtained from

American Radiolabled Chemicals, Inc. (St. Louis, MO). ATP-Mg2, catechol, DA,
disodiumethylenediamine tetraacetate (EDTA), ethylene glycol tetraacetate
(EGTA), fluoxetine HCl, 1-(2-(bis-(4-fluorophenyl)methoxy)ethyl)-4-(3120

phenylpropyl)piperazine (GBR 12909), α-D-glucose, S-glycidol, R-glycidol, N-[2hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES), MgSO4, pargyline
HCl, polyethyleneimine (PEI), KOH, potassium tartrate and sucrose were
purchased from Sigma-Aldrich, Inc. (St. Louis, MO). L-Ascorbic acid and
NaHCO3 were purchased from Aldrich Chemical Co. (Milwaukee, WI).
Ammonium hydroxide, CaCl2, diethyl ether, KCl, K2PO4, methylene chloride,
methanol, MgCl2, NaCl and NaH2PO4 were purchased from Fisher Scientific Co.
(Pittsburgh, PA). Ethanol was purchased from Pharmco-AAPER Alcohol and
Chemical Co., (Shelbyville, KY). Complete counting cocktail 3a70B was
purchased from Research Products International Corp. (Mount Prospect, IL).
(2R,3S,11bS)-2-Ethyl-3-isobutyl-9,10-dimethoxy-2,2,4,6,7,11b-hexahydro-1Hpyrido[2,1-a]isoquinolin-2-ol (Ro-4-1284) was a generous gift from HoffmanLaRoche Inc. (Nutley, NJ).
IIc.

General synthetic procedure for N-1,2-diol analogs. Based on

computational modeling utilizing ACD/ADME algorithms (www.acdlabs.com),
replacement of the N-methyl moiety on the central piperidine ring with a N-1,2diol moiety was predicted to enhance water solubility. For example, a 365%
increase in water solubility was predicted as a consequence of replacing the Nmethyl group in para-methoxyphenyl lobelane (GZ-252C) with an N-1,2-diol
moiety in GZ-793A (solubility of 2.0 and 7.3 mg/ml in water, respectively;
structures in Fig. 19 and Nickell et al., 2011). Synthesis of (R)-3-(2,6-cisdiphenethylpiperidin-1-yl)propane-1,2-diol (GZ-745A), which contains a N-1,2(R)dihydroxylpropyl group, and (S)-3-(2,6-cis-diphenethylpiperidin-1-yl)propane-1,2121

diol (GZ-745B), which contains a N-1,2(S)-dihydroxylpropyl group, was
accomplished by reacting nor-lobelane with S-glycidol or R-glycidol in ethanol,
respectively. The phenyl ring-modified nor-lobelane analogs were synthesized
using previously reported methods (Zheng et al., 2005b), and the latter analogs
served as intermediates for the synthesis of the current series of analogs via
reaction with S-glycidol or R-glycidol in ethanol [i.e., (R)-3-[2,6-cis-di(3methoxyphenethyl)piperidin-1-yl]propane-1,2-diol (GZ-790A), (R)-3-[2,6-cis-di(3fluorophenethyl) piperidin-1-yl]propane-1,2-diol (GZ-791A), (R)-3-[2,6-cis-di(2methoxyphenethyl) piperidin-1-yl]propane-1,2-diol (GZ-792A), GZ-793A, (R)-3[2,6-cis-di(1-naphthylethyl)piperidin-1-yl]propane-1,2-diol (GZ-794A), (R)-3-[2,6cis-di(2,4-dichlorophenethyl)piperidin-1-yl]propane-1,2-diol (GZ-795A), (R)-3[2,6-cis-di(4-biphenylethyl)piperidin-1-yl]propane-1,2-diol (GZ-796A), and (R)-3[2,6-cis-di(3,4-methylenedioxyphenethyl)piperidin-1-yl]propane-1,2-diol (GZ797A), and the respective enantiomers (S)-3-[2,6-cis-di(3methoxyphenethyl)piperidin-1-yl]propane-1,2-diol (GZ-790B), (S)-3-[2,6-cis-di(3fluorophenethyl)piperidin-1-yl]propane-1,2-diol (GZ-791B), (S)-3-[2,6-cis-di(2methoxyphenethyl)piperidin-1-yl]propane-1,2-diol (GZ-792B), (S)-3-[2,6-cis-di(4methoxyphenethyl) piperidin-1-yl]propane-1,2-diol (GZ-793B), (S)-3-[2,6-cis-di(1naphthylethyl)piperidin-1-yl]propane-1,2-diol (GZ-794B), (S)-3-[2,6-cisdi(2,4dichlorophenethyl)piperidin-1-yl]propane-1,2-diol (GZ-795B), (S)-3-[2,6-cis-di(4biphenylethyl)piperidin-1-yl]propane-1,2-diol (GZ-796B), and (S)-3-[2,6-cis-di(3,4methylenedioxyphenethyl)piperidin-1-yl]propane-1,2-diol (GZ-797B)]. The final
products were purified by silica gel column chromatography [eluting with
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methylene chloride/methanol/ammonium hydroxide, 30:1:0.2 (v/v/v)], followed by
recrystallization from ethanol and diethyl ether after conversion into salt forms.
Structures and purities of the analogs were determined by 1H-NMR, 13C-NMR,
mass spectrometry, HPLC, and combustion analysis.
IId.

Synaptosomal [3H]DA and [3H]5-HT uptake assays. Analog-

induced inhibition of [3H]DA and [3H]5-HT uptake into rat striatal and hippocampal
synaptosomes, respectively, was determined using modifications of a previously
described method (Chapter 2, Horton et al., 2011a). Brain regions were
homogenized in 20 ml of ice-cold 0.32 M sucrose solution containing 5 mM
NaHCO3 (pH 7.4) with 16 up-and-down strokes of a Teflon pestle homogenizer
(clearance ~ 0.005”). Homogenates were centrifuged at 2,000 g for 10 min at 4
°C, and resulting supernatants centrifuged at 20,000 g for 17 min at 4 °C. Pellets
were resuspended in 1.5 ml of Krebs’ buffer, containing: 125 mM NaCl, 5 mM
KCl, 1.5 mM MgSO4, 1.25 mM CaCl2, 1.5 mM KH2PO4, 10 mM α-D-glucose, 25
mM HEPES, 0.1 mM EDTA, with 0.1 mM pargyline and 0.1 mM ascorbic acid,
saturated with 95% O2 /5% CO2, pH 7.4). Synaptosomal suspensions (20 µg
protein/50 µl) were added to duplicate tubes containing 50 µl analog (7-9
concentrations, 0.1 nM – 1 mM, final concentration in assay buffer) and 350 µl of
buffer and incubated at 34 °C for 5 min in a total volume of 450 µl. Samples were
placed on ice and 50 µl of [3H]DA or [3H]5-HT (10 nM; final concentration) was
added to each tube for a final volume of 500 µl. Reactions proceeded for 10 min
at 34°C and were terminated by the addition of 3 ml of ice-cold Krebs’ buffer.
Nonspecific [3H]DA and [3H]5-HT uptake were determined in the presence of 10
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µM GBR 12909 and 10 µM fluoxetine, respectively. Samples were rapidly filtered
through Whatman GF/B filters using a cell harvester (MP-43RS; Brandel Inc.).
Filters were washed 3 times with 4 ml of ice-cold Krebs’ buffer containing
catechol (1 mM). Complete counting cocktail was added to the filters and
radioactivity determined by liquid scintillation spectrometry (B1600 TR scintillation
counter; PerkinElmer, Inc.).
IIe.

[3H]DTBZ vesicular binding assays. Analog-induced inhibition of

[3H]DTBZ binding, a high affinity ligand for VMAT2, was determined using
modifications of a previously published method (Chapter 2, Horton et al., 2011a).
Rat whole brain (excluding cerebellum) was homogenized in 20 ml of ice-cold
0.32 M sucrose solution with 10 up-and-down strokes of a Teflon pestle
homogenizer (clearance ~ 0.008”). Homogenates were centrifuged at 1,000 g for
12 min at 4 °C and resulting supernatants were centrifuged at 22,000 g for 10
min at 4 °C. Resulting pellets were osmotically lyzed by incubation in 18 ml of
cold water for 5 min. Osmolarity was restored by adding 2 ml of 25 mM HEPES
and 100 mM potassium tartrate solution. Samples were centrifuged (20,000 g for
20 min at 4°C), and then 1 mM MgSO4 solution was added to the supernatants.
Samples were centrifuged at 100,000 g for 45 min at 4°C. Pellets were
resuspended in cold assay buffer, containing 25 mM HEPES, 100 mM potassium
tartrate, 5 mM MgSO4, 0.1 mM EDTA, and 0.05 mM EGTA, pH 7.5. Assays were
performed in duplicate using 96-well plates. Vesicular suspensions (15 µg
protein/100 µl) were added to wells containing 50 µl analog (7-9 concentrations,
0.01 nM – 0.1 mM, final concentration in assay buffer), 50 µl of buffer, and 50 µl
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of [3H]DTBZ (3 nM; final concentration) for a final volume of 250 µl and incubated
for 1 hr at room temperature. Nonspecific binding was determined in the
presence of 50 µl of 20 µM Ro-4-1284. Reactions were terminated by filtration
onto Unifilter-96 GF/B filter plates (presoaked in 0.5% PEI). Filters were washed
3 times with 350 µl of ice-cold buffer containing: 25 mM HEPES, 100 mM
potassium-tartrate, 5 mM MgSO4, and 10 mM NaCl, pH 7.5. Filter plates were
dried, bottom-sealed and each well filled with 40 µl of scintillation cocktail
(MicroScint 20; PerkinElmer, Inc.). Radioactivity on the filters was determined by
liquid scintillation spectrometry.
IIf.

Vesicular [3H]DA uptake assay. Analog-induced inhibition of

[3H]DA uptake into rat striatal vesicles was determined using modifications of a
previously published method (Chapter 2, Horton et al., 2011a). Striata were
homogenized in 14 ml of ice-cold 0.32 M sucrose solution containing 5 mM
NaHCO3 (pH 7.4) with 10 up-and-down strokes of a Teflon pestle (clearance ~
0.008”). Homogenates were centrifuged at 2,000 g for 10 min at 4 °C and
resulting supernatants centrifuged at 10,000 g for 30 min at 4 °C. Pellets were
resuspended in 2.0 ml of 0.32 M sucrose and were transferred to tubes
containing 7 ml of milliQ water and homogenized with 5 up-and-down strokes
using the above homogenizer. Homogenates were transferred to tubes
containing 900 μl of 0.25 M HEPES and 900 μl of 1.0 M potassium tartrate
solution and centrifuged at 20,000 g for 20 min at 4 ºC. Resulting supernatants
were centrifuged at 55,000 g for 60 min at 4 ºC. Subsequently, 100 μl of 1 mM
MgSO4, 100 μl of 0.25 M HEPES and 100 μl of 1.0 M potassium tartrate were
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added to the supernatant and centrifuged at 100,000 g for 45 min at 4 ºC. Final
pellets were resuspended in assay buffer, containing 25 mM HEPES, 100 mM
potassium tartrate, 50 μM EGTA, 100 μM EDTA, and 1.7 mM ascorbic acid, 2
mM ATP-Mg2+, pH 7.4. Vesicular suspensions (10 µg protein/100 µl) were added
to duplicate tubes containing 50 µl analog (7-9 concentrations, 1 nM – 0.1 mM,
final concentration in assay buffer), 300 µl of buffer, and 50 µl of [3H]DA (0.1 µM;
final concentration) for a final volume of 500 µl and incubated for 8 min at 34 °C.
Nonspecific [3H]DA uptake was determined in the presence of 10 µM Ro-4-1284.
Samples were filtered rapidly through Whatman GF/B filters using the cell
harvester and washed 3 times with assay buffer containing 2 mM MgSO4 in the
absence of ATP. Radioactivity retained by the filters was determined as
previously described.
IIg.

Kinetics of vesicular [3H]DA uptake. Vesiclar suspensions were

prepared as described above except that striata were pooled from 2 rats.
Vesicular suspensions (20 µg protein/50 µl) were added to duplicate tubes
containing 25 µl analog (final concentration approximating the Ki from inhibition
curves for each analog), 150 µl of buffer, and 25 µl of various concentrations of
[3H]DA (1 nM – 5 μM; final concentration) for a final volume of 250 µl, and
incubated for 8 min at 34 °C. Nonspecific [3H]DA uptake was determined using
10 µM Ro4-1284. Samples were processed as previously described.
IIh.

Endogenous DA release assay. HPLC-EC determination of DA

release was performed by Kiran Siripurapu, Ph.D.. Rat coronal striatal slices of
0.5 mm thickness were prepared and incubated in Krebs’ buffer, containing 118
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mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 1.0 mM NaH2PO4, 1.3 mM CaCl2, 11.1
mM -D-glucose, 25 mM NaHCO3, 0.11 mM L-ascorbic acid and 0.004 mM
EDTA, pH 7.4, saturated with 95%O2/5%CO2 at 34 ºC in a metabolic shaker for
60 min (Chapter 2, Horton et al., 2011a). Each slice was transferred to a glass
superfusion chamber and superfused with Krebs’ buffer at 1 ml/min for 60 min
before sample collection. Two basal samples (1ml) were collected at the 5-min
and 10-min time points. To determine the ability of analog to evoke DA overflow,
each slice was superfused for 30 min in the absence or presence of a single
concentration of analog (0.3 -10 M); analog was included in the buffer until the
end of the experiment. METH (5 M) was added to the buffer after 30 min of
superfusion, and slices were superfused for an additional 15 min with METH,
followed by 20 min of superfusion in the absence of METH. In each experiment,
a striatal slice was superfused for 90 min in the absence of both analog and
METH, serving as the buffer control condition. In each experiment, duplicate
slices were superfused with METH in the absence of analog, serving as the
METH control condition. The METH concentration was selected based on pilot
concentration-response data showing a reliable response of sufficient magnitude
to allow evaluation of analog-induced inhibition. Each superfusate sample (1 ml)
was collected into tubes containing 100 l of 0.1 M perchloric acid. Prior to
HPLC-EC analysis, ascorbate oxidase (20 µl, 168 U/mg reconstituted to 81 U/ml)
was added to 500 µl of each sample and vortexed for 30 s, and 100 µl injected
onto the HPLC-EC. The HPLC-EC consisted of a pump (model 126, Beckman
Coulter, Inc, Fullerton, CA) and autosampler (model 508 Beckman Coulter, Inc),
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an ODS Ultrasphere C18 reverse-phase 80 × 4.6 mm, 3-µm column, a
Coulometric-II detector with guard cell (model 5020) maintained at +0.60 V, and
an analytical cell (model 5011) maintained at potentials E1 = -0.05 V and
E2 = +0.32 V (ESA Inc., Chelmsford, MA). HPLC mobile phase (flow rate, 1.5
ml/min) was 0.07 M citrate/0.1 M acetate buffer pH 4, containing 175 mg/l
octylsulfonic acid sodium salt, 650 mg/l NaCl and 7% methanol. Separations
were performed at room temperature, and 5-6 min were required to process each
sample. Retention times of DA standards were used to identify respective peaks.
Peak heights were used to quantify the detected amounts of analyte based on
standard curves. Detection limit for DA was 1-2 pg/100 µl.
IIi.

Data analysis. Specific [3H]DTBZ binding and specific [3H]DA and

[3H]5-HT uptake were determined by subtracting the nonspecific binding or
uptake from the total binding or uptake, respectively. Analog concentrations that
produced 50% inhibition of the specific binding or uptake (IC50 values) were
determined from the concentration-effect curves via an iterative curve-fitting
program (Prism 5.0; GraphPad Software Inc., San Diego, CA). Inhibition
constants (Ki values) were determined using the Cheng-Prusoff equation. For
kinetic analyses, Km and Vmax were determined using one-site binding curves.
Paired two-tailed t-tests were performed on the arithmetic Vmax and the log Km
values to determine significant differences between analog and control (absence
of analog). Pearson’s correlation analysis determined the relationship between
affinity for the [3H]DTBZ binding site and vesicular [3H]DA uptake.
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For endogenous neurotransmitter release assays, fractional release is
defined as the DA concentration in each sample divided by the slice weight.
Basal DA outflow was calculated as the average fractional release of the two
basal samples collected 10 min prior to addition of analog to the buffer. Intrinsic
DA overflow was calculated as the sum of the increases in fractional release
above basal outflow during superfusion with analog alone (in the absence of
METH). One-way repeated-measures ANOVAs determined concentrationdependent effects on DA overflow. Peak DA fractional release evoked by METH
was determined from the time course. Analog-induced inhibition of METHevoked fractional DA release was evaluated using one-way repeated-measures
ANOVA. When appropriate, Dunnett’s post hoc test determined concentrations of
analog that significantly decreased the effect of METH. Log IC50 value for each
analog was generated using an iterative nonlinear least squares curve-fitting
program (PRISM version 5.0). Statistical significance was defined as p < 0.05.
III.

Results
IIIa.

N-1,2-Diol analogs inhibit [3H]DA uptake at DAT. Concentration-

response curves for GBR 12909, cocaine, lobeline, lobelane, and the N-1,2-diol
analogs to inhibit [3H]DA uptake into striatal synaptosomes are illustrated in Fig.
20. Ki values for GBR 12909, cocaine, lobeline, and lobelane (Table 2) are
consistent with previously reported findings (Reith et al., 1994; Han and Gu,
2006; Nickell et al., 2011). Replacement of the N-methyl in lobelane with a N-1,2diol moiety generally afforded analogs that were 1 to 10-fold less potent (Ki =
1.43-9.5 μM) at DAT compared to lobelane. Alteration of the configuration of the
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N-1,2-diol and incorporation of phenyl ring substitutents did not alter affinity for
DAT. Of note, lead analogs, GZ-793A (4-methoxyphenyl-N-1,2(R)-diol analog)
and GZ-794A (1-naphthalene-N-1,2(R)-diol analog) inhibited [3H]DA uptake with
potencies not different from lobelane.
IIIb.

N-1,2-Diol analogs inhibit [3H]5-HT uptake at SERT.

Concentration-response curves for fluoxetine, lobeline, lobelane, and the N-1,2diol analogs to inhibit [3H]5-HT uptake into hippocampal synaptosomes are
illustrated in Fig. 21. Ki values for fluoxetine, lobeline and lobelane (Table 2) are
consistent with previously reported findings (Owens, 2001; Miller et al., 2004).
Generally, replacement of the N-methyl moiety with the N-1,2-diol moiety,
alteration of the configuration of the N-1,2-diol and incorporation of phenyl ring
substitutents did not alter affinity for SERT (Ki = 0.94 -11.0 μM vs 3.6 μM).
Exceptions include the 1-naphthalene enantiomers, GZ-794A and GZ-794B (Ki =
0.31 and 0.16 µM, respectively), which afforded a 10-20-fold increase in potency
compared with lobelane. Of note, the lead compound, GZ-793A, exhibited
potency not different from lobelane.
IIIc.

N-1,2-Diol analogs inhibit [3H]DTBZ binding at VMAT2.

Concentration-response curves for Ro-4-1284, lobeline, lobelane, and the N-1,2diol analogs to inhibit [3H]DTBZ binding to whole brain membranes are illustrated
in Fig. 22, and Ki values are provided in Table 2. The Ki value for Ro-4-1284 to
inhibit [3H]DTBZ binding is consistent with previously reported results (Cesura et
al., 1990). Generally, replacement of the N-methyl moiety with the N-1,2-diol
moiety, alteration of the configuration of the N-1,2-diol and incorporation of
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phenyl ring substitutents did not alter affinity for the DTBZ site on VMAT2 (Ki =
0.46-5.6 μM vs 0.97 μM). Of note, GZ-794A (1-naphthalene N-1,2(R)-diol analog)
exhibited potency not different from lobelane. Exceptions include the 4methoxyphenyl enantiomers (GZ-793A and GZ-793B) and the 2,4-dichlorophenyl
enantiomers (GZ-795A and GZ-795B), which exhibited 8-10-fold lower potency
compared with lobelane. Also, GZ-796A and GZ-796B, the 4-biphenyl
enantiomers, exhibited 90-100-fold lower potency than lobelane.
IIId.

N-1,2-Diol analogs inhibit [3H]DA uptake at VMAT2.

Concentration-response curves for Ro-4-1284, lobeline, lobelane, and the N-1,2diol analogs to inhibit [3H]DA uptake into striatal vesicles are illustrated in Fig. 23.
Ki values for Ro-4-1284, lobeline and lobelane (Table 2) are consistent with
previous reports (Nickell et al., 2011). Replacement of the N-methyl moiety with
the N-1,2-diol and incorporation of the phenyl ring substituents resulted in a 5-45
fold lower potency inhibiting [3H]DA uptake at VMAT2 compared to lobelane.
Exceptions include GZ-793A (4-methoxyphenyl N-1,2(R)-diol analog) and GZ794A (1-naphthalene N-1,2(R)-diol analog), which were equipotent with lobelane.
Generally, the R-configuration of the N-1,2-diol analogs was more potent than
the S-configuration inhibiting VMAT2 function. Correlation analysis revealed no
correlation between the Ki values for inhibiting [3H]DA uptake at VMAT2 and
[3H]DTBZ binding at VMAT2 (Pearson’s correlation coefficient r = 0.37, p = 0.13,
Fig. 24).
IIIe.

N-1,2-Diol analogs inhibit [3H]DA uptake at VMAT2

competitively. To elucidate the mechanism of inhibition at VMAT2, i.e.
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competitive or noncompetitive, kinetic analyses of [3H]DA uptake at VMAT2 were
conducted using the most potent analog inhibitors of VMAT2 function, i.e., GZ793A and GZ-794A. GZ-793A had relatively low affinity for the [3H]DTBZ binding
site, whereas GZ-794A had high affinity for this site. For comparison, kinetic
analysis of GZ-796A was performed to evaluate the mechanism of inhibition of
an analog with moderate potency inhibiting DA uptake at VMAT2, but low
potency at the [3H]DTBZ binding site. Results show an increased Km value with
no change in Vmax for each analog compared to control (Fig. 25), indicating a
competitive mechanism of action.
IIIf.

N-1,2-Diol analogs inhibit METH-evoked endogenous DA

release. In the absence of METH, GZ-793A, GZ-794A and GZ-796A did not
evoke DA overflow above basal outflow (one-way repeated measures ANOVA:
F5,29 = 0.31, F5,29 = 1.32, F5,29 = 0.48, respectively, ps > 0.05). Importantly, GZ793A, GZ-794A and GZ-796A inhibited METH-evoked DA release in a
concentration-dependent manner (Fig. 26; repeated measures one-way
ANOVAs: F5,29 = 4.55, F5,29 = 3.16, and F5,29 = 3.03, respectively, ps < 0.05).
Even though GZ-793A and GZ-794A inhibited DA uptake at VMAT2 equipotently,
GZ-793A was 25-fold less potent than GZ-794A inhibiting METH-evoked DA
release. Further, GZ-793A exhibited ~35% greater inhibitory activity compared
with GZ-794A. Although GZ-796A had 25-fold lower potency than either GZ793A or GZ-794A inhibiting DA uptake at VMAT2, GZ-796A was equipotent with
GZ-794A and 10-fold less potent than GZ-793A inhibiting METH-evoked DA
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release. Inhibitory activity of GZ-796A (Imax = 56%) was not different than that
exhibited by GZ-794A.
IV.

Discussion
The current study reports on an iterative process of drug discovery aimed

at identifying a novel lead candidate for the treatment of METH abuse. Rationale
for VMAT2 as the pharmacological target evolved from the observation that
METH interacts with this presynaptic protein to inhibit DA uptake into presynaptic
vesicles. Inhibition of VMAT2 increases cytosolic DA levels available for METHinduced reverse transport by DAT, leading to an increase in extracellular DA
(Sulzer, 2005). Through an interaction with VMAT2, lobeline inhibits the
neurochemical and behavioral effects of METH (Teng et al., 1997, 1998; Miller et
al., 2001, Harrod et al., 2001; Dwoskin and Crooks, 2002; Nickell et al., 2010).
Lobelane, a lobeline analog with greater selectivity for VMAT2, decreased both
METH-evoked DA release (IC50 = 0.65 µM; Imax = 73.2%; same experimental
conditions as the current work) and METH self-administration (Zheng et al.,
2005a; Neugebauer et al., 2007; Beckmann et al., 2010; Nickell et al., 2010,
2011). Unfortunately, further development of lobelane as an effective
pharmacotherapy was hindered by unacceptable drug-likeness properties. The
current study identified novel analogs of lobelane incorporating a N-1,2-diol
moiety into the molecule to specifically enhance its drug-likeness properties. GZ793A emerged as a potent, VMAT2-selective, drug-like lead candidate for the
treatment of METH abuse.
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The current SAR provided several insights regarding the optimization of
the pharmacophore for inhibition of VMAT2 function (Tables 2 and 3). Merely
replacing the N-methyl group of lobelane with a N-1,2(R)-diol moiety (GZ-745A)
resulted in a 4-fold decrease in VMAT2 inhibitory potency. Also, the specific
configuration of the N-1,2-diol moiety is a factor determining potency to inhibit DA
uptake at VMAT2. The R enantiomer of N-1,2-diol analogs bearing no phenyl
substituents, and those containing 3-flourophenyl, 3-methoxyphenyl, 4methoxyphenyl or 3,4-methylenedioxyphenyl moieties exhibited 4-6-fold higher
inhibitory potency compared to the corresponding S enantiomer. These results
indicate that the pharmacophore for inhibition of VMAT2 function has a
configurational restriction at the chiral N-1,2-diol moiety in the current series of
analogs. Furthermore, N-1,2-diol analogs of lobelane with 3-fluoro, 2,4-dichloro,
2-methoxy, 3-methoxy, or 3,4-methylenedioxy substituents in both phenyl rings,
or in which the phenyl rings were replaced with 1-naphthalene or 4-biphenyl
rings, exhibited a 4 to 34-fold lower potency compared to lobelane, and a 3 to 66fold lower potency compared to the corresponding N-methyl substituted analog.
Thus, although N-methyl analogs with substituents on the phenyl rings retained
potency as inhibitors of VMAT2 relative to lobelane, introduction of these
substituents into the phenyl rings in the N-1,2-diol analogs resulted in reduced
potency. Exceptions include the two lead N-1,2(R)-diol analogs, GZ-793A (4methoxyphenyl analog) and GZ-794A (1-naphthalene analog), which inhibited
VMAT2 with potencies not different from either lobelane or the corresponding Nmethyl analogs. These results indicate that for GZ-793A and GZ794A, structural
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modifications which enhanced drug-likeness did not alter VMAT2 inhibitory
potency.
The use of [3H]DTBZ to probe interaction with VMAT2 has been
established in rodent models and in evaluation of patients with specific
pathologies (Lehericy et al., 1994; Kilbourn et al., 1995). However, studies have
reported that inhibition of VMAT2 function does not correlate with affinity for the
[3H]DTBZ binding site on VMAT2 (Chapter 2, Horton et al., 2011a; Nickell et al.,
2011). These studies evaluated the SAR for conformationally restricted MTD
analogs and for a series of phenyl ring substituted lobelane analogs. Results
obtained from the current series of novel N-1,2-diol analogs are consistent with
the latter observations, i.e., a correlation was not observed between VMAT2
binding and uptake. Together, the SAR indicates that [3H]DTBZ binding site is
more tolerant of structural alterations relative to the uptake site on VMAT2. One
analog in the current series (GZ-796A, the 4-biphenyl N-1,2(R)-diol analog)
inhibited DA uptake at VMAT2, but did not inhibit [3H]DTBZ binding, consistent
with previous results that 4-biphenyl nor-lobelane as well as several extensively
aromatized N-methyl lobelane analogs inhibited VMAT2 function, but not
[3H]DTBZ binding (Nickell et al., 2011). Thus, analogs in these structural series
appear to interact with two distinct sites on VMAT2.
Although VMAT2 and plasma membrane transporters (e.g., DAT and
SERT) belong to two different transporter families and exhibit little structural
homology (Liu and Edwards, 1997), these proteins are promiscuous and
translocate DA and 5-HT (Norrholm et al., 2007), suggesting that there are
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similarities in the substrate sites between these transporters. Since the parent
compound lobelane exhibited only 15-fold selectivity for VMAT2 over DAT and
SERT, it was imperative to assess interaction of the N-1,2-diol analogs with DAT
and SERT to ascertain selectivity for VMAT2. Only the 1-naphthalene analogs
exhibited a 10-fold higher potency inhibiting SERT compared with lobelane,
whereas the remainder of the series of N-1,2-diol analogs exhibited affinity not
different from lobelane at both DAT and SERT. Configuration of the N-1,2-diol
moiety influenced potency to inhibit VMAT2 function, but did not influence
potency at DAT and SERT.
The next critical step in our drug discovery approach is to determine the
ability of the lead compounds to inhibit the neurochemical effects of METH.
Representative analogs of the N-1,2(R)-diol series were evaluated for their ability
to decrease METH-evoked DA release in striatum. The leads, GZ-793A and GZ794A, which exhibited the highest potency for inhibition of VMAT2 function, and
GZ-796A, which inhibited VMAT2 function but not [3H]DTBZ binding, were
chosen for evaluation. All three N-1,2(R)-diol analogs did not evoke DA overflow
in the absence of METH (had no intrinsic activity) and inhibited METH-evoked
DA release in a concentration-dependent manner. These preclinical results
support the further evaluation of these analogs for development as potential
pharmacotherapies for METH abuse.
The current results suggest that GZ-793A, GZ-794A and GZ-796A interact
with VMAT2 to inhibit the pharmacological effects of METH. However, the order
of potency for inhibition of VMAT2 function (GZ-793A = GZ-794A > GZ-796A)
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was different from the order of potency for inhibition of METH-evoked DA release
(GZ-794A > GZ-796A > GZ-793A). Furthermore, correlation analysis with a
limited number of structurally-related compounds (GZ-793A, GZ-794A, GZ-796,
lobelane, lobeline, MTD, UKCP-110; , cis-2,5-di-(2-phenethyl)-pyrrolidine
hydrochloride and UKMH-106) for which data are available from both assays
(current study; Miller et al., 2001, 2004; Nickell et al., 2010; Beckmann et al.,
2010; Chapter 2, Horton et al., 2011a) reveal a lack of correlation between
affinity for inhibition of DA uptake at VMAT2 and ability to inhibit METH-evoked
DA release. There are several alternative explanations for this lack of correlation.
First, variability in the physicochemical properties between the analogs may
explain the lack of correlation between affinity for VMAT2 and efficacy for
inhibition of METH-evoked DA release from slices. Such physicochemical
properties are expected to differentially affect the ability of the analogs to
distribute across cell membranes to reach its intracellular target. Further, VMAT2
has greater accessibility in the vesicular preparation compared to the more intact
slice preparation in which cell membranes impede analog accessibility.
Another possibility is that the analogs may be interacting with an alternate
site on VMAT2 other than the DA uptake site to inhibit METH-evoked DA release.
Research demonstrates that the extracellular and intracellular faces of DAT
expresses distinct sites for DA translocation that are regulated differentially
(Gnegy, 2003), which provides precedence for alternate recognition sites on
VMAT2 that mediate uptake of DA and METH-evoked release of DA from the
vesicle. Thus, the analogs may have different affinities for these alternative sites
137

on VMAT2 which may explain the lack of correlation between affinity for VMAT2
and efficacy for inhibition of METH-evoked DA release from slices.
Further, the analogs may be interacting with an alternative target other
than VMAT2, i.e., nicotinic receptors, to inhibit METH-evoked DA release.
Lobeline interacts with both α4β2* and α7* nicotinic receptors; however, chemical
defunctionalization (i.e., removal of the keto and hydroxyl groups from the phenyl
ring side chains) of the lobeline molecule (affording analogs such as lobelane
and the N-1,2-diol analogs) exhibit little or no affinity for α4β2* and α7* nicotinic
receptors (Miller et al., 2001; Zheng et al., 2005a; Beckmann et al., 2010;
Chapter 2, Horton et al., 2011a). Further, GZ-793A does not inhibit nicotinic
receptors mediating nicotine-evoked DA release (unpublished observations). An
alternative potential site of analog interaction is DAT. GZ-793A, GZ-794A and
GZ-796A exhibit affinity for DAT within the concentration range that inhibits
METH-evoked DA release. However, the observation that GZ-793A is not selfadministered in rats diminishes support for an interaction with DAT as its
mechanism of action (Beckman et al., 2011). Finally, the observation that these
analogs are 10 to 50-fold more potent at VMAT2 than at DAT provides support
for VMAT2 as the pharmacological target.
Of the series, GZ-793A, the 4-methoxyphenyl N-1,2(R)-diol analog,
exhibited the best profile with the greatest selectivity (50-fold) for VMAT2 and
maximal inhibition (86%) of the effect of METH. The N-1,2(R)-diol moiety in GZ793A improved water solubility compared with its N-methyl counterpart, GZ252C. Importantly, GZ-793A has been shown recently to decrease METH self138

administration and METH conditioned-place preference, without altering food
maintained responding (Beckmann et al., 2011), providing preclinical data which
support its potential utility as a novel pharmacotherapy for METH abuse. Results
from these preclinical studies provide support for GZ-793A as a lead compound
in the search for pharmacotherapies to treat METH abuse.
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Table 2. Affinity values (Ki) of N-1,2-diol analogs, lobeline, lobelane and
standard compounds for DAT, SERT, and VMAT2 binding and function
DAT
[ H]DA Uptake
Ki ± SEM
(μM)

SERT
[3H]5-HT
Uptake
Ki ± SEM
(μM)

VMAT2
[3H]DTBZ
Binding
Ki ± SEM
(μM)

VMAT2
[3H]DA Uptake
Ki ± SEM
(μM)

GBR 12909

0.0009 ± 0.0001 a

NDb

NDb

NDb

Cocaine

0.48 ± 0.07

ND

ND

ND

Fluoxetine

NDb

0.007 ± 0.0001 a

ND

ND

Ro-4-1284

0.04 ± 0.005

0.02 ± 0.003

0.03 ± 0.003 a

0.02 ± 0.002 a

46.8 ± 3.70

2.04 ± 0.26c

1.27 ± 0.46

c

3

Compound

Standards

Lobeline, lobelane and N-1,2-diol analogs
Lobeline

28.2 ± 6.73

Lobelane

1.05 ± 0.03

3.60 ± 0.35

0.97 ± 0.19

0.067 ± 0.007

GZ-745A

0.60 ± 0.06

8.43 ± 2.80

0.56 ± 0.08

0.19 ± 0.05

GZ-745B

1.08 ± 0.12

11.0 ± 3.12

1.28 ± 0.13

0.86 ± 0.12

N-1,2-Diol analogs containing 1-naphthyl or 4-biphenyl substituents
GZ-794A

1.43 ± 0.14

0.31 ± 0.08

0.31 ± 0.07

0.033 ± 0.002

GZ-794B

1.57 ± 0.16

0.16 ± 0.04

0.13 ± 0.01

0.08 ± 0.01

GZ-796A

8.33 ± 1.46

5.30 ± 0.96

>100

0.79 ± 0.23

GZ-796B

3.43 ± 0.63

2.55 ± 0.77

90.2 ± 9.70

2.25 ± 1.30

N-1,2-Diol analogs containing aromatic methoxy or methylene-dioxy substituents
GZ-790A

3.80 ± 0.69

3.14 ± 1.18

0.46 ± 0.22

0.14 ± 0.02

GZ-790B

6.67 ± 2.15

8.03 ± 2.30

2.73 ± 0.68

0.52 ± 0.04

GZ-792A

2.90 ± 0.23

1.33 ± 0.46

1.04 ± 0.73

0.49 ± 0.06

GZ-792B

4.77 ± 1.03

0.94 ± 0.14

1.87 ± 0.69

0.79 ± 0.08

GZ-793A

1.44 ± 0.27

9.36 ± 2.74

8.29 ± 2.79

0.029 ± 0.008

GZ-793B

3.40 ± 0.82

10.4 ± 2.75

7.74 ± 2.34

0.18 ± 0.04

GZ-797A

2.46 ± 0.16

2.10 ± 0.70

1.30 ± 0.05

0.16 ± 0.04

GZ-797B

2.21 ± 0.31

2.63 ± 0.60

5.61 ± 0.62

0.76 ± 0.04

N-1,2-Diol analogs containing aromatic halogeno substituents
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GZ-791A

0.25 ± 0.07

1.32 ± 0.46

1.00 ± 0.16

0.19 ± 0.06

GZ-791B

0.62 ± 0.05

2.87 ± 0.50

1.08 ± 0.38

1.03 ± 0.16

GZ-795A

3.87 ± 0.89

2.15 ± 0.38

10.4 ± 0.65

0.14 ± 0.04

GZ-795B

9.50 ± 2.53

1.86 ± 0.39

13.9 ± 0.38

0.09 ± 0.04

a

n = 3-4 rats; bND, not determined; c data for [3H]DTBZ binding for lobeline and
lobelane taken from Nickell et al., 2010

141

Table 3. Summary of comparisons between phenyl ring substituted N-1,2diol and respective N-methyl analog.

Configuration
of the N-1,2diol

VMAT2
3
[ H]DA
Uptake
(Ki; µM)

Selectivity
for VMAT
over DAT
or SERT

N-Methyl
Analog

VMAT2
3
[ H]DA
Uptake
(Ki; µM)

Ratio of
VMAT2
Uptake for the
N-1,2-diol
relative to the
N-methyl
analog

Ratio of
VMAT2
Uptake for
the N-1,2diol relative
to lobelane

Compound

Phenyl Ring
Substituent

Lobelane

NA

NA

0.067

15.6

NA

NA

NA

NA

GZ-745A

No Change

R

0.19

3.16

Lobelan
e

0.067

2.84

2.84

GZ-745B

No Change

S

0.86

1.26

12.8

12.8

0.36

0.49

0.88

1.19

23.2

11.8

66.2

33.6

4.67

2.09

17.3

7.76

7.31

2.84

30.4

11.8

1.93

0.43

12

2.69

3.72

2.39

17.7

11.3

2.04

2.84

11.1

15.4

8.75

2.09

5.63

1.34

a

a

GZ-794A

Naphthalene

R

0.033

9.39

GZ-794B

Naphthalene

S

0.080

2.00

GZ-796A

Biphenyl

R

0.79

6.70

GZ-796B

Biphenyl

S

2.25

1.13

GZ-790A

3-Methoxy

R

0.14

22.4

GZ-790B

3-Methoxy

S

0.52

12.8

GZ-792A

2-Methoxy

R

0.19

2.71

GZ-792B

2-Methoxy

S

0.79

1.19

GZ-793A

4-Methoxy

R

0.029

49.7

GZ-793B

4-Methoxy
3,4-Methylene
Dioxy
3,4-Methylene
Dioxy

S

0.18

18.9

R

0.16

13.1

S

0.76

2.90

GZ-791A

3-Flouro

R

0.19

1.32

GZ-791B

3-Flouro

S

1.03

0.60

GZ-795A

2,4-Dichloro

R

0.14

15.4

GZ-795B

2,4-Dichloro

S

0.090

20.7

GZ-797A
GZ-797B

a

b

a

GZb
258C
GZb
272C
GZb
261C
GZb
273C
GZb
252C
GZb
250C

GZb
275C
GZb
260C

a

0.091

a

b

0.034

b

0.030

b

0.026

b

0.015

b

0.043

b

0.093

0.016

b

b

NA, Not Applicable; data taken from Nickell et al., 2011; GZ-250C, 2,6-bis(2-(3,4methylenedioxyphenyl)ethyl)-1-methylpiperidine hydrochloride;GZ-252C, paramethoxy-phenyl
lobelane or 2,6-bis(2-(4-methoxyphenyl)ethyl)-1-methylpiperidine hydrochloride; GZ-260C, 2,6bis(2-(2,4-dichlorophenyl)ethyl)-1-methylpiperidine hydrochloride; GZ-261C, 2,6-bis(2-(3methoxyphenyl)ethyl)-1-methylpiperidine hydrochloride; GZ-272C, 2,6-bis(2-(biphenyl-4-yl)ethyl)1-methylpiperidine hydrochloride; GZ-273C, 2,6-bis(2-(2-methoxyphenyl)ethyl)-1-methylpiperidine
hydrochloride; GZ-275C, 2,6-bis(2-(3-fluorophenyl)ethyl)-1-methylpiperidine hydrochloride

.
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a

Fig. 19. Chemical structures of lobeline, lobelane and N-1,2-diol analogs.
For clarity of presentation, compounds are grouped according to structural
similarity of substituent additions to the phenyl rings: lobeline, lobelane and N1,2-diol; N-1,2-diol analogs containing 1-naphthyl or 4-biphenyl substituents; N1,2-diol analogs containing aromatic methoxy or methylenedioxy substituents; N1,2-diol analogs containing aromatic halogeno substituents.
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N
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O
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O

OH
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OH

O
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O
N
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O

N
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N

O
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Cl
Fumaric acid

OH

143

Cl
N

N
OH
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Cl Cl
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Fumaric acid

Cl

OH GZ-795B

Fig. 20. N-1,2-Diol analogs inhibit [3H]DA uptake into rat striatal
synaptosomes. For clarity of presentation, compounds are grouped according
to structural similarity of substituent additions to the phenyl rings: standards,
lobeline, lobelane and N-1,2-diol analogs (top left panel), N-1,2-diol analogs
containing 1-naphthyl or 4-biphenyl substituents (top right panel), N-1,2-diol
analogs containing aromatic methoxy or methylenedioxy substituents (bottom left
panel), or N-1,2-diol analogs containing aromatic halogeno substituents (bottom
right panel). Nonspecific [3H]DA uptake was determined in the presence of 10
μM GBR 12909. Control (CON) represents specific [3H]DA uptake in the
absence of analog (19.3 ± 0.94 pmol/mg/min). Legend provides compounds in
order from highest to lowest affinity. n = 4 rats/analog.
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Fig. 21. N-1,2-Diol analogs inhibit [3H]5-HT uptake into rat hippocampal
synaptosomes. For clarity of presentation, compounds are grouped according
to structural similarity of additions to the phenyl rings: standards, lobeline,
lobelane and N-1,2-diol analogs (top left panel), N-1,2-diol analogs containing 1naphthyl or 4-biphenyl substituents (top right panel), N-1,2-diol analogs
containing aromatic methoxy or methylenedioxy substituents (bottom left panel),
or N-1,2-diol analogs containing aromatic halogeno substituents (bottom right
panel). Nonspecific [3H]5-HT uptake was determined in the presence of 10 μM
fluoxetine. Control (CON) represents specific [3H]5-HT uptake in the absence of
analog (0.56 ± 0.06 pmol/mg/min). Legend provides compounds in order from
highest to lowest affinity. n = 4 rats/analog.
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Fig 22. N-1,2-diol analogs inhibit [3H]DTBZ binding to vesicle membranes
from rat whole brain preparations. For clarity of presentation, compounds are
grouped according to structural similarity of additions to the phenyl rings:
standards, lobeline, lobelane and N-1,2-diol analogs (top left panel), N-1,2-diol
analogs containing 1-naphthyl or 4-biphenyl substituents (top right panel), N-1,2diol analogs containing aromatic methoxy or methylenedioxy substituents
(bottom left panel), or N-1,2-diol analogs containing aromatic halogeno
substituents (bottom right panel). Nonspecific [3H]DTBZ binding was determined
in the presence of 10 μM Ro-4-1284. Control (CON) represents specific
[3H]DTBZ binding in the absence of analog (0.41 ± 0.01 pmol/mg protein).
Legend provides compounds in order from highest to lowest affinity. n = 4
rats/analog. Previous results for lobeline and lobelane were obtained from
Nickell et al., 2010.
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Fig 23. N-1,2-diol analogs inhibit [3H]DA uptake into vesicles prepared from
rat striatum. For clarity of presentation, compounds are grouped according to
structural similarity of additions to the phenyl rings: standards, lobeline, lobelane
and N-1,2-diol analogs (top left panel), N-1,2-diol analogs containing 1-naphthyl
or 4-biphenyl substituents (top right panel), N-1,2-diol analogs containing
aromatic methoxy or methylenedioxy substituents (bottom left panel), or N-1,2diol analogs containing aromatic halogeno substituents (bottom right panel).
Nonspecific [3H]DA uptake was determined in the presence of 10 μM Ro-4-1284.
Control (CON) represents specific vesicular [3H]DA uptake in the absence of
analog (34.1 ± 1.18 pmol/mg/min). Legend provides compounds in order from
highest to lowest affinity. n = 4 rats/analog.
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Fig 24. Lack of correlation between N-1,2-diol analogs inhibition of
[3H]DTBZ binding and [3H]DA uptake at VMAT2. Data presented are Ki values
obtained from concentration-response curves for analog-induced inhibition of
[3H]DTBZ binding and [3H]DA uptake at VMAT2 (Figs. 21 and 22, respectively).
Pearson’s correlation analysis revealed a lack of correlation (Pearson’s
correlation coefficient r = 0.37; p = 0.13) between the ability of N-1,2-diol analogs
to inhibit [3H]DTBZ binding to VMAT2 and to inhibit [3H]DA uptake at VMAT2.
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Fig 25. N-1,2-Diol analogs competitively inhibit [3H]DA uptake into vesicles
prepared from rat striatum. Concentrations of GZ-793A (0.029 µM), GZ-794A
(0.060 µM), and GZ-796A (0.79 µM) approximated the Ki values for inhibiting
[3H]DA uptake into isolated synaptic vesicles obtained from the data shown in
Fig. 22. Km (top panel) and Vmax (bottom panel) values are mean ± S.E.M. (** p <
0.01 different from control; *** p < 0.001 different from control; n = 4 - 7
rats/analog)
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Fig 26. In a concentration-dependent manner, GZ-793A, GZ-794A, and GZ796A inhibit METH-evoked peak DA fractional release from striatal slices.
Peak response data are expressed as mean ± S.E.M. pg/ml/mg of the slice
weight. Slices were superfused with analog (10 nM – 10 µM) and after a 10 min
collection to determine intrinsic activity, METH (5 µM) was added to the buffer for
15 minutes. Analog remained in the buffer until the end of the experiment. *p <
0.05 different from METH alone (CON). n = 5 rats
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CHAPTER FOUR

GZ-793A, a Novel VMAT2 Inhibitor that Probes Multiple Sites on VMAT2 as
a Potential Treatment for METH Abuse
Portions of this chapter have been submitted for publication in the manuscript:
Horton DB, Zheng G, Crooks PA, Dwoskin LP. GZ-793A interacts with the
vesicular monoamine transporter-2 to inhibit the effect of
methamphetamine. J Neurochem, submitted, 2011.

I.

Introduction
METH abuse is a serious public health concern. According to the 2010

National Survey on Drug Use and Health, over 350,000 people in the United
States reported using METH in the past month (NSDUH, 2011). Currently, no
FDA-approved pharmacotherapies are available to treat METH abuse. METH
produces reward by increasing extracellular DA concentrations through DATmediated reverse transport (Fischer and Cho, 1979; Wise and Bozarth, 1987; Di
Chiara and Imperato, 1988). METH is transported into the synaptic vesicles via
VMAT2 and/or passively diffuses across the vesicular membrane (Peter et al.
1995). METH inhibits DA uptake at VMAT2, promotes DA release from synaptic
vesicles and inhibits monoamine oxidase leading to increases in cytosolic DA
available for DAT-mediated reverse transport (Sulzer and Rayport 1990; Pifl et
al. 1995; Sulzer et al. 2005). METH is transported into vesicles through VMAT2
and simultaneously releases DA from synaptic vesicles, similar to the facilitated
diffusion exchange model of DA release at DAT (Fischer and Cho, 1979; Sulzer
et al. 2005). Thus, the primary site of METH action is VMAT2, which increases
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cytosolic DA available for reverse transport of DAT to increase extracellular DA
concentrations leading to reward.
Based on the role of VMAT2 in METH effects, drug discovery efforts have
focused on VMAT2 as a pharmacological target for the development of novel
compounds to treat METH abuse. Lobeline (Fig. 27), the principal alkaloid of
Lobelia inflata, inhibits [3H]DTBZ binding to VMAT2, [3H]DA uptake at VMAT2,
and METH-evoked DA release from striatal slices (Teng et al. 1997, 1998; Nickell
et al. 2010). Lobeline inhibits METH-induced hyperactivity, behavioral
sensitization and METH self-administration in rats, supporting its potential as a
treatment for METH abuse (Harrod et al. 2001, 2003; Dwoskin and Crooks,
2002). Lobeline has been evaluated in clinical trials for this indication (Jones,
2007). Importantly, lobeline has limited selectivity for VMAT2, also having high
affinity for nicotinic acetylcholine receptors (Damaj et al. 1997; Miller et al. 2004).
Structure activity relationships revealed that lobelane (Fig. 27), a
saturated, chemically defunctionalized lobeline analog, exhibited low affinity for
nicotinic receptors and enhanced affinity and selectivity for VMAT2 compared to
its parent compound (Miller et al. 2004; Nickell et al. 2010). Lobelane also
inhibited METH-evoked DA release from striatal slices and decreased METH
self-administration in rats (Neugebauer et al. 2007; Nickell et al. 2010). However,
tolerance developed to the behavioral effects of lobelane (Neugebauer et al.
2007). The physicochemical properties of lobelane were not optimal, including
low water solubility, which limited development with respect to clinical
investigation.
157

Structural modification of lobelane was pursued with the aim of improving
water solubility. Replacement of the N-methyl group of lobelane with a N-propan1,2-diol moiety afforded the lead analog, GZ-793A [R-N-(1,2-dihydroxypropyl)2,6-cis-di-(4-methoxyphenethyl)piperidine hydrochloride] (Fig. 27). GZ-793A
potently and selectively inhibited DA uptake at VMAT2, increasing the Km value
with no change in Vmax, indicative of a competitive mechanism of inhibition
(Chapter 3, Horton et al. 2011). Further, GZ-793A decreased METH-evoked DA
release from striatal slices, without altering field stimulation- and nicotine-evoked
DA release, indicating specific inhibition of the effects of METH (Chapter 3,
Horton et al., 2011; unpublished observations). Importantly, GZ-793A specifically
decreased METH self-administration without altering food-maintained responding
(Beckmann et al. 2011). Thus, the ability of GZ-793A to inhibit METH in vitro
translated into efficacy against METH in the in vivo animal model. However, the
cellular mechanism underlying the GZ-793A-induced inhibition of METH both in
vitro and in vivo has not been evaluated fully. The current study determined the
ability of GZ-793A to inhibit the effects of METH to release DA from isolated
synaptic vesicles. Considering that VMAT2 is a primary target for the mechanism
of action of METH, the ability of GZ-793A to evoke [3H]DA release and inhibit
METH-evoked [3H]DA release from vesicles was investigated, and these effects
were compared to those of the classical VMAT2 inhibitors, TBZ and reserpine.
The hypothesis of this chapter is that GZ-793A interacts with VMAT2 to
release DA from striatal vesicles and inhibit METH-evoked DA release from
striatal vesicles.
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II.

Methods
IIa.

Animals. Male Sprague-Dawley rats (200–250g, Harlan,

Indianapolis, IN) were housed two per cage with ad libitum access to food and
water in the Division of Laboratory Animal Resources at the University of
Kentucky (Lexington, KY). Experimental protocols involving the animals were in
accord with the 1996 NIH Guide for the Care and Use of Laboratory Animals and
were approved by the Institutional Animal Care and Use Committee at the
University of Kentucky.
IIb.

Materials. [3H]Dopamine ([3H]DA; dihydroxyphenylethylamine, 3,4-

[7-3H]; specific activity, 28 Ci/mmol) was purchased from PerkinElmer, Inc.
(Boston, MA, USA). ATP-Mg2+, DA, EDTA, EGTA, HEPES, MgSO4,
polyethyleneimine (PEI), KOH, potassium tartrate, reserpine and sucrose were
purchased from Sigma-Aldrich, Inc. (St. Louis, MO, USA). Ascorbic acid and
NaHCO3 were purchased from Aldrich Chemical Co. (Milwaukee, WI, USA).
Complete counting cocktail 3a70B was purchased from Research Products
International Corp. (Mount Prospect, IL, USA). TBZ was a generous gift from
Hoffman-LaRoche Inc. (Nutley, NJ, USA).
IIc.

Vesicular [3H]DA release assay. GZ-793A- and METH-evoked

vesicular [3H]DA release were determined using previously described methods
(Nickell et al., 2011). Briefly, striata were homogenized in 14 ml of ice-cold 0.32
M sucrose solution containing 5 mM NaHCO3 (pH 7.4) with 10 up-and-down
strokes of a Teflon pestle homogenizer (clearance, ~ 0.008”). Homogenates were
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centrifuged at 2,000 × g for 10 min at 4 °C and resulting supernatants centrifuged
at 10,000 × g for 30 min at 4 °C. Pellets were resuspended in 2.0 ml of 0.32 M
sucrose and were transferred to tubes containing 7 ml of milliQ water and
homogenized with 5 up-and-down strokes of the Teflon pestle homogenizer.
Homogenates were transferred to tubes containing 900 μl of 0.25 M HEPES and
900 μl of 1.0 M potassium tartrate solution and centrifuged at 20,000 × g for 20
min at 4 ºC. Resulting supernatants were centrifuged at 55,000 × g for 60 min at
4 ºC. Subsequently, 100 μl of 1 mM MgSO4, 100 μl of 0.25 M HEPES and 100 μl
of 1.0 M potassium tartrate were added to the supernatant and centrifuged at
100,000 × g for 45 min at 4 ºC. Pellets were resuspended in 2.7 ml of assay
buffer, containing: 25 mM HEPES, 100 mM potassium tartrate, 50 μM EGTA, 100
μM EDTA, and 1.7 mM ascorbic acid, 2 mM ATP-Mg2+ (pH 7.4). Then, [3H]DA
(300 μl of 0.3 μM) was added and samples incubated for 8 min at 37 ºC.
Following incubation, samples were centrifuged at 100,000 × g for 45 min at 4 ºC
and resulting pellets were resuspended in a final volume of 4.2 ml of assay
buffer. [3H]DA-preloaded vesicles (180 μl) were added to duplicate tubes in the
absence or presence of various concentrations (1 nM – 1 mM; 20 μl) of GZ-793A,
METH or reserpine, for a final volume of 200 µl and incubated for 8 min at 37 °C.
Reactions were terminated by the addition of 2.5 ml of ice-cold assay buffer and
rapid filtration through Whatman GF/B filters. Samples were washed 3 times with
assay buffer containing 2 mM MgSO4 in the absence of ATP. Radioactivity
retained by the filters was determined by liquid scintillation spectrometry (B1600
TR scintillation counter; PerkinElmer, Inc.). GZ-793A-, METH- or reserpine-
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evoked [3H]DA release was calculated for each test compound concentration by
subtracting the radioactivity remaining on the filter in the presence of compound
from the amount of radioactivity remaining on the filter in the absence of
compound (control samples).
To determine if GZ-793A-induced [3H]DA release from striatal synaptic
vesicles was inhibited by TBZ (TBZ-sensitive) or reserpine (reserpine-sensitive),
[3H]DA-preloaded synaptic vesicles (180 μl) were added to duplicate tubes
containing a range of concentrations (1 nM – 1 mM) of GZ-793A in the absence
and presence of TBZ (35 nM) or reserpine (50 nM), and incubated (final volume,
200 μl) for 8 min at 37 ºC. Samples were processed as previously described.
To determine if METH-induced [3H]DA release from striatal synaptic
vesicles was TBZ- or GZ-793A-sensitive, [3H]DA-preloaded synaptic vesicles
(180 μl) were added to duplicate tubes containing a range of concentrations (1
nM – 1 mM) of METH in the absence and presence of TBZ (30 nM – 10 μM) or
GZ-793A (7 nM - 1μM), and incubated (final volume, 200 μl) for 8 min at 37 ºC.
Samples were processed as previously described.
To determine if GZ-793A-induced inhibition of METH-evoked DA release
was the result of a rate-dependent slow-offset dissociation, [3H]DA-preloaded
synaptic vesicles (180 μl) were added to duplicate tubes containing a range of
concentrations (1 μM – 1 mM) of METH in the absence and presence of GZ793A (1 μM), and incubated (final volume, 200 μl) for either 8 min or 15 min at 37
ºC. Samples were processed as previously described.
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IId.

Data analysis. EC50 values for GZ-793A, METH and reserpine

were determined from the concentration-effect curves via an iterative curve-fitting
program (Prism 5.0; GraphPad Software Inc., San Diego, CA). EC50 values for
GZ-793A evoked [3H]DA release in the presence of TBZ or reserpine were
determined also using the Prism 5.0 curve-fitting program TBZ-induced and GZ793A-induced inhibition of METH-evoked [3H]DA release were analyzed using
separate two-way repeated-measures ANOVA. If significant TBZ x METH or GZ793A x METH interactions were found, one-way ANOVAs followed by Dunnetts’s
post hoc test were performed at each METH concentration to determine the
concentrations that decreased METH-evoked [3H]DA release. To determine if the
various concentrations of TBZ or GZ-793A increased the log EC50 value or
decreased the Emax for METH compared to the values for these parameters in the
absence of inhibitor (control), one-way ANOVAs were conducted followed by
Dunnett’s post hoc test. Schild analyses were performed using the dose ratios
(DR) obtained by dividing the EC50 for METH-evoked [3H]DA release in the
presence of inhibitor by that in the absence of inhibitor. Log (DR-1) was plotted
as a function of log inhibitor concentration to provide the Schild regression. The
data were fit by linear regression and the slope determined and linearity was
assessed using Prism 5.0. Significant difference from unity was concluded if the
95% confidence intervals (CI) of the slope did not include unity (Kenakin, 2006).
To determine if the effect of GZ-793A to inhibit METH was rate dependent,
a three-way repeated-measures ANOVA was performed. If significant
interactions were found, follow-up ANOVAs were performed to identify the source
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of the interaction. Differences between EC50 values and between Emax values
were determined using repeated-measures two-way ANOVAs. For all analyses,
significance was defined as p < 0.05.
III.

Results
IIIa. GZ-793A evoked [3H]DA release from striatal vesicles. GZ-

793A-evoked [3H]DA release from isolated striatal synaptic vesicles is illustrated
in Fig. 28. Nonlinear regression of the GZ-793A concentration-response revealed
a two-site model of GZ-793A interaction with VMAT2 (R2 = 0.89, p < 0.001; Hi
and Low EC50 = 14.3 ± 4.46 nM and 33.0 ± 4.00 µM, respectively; Hi and Low
Emax = 37.5 ± 4.32% and 86.1 ± 2.69% vesicular [3H]DA content, respectively).
To evaluate inhibition of the effect of GZ-793A on DA release, the highest
concentration (35 nM) of TBZ that did not evoke DA release from isolated
vesicles was chosen (Nickell et al., 2011). TBZ inhibited only the effect of GZ793A to release DA via the Hi affinity sites on VMAT2 (Fig. 28). Nonlinear
regression revealed a one-site model of GZ-793A interaction with VMAT2 in the
presence of TBZ (R2 = 0.95, p < 0.001; EC50 = 23.7 ± 6.53 µM).
The effect of reserpine to increase [3H]DA release from vesicles was
determined (Fig. 29). Nonlinear regression of the reserpine concentration
response revealed a significant fit to a one-site model (R2 = 0.25, p < 0.001; EC50
= 1.44 ± 0.47 µM, Emax = 28.4 ± 7.48%). The highest concentration (50 nM) of
reserpine that did not evoke DA release from isolated vesicles was chosen to
evaluate if GZ-793A-evoked [3H]DA release was reserpine sensitive.
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Concentration response for GZ-793A-evoked [3H]DA release from striatal
vesicles in the absence and presence of reserpine (50 nM) is illustrated in Fig.
28. Reserpine inhibited only the effect of GZ-793A to release DA via the Hi
affinity sites on VMAT2. Nonlinear regression revealed a one-site model of GZ793A interaction with VMAT2 in the presence of reserpine (R2 = 0.92, p < 0.001;
EC50 = 20.2 ± 3.17 µM).
IIIb.

TBZ inhibits METH-evoked [3H]DA release from striatal

vesicles. The concentration response for METH to evoke [3H]DA release from
synaptic vesicles was analyzed using nonlinear regression and a significant fit to
a single site model was found (R2 = 0.95, p < 0.001;Fig. 30). The EC50 value for
METH was 8.93 ± 1.36 µM and Emax was 87.4 ± 1.37% (Table 4), consistent with
our previous findings (Nickell et al., 2011). Based on our previous concentration
response (Nickell et al., 2011), a full range of TBZ concentrations were chosen to
evaluate the ability of TBZ to decrease METH-evoked [3H]DA release from
synaptic vesicles. TBZ produced a rightward shift in the METH concentrationresponse, consistent with surmountable inhibition. A linear fit (r2 = 0.79, p <
0.001) to the Schild regression revealed a slope (s = 0.92 ± 0.33) not significantly
different from unity, consistent with competitive inhibition (Fig. 30, inset). Twoway repeated measures ANOVA revealed a main effect of METH (F11,209 = 435, p
< 0.0001) and TBZ (F4,19 = 7.61, p < 0.001), and a METH × TBZ interaction
[F44,209 = 12.8, p < 0.0001). To further evaluate the interaction, one-way ANOVAs
were conducted at each METH concentration to determine the TBZ concentration
which decreased release (Table 5; METH 3 µM, F4,20 = 3.96, p < 0.05; 10 µM,
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F4,20 = 18.2, p < 0.0001; 30 µM, F4,20 = 31.1, p < 0.0001; 100 µM, F4,20 = 46.4, p <
0.0001; 300 µM, F4,19 = 29.3, p < 0.0001; 1 mM, F4,30 = 9.39, p < 0.001). Post hoc
analyses revealed that at 3 µM METH, only 10 µM TBZ significantly decreased
METH-evoked [3H]DA release. At 10 µM - 1 mM METH, TBZ (100 nM, 1 µM,
and 10 µM) significantly decreased METH-evoked [3H]DA release. Analysis of
the log EC50 for METH-evoked [3H]DA release revealed that TBZ (100 nM - 10
µM) increased the METH EC50 value (Table 4; F4,20 = 43.6, p < 0.0001).
IIIc.

GZ-793A inhibits METH-evoked [3H]DA release from striatal

vesicles. The concentration response for METH to evoke [3H]DA release from
synaptic vesicles is illustrated in Fig. 31. Using nonlinear regression a significant
fit to a one-site model was obtained for the METH concentration response (R2 =
0.90, p < 0.001). The EC50 value for METH was 19.5 ± 5.19 µM and Emax was
88.0 ± 1.21% (Table 4), in agreement with our previous findings (Nickell et al.,
2011). Fig. 31 also illustrates that concentrations of GZ-793A, which selectively
interact with the Hi-affinity site on VMAT2 (Fig. 28), inhibited the METH-evoked
[3H]DA release. A rightward shift in the METH concentration-response curve was
evident with increasing concentrations of GZ-793A, consistent with surmountable
inhibition. A linear fit (r2 = 0.95, p < 0.001) to the Schild regression revealed a
slope (s = 0.49 ± 0.08) significantly different from unity based on the 95%
confidence interval (CI: 0.15 to 0.83), consistent with allosteric inhibition (Fig. 31,
inset). Analysis of the concentration response by two-way repeated measures
ANOVA revealed main effects of METH (F11,308 = 821, p < 0.001) and GZ-793A
(F4,28 = 8.82, p < 0.001), and a METH × GZ-793A interaction (F44,308 = 8.13, p <
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0.001). To further evaluate the interaction, one-way ANOVAs were conducted at
each METH concentration to determine the GZ-793A concentrations which
decreased release (Table 5; METH 1 µM, F4,30 = 3.31, p < 0.05; 3 µM, F4,30 =
9.10, p < 0.0001; 10 µM, F4,30 = 12.9, p < 0.0001; 30 µM, F4,30 = 20.4, p < 0.0001;
100 µM, F4,30 = 25.1, p < 0.0001; 300 µM, F4,28 = 15.6, p < 0.0001; 1 mM, F4,30 =
7.12, p < 0.001). Post hoc analyses revealed that at 1 µM METH, only 1 µM GZ793A significantly decreased [3H]DA release and at 3 µM METH, GZ-793A (70
nM, 100 nM, and 1 µM) significantly decreased [3H]DA release. At higher
concentrations of METH, GZ-793A (70 nM – 1 µM) significantly decreased
METH-evoked [3H]DA release. Analysis of the log EC50 for METH-evoked [3H]DA
release revealed that GZ-793A (70 nM - 1 µM) increased the METH EC50 value
(Table 4; F4,30 = 26.6, p < 0.0001).
IIId.

GZ-793A-induced inhibition of METH-evoked [3H]DA release

was not rate-dependent. To provide further evidence regarding the mechanism
of GZ-793A inhibition of the effect of METH at synaptic vesicles, additional
experiments determined if the GZ-793A-induced inhibition of METH-evoked
[3H]DA release was rate-dependent. The highest concentration of GZ-793A (1
µM), shown to selectively interact with the Hi-affinity site on VMAT2 (Fig. 28),
was evaluated for inhibition of METH-evoked [3H]DA release after 8- and 15-min
incubation (Fig. 32). Three-way repeated measures ANOVA revealed a main
effect of METH F4,32 = 498, p < 0.0001) and GZ-793A (F1,8 = 62.2, p < 0.0001),
and a METH × GZ-793A interaction (F4,32 = 39.2, p < 0.0001); however, no main
effect of time or interactions of METH × time, GZ-793A × time or METH × GZ166

793A × time were observed. Increasing the incubation time from 8 to 15 min did
not alter EC50 or Emax for METH-evoked [3H]DA release.
IV.

Discussion
METH inhibits DA uptake at VMAT2 and evokes DA release from synaptic

vesicles increasing intracellular DA concentrations available for METH-induced
reverse transport via DAT to ultimately increase extracellular DA concentrations
(Sulzer et al., 2005). The lead compound emerging from our iterative drug
discovery approach, GZ-793A, decreases METH-evoked DA release from
superfused striatal slices and decreases METH self-administration in rats
(Beckmann et al. 2011; Chapter 3, Horton et al. 2011b). The cellular mechanism
underlying the GZ-793A-induced inhibition of METH’s effects has not been
elucidated fully. The current results show that GZ-793A potently released [3H]DA
from isolated striatal synaptic vesicles. GZ-793A-induced release was mediated
by two sites on VMAT2, i.e., a Hi-affinity, TBZ- and reserpine-sensitive site, and a
Low-affinity, TBZ- and reserpine-insensitive site. Moreover, GZ-793A inhibited
METH-evoked [3H]DA release from vesicles by interacting with the Hi-affinity
VMAT2 site. Thus, GZ-793A inhibits the effects of METH at VMAT2, which may
underlie the previously reported GZ-793A-induced decrease in METH selfadministration.
Previous research from our laboratories demonstrated that GZ-793A
potently (Ki = 29 nM) and competitively inhibits [3H]DA uptake at VMAT2 using
isolated synaptic vesicle preparations. Interestingly, GZ-793A exhibited a 285fold higher affinity for the DA translocation site compared with the [3H]DTBZ
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binding site (Ki = 8.29 µM), suggesting that the inhibition of DA uptake is not via
an interaction at the DTBZ site on VMAT2 (Chapter 3, Horton et al. 2011b). TBZ
and reserpine have been shown to act at two different sites on VMAT2 (Yelin and
Schuldiner, 2000). Relative to the classical VMAT2 inhibitors, GZ-793A was
found to be equipotent with TBZ and reserpine inhibiting DA uptake at VMAT2,
but was 1-2-orders of magnitude less potent than TBZ and reserpine at the
[3H]DTBZ binding site (Partilla et al., 2006; Chapter 3, Horton et al., 2011b;
Meyer et al., 2011; Nickell et al., 2011), consistent with these sites being
different.
Since GZ-793A exhibited a higher affinity for the DA translocation site
compared with the [3H]DTBZ binding site on VMAT2, GZ-793A inhibition of
METH-evoked [3H]DA release appeared to be due to inhibition of DA uptake at
VMAT2. However, GZ-793A was significantly more potent (365-fold) inhibiting
[3H]DA uptake into vesicles than it was inhibiting METH-evoked DA release from
striatal slices, warranting further evaluation of the cellular mechanism underlying
the pharmacological effects of GZ-793A. Our working hypothesis was based on
the idea that METH interacts with an extravesicular site on VMAT2 to inhibit DA
uptake into the vesicle, and with an intravesicular site on VMAT2 to evoke DA
release from the vesicle (Fig. 33). The current results show that GZ-793A also
releases DA from the synaptic vesicle, presumably by interacting with
intravesicular sites on VMAT2. Moreover, the biphasic concentration-response
curve for GZ-793A to release [3H]DA supports an interaction with two different
intravesicular sites, a Hi-affinity site and a Low-affinity site (Fig. 28). The current
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results also show that the intravesicular Hi-affinity site for GZ-793A was both
TBZ- and reserpine-sensitive. The Low-affinity site was insensitive to both TBZ
and reserpine, suggesting that the Low-affinity site may represent a nonspecific
effect of GZ-793A, e.g., disruption of the proton gradient responsible for retention
of DA in the synaptic vesicle (Sulzer et al. 2005). The ability of TBZ and
reserpine to inhibit GZ-793A-evoked DA release at the intravesicular Hi-affinity
site appears to be via an allosteric interaction, since TBZ and reserpine act at
different sites on VMAT2 (Pletscher, 1977; Darchen et al., 1989; Yelin and
Schuldiner, 2000). Thus, TBZ and reserpine may conformationally change the
VMAT2 protein resulting in inhibition of GZ-793A-evoked DA release.
Concentration-response curves for both TBZ and reserpine to release DA
were consistent with a one-site model of interaction (current results; Nickell et al.,
2011), further indicating that GZ-793A acts differently than the classical VMAT2
standards at the DA release site on VMAT2. Although GZ-793A, TBZ and
reserpine were equipotent at the extravesicular DA translocation site on VMAT2,
the order of potency for DA release via the intravesicular site on VMAT2 was GZ793A > TBZ > reserpine, suggesting that DA uptake and DA release are
mediated by two different sites on VMAT2. Of note, GZ-793A interacts with the Hi
affinity site mediating DA release across the same concentration range that it
inhibits DA uptake by VMAT2 (Hi affinity DA release site, EC50 = 15 nM; DA
uptake site, Ki = 29 nM; current results; Chapter 3, Horton et al., 2011b).
Differential protein kinase C regulation of DA uptake and release sites on DAT
(Gnegy, 2003) provides precedence for alternate recognition sites on VMAT2
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that mediate DA uptake into and DA release from the vesicle. Thus, GZ-793A
interacts with at least 3 sites on VMAT2 (Fig. 33), i.e., the intravesicular DA
release site, the extravesicular DA uptake site and the extravesicular DTBZ
binding site.
The goal of the current work was to identify compounds which have
efficacy decreasing the neurochemical effects of METH as potential
pharmacotherapeutics to treat METH abuse. METH evokes DA release from
synaptic vesicles increasing the concentration of cytosolic DA available for
reverse transport by DAT, leading to an increase in DA in the extracellular space
(Sulzer et al. 2005). The current results demonstrate that low concentrations of
the lead compound GZ-793A, that selectively interact with Hi-affinity sites on
VMAT2 to evoke DA release, inhibit METH-evoked DA release from striatal
synaptic vesicles. Results show that increasing concentrations of GZ-793A
produced a rightward shift in the METH concentration response; however, the
Schild regression revealed a slope different from unity, consistent with
surmountable allosteric inhibition. Precedence for surmountable allosteric
inhibition has been provided by previous research on nicotinic and muscarinic
acetylcholine receptor antagonists (Tucek and Proska, 1995; Kukkonen et al.,
2004; Wooters et al., 2011). Interpretations of concentration-response curves
using Schild regression analysis are unambiguous with receptor binding data
relative to functional data (Kenakin, 1993). However, the distinction between
ligand-gated ion channel receptors and transporters has become blurred with a
greater understanding of these proteins (Sonders and Amara, 1996; Galli et al.,
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1996; Sonders et al., 1997). In accordance with the characteristics of an
allosteric mechanism of inhibition (Kenakin, 2006), the shift to the right in the
concentration response for METH-evoked DA release via VMAT2 should be
diminished, as the allosteric site becomes saturated with increasing GZ-793A
concentrations. Current results show a 5-fold shift in EC50 as the GZ-793A
concentration progressed from 7 to 70 nM, but only a 1-2-fold shift was apparent
with GZ-793A concentrations ranging from 70 to 1000 nM, consistent with an
allosteric mechanism. Further support for surmountable allosteric inhibition of
METH-evoked DA release by GZ-793A is derived from the current observation
that the inhibitory effect of GZ-793A was not rate dependent, as evidenced by no
differences in the METH concentration-response curves in the presence of GZ793A with increasing incubation time. Thus, GZ-793A inhibits METH by
producing a conformational change in the VMAT2 protein, reducing the affinity of
METH for the intravesicular DA release site, without altering efficacy of METH to
release DA.
While GZ-793 shares pharmacological characteristics with the classical
VMAT2 inhibitors, TBZ and reserpine, there are also notable differences in their
interaction with VMAT2. First, although GZ-793A, TBZ and reserpine are
equipotent and completely inhibit DA uptake at the extravesicular site on VMAT2
(Partilla et al., 2006; Chapter 3, Horton et al., 2011b; Nickell et al., 2011), the
inhibition produced by reserpine is irreversible (Rudnick et al., 1990), whereas
inhibition produced by TBZ and GZ-793A is not (Near, 1986; data not shown).
TBZ has been classified as a noncompetitive inhibitor of the DA uptake site on
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VMAT2 (Scherman and Henry, 1984); however, our results indicate that TBZ
inhibits DA uptake through a surmountable allosteric mechanism (Nickell et al.,
2011). GZ-793A inhibition of DA uptake at VMAT2 also has been shown to be
surmountable (Chapter 3, Horton et al., 2011b); although a Schild analysis has
not been carried out to determine if GZ-793A-induced inhibition of DA uptake is
via an allosteric or orthosteric mechanism. Second, these compounds differ in
the order of potency for interaction at the extravesicular DTBZ binding site on
VMAT2 (TBZ>reserpine>GZ-793A; Partilla et al., 2006; Chapter 3, Horton et al.,
2011), supporting the interpretation that GZ-793A acts differently than TBZ and
reserpine. Third, with respect to the intravesicular DA release sites, GZ-793A
exhibited a different pattern for the concentration response compared to that for
TBZ and reserpine. Specifically, the concentration-response curves for GZ-793A
to evoke DA release from synaptic vesicles fit a two-site model of interaction,
while those for TBZ and reserpine fit a one-site model. Further, GZ-793A
released DA with greater efficacy (Emax = 88%) than either TBZ or reserpine
(Emax = 48.5 and 28.4%, respectively), suggesting that GZ-793A has greater
access to the ATP-associated pool of DA within the synaptic vesicles. Moreover,
GZ-793A inhibited METH-evoked DA release at the Hi affinity DA release site via
a surmountable allosteric mechanism, while TBZ-induced inhibition of METHevoked DA release is consistent with a competitive mechanism of action. Taken
together, GZ-793A exhibits a unique pharmacological profile in terms of its
interaction with VMAT2.

172

In summary, GZ-793A likely interacts with at least three distinct sites on
VMAT2: 1) the extravesicular DTBZ binding site (low affinity), 2) the
extravesicular DA uptake site (high affinity) and 3) intravesicular DA release sites
(high and low affinity). GZ-793A inhibits METH-evoked DA release from synaptic
vesicles via a surmountable allosteric mechanism. As such, GZ-793A inhibits
METH-induced increases in cytosolic DA by interacting with VMAT2. There are a
limited number of available compounds that interact with VMAT2. The addition of
GZ-793A to our armamentarium has augmented our understanding of VMAT2
function and has identified a specific pharmacological target to prevent METH’s
neurochemical action. GZ-793A represents a lead in the development of novel
therapeutics for the treatment of METH abuse.
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Table 4. Summary of EC50 and Emax for METH-evoked [3H]DA release in the
absence and presence of TBZ or GZ-793A

EC50 (µM)

Emax (%)

TBZ on METH-evoked [3H]DA release
TBZ (0 nM)

8.93 ± 1.36

82.1 ± 1.21

TBZ (30 nM)

9.89 ± 2.44

83.4 ± 1.23

TBZ (100 nM)

45.5 ± 12.7 *

72.0 ± 1.39

TBZ (1 µM)

185 ± 31.1 *

88.1 ± 4.55

TBZ (10 µM)

366 ± 115 *

91.9 ± 10.3

GZ-793A on METH-evoked [3H]DA release
GZ-793A (0 nM)

18.9 ± 5.21

85.7 ± 1.22

GZ-793A (7 nM)

11.6 ± 1.37

86.2 ± 0.90

GZ-793A (70 nM)

56.3 ± 6.16 *

80.7 ± 3.50

GZ-793A (100 nM)

62.4 ± 8.10 *

82.7 ± 2.33

GZ-793A (1 µM)

119 ± 12.2 *

79.1 ± 4.02

*p<0.05 different from [3H]DA release in the presence of METH alone and
absence of TBZ or GZ-793A.
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Table 5. Summary of TBZ and GZ-793A concentrations that significantly
decreased METH-evoked [3H]DA release compared to control.
METH

TBZ

GZ-793A

1 nM

-

-

10 nM

-

-

100 nM

-

-

300 nM

-

-

1 µM

-

1 µM

3 µM

10 µM

70 nM, 100 nM, 1 µM

10 µM

100 nM, 1 µM, 10 µM

70 nM, 100 nM, 1 µM

30 µM

100 nM, 1 µM, 10 µM

70 nM, 100 nM, 1 µM

100 µM

100 nM, 1 µM, 10 µM

70 nM, 100 nM, 1 µM

300 µM

100 nM, 1 µM, 10 µM

100 nM, 1 µM

1 mM

100 nM, 1 µM, 10 µM

100 nM, 1 µM
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Fig. 27. Chemical structures of lobeline, lobelane, GZ-793A, TBZ,
reserpine. Lobeline is the principal alkaloid found in lobelia inflata. Lobelane is
the chemically defunctionalized, saturated analog of lobeline. GZ-793A is a paramethoxy analog of lobelane incorporating an N-propan-1,2-diol moiety. TBZ is a
benzoquinolizine compound and VMAT2 inhibitor proposed to interact with a site
distinct from the DA uptake site on VMAT2. Reserpine is an indole alkaloid and
VMAT2 inhibitor, proposed to interact with the DA uptake site on VMAT2.
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Fig. 28. GZ-793A-evoked [3H]DA release from striatal vesicles fits a two-site
model; DA release mediated by the high affinity site is TBZ- and reserpinesensitive. Data represents the ability of GZ-793A to evoke [3H]DA release from
striatal vesicles in the absence (closed circles) and presence of TBZ (35 nM;
open squares) or reserpine (50 nM, closed triangle). Control (CON) represents
[3H]DA release in the absence of GZ-793A. Data are mean (± S.E.M) [3H]DA
release as a percentage of the control. n = 4-8 rats/experiment.
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Fig. 29. Reserpine evoked [3H]DA release from striatal synaptic vesicles.
Data represents the ability of reserpine to evoke [3H]DA release from striatal
vesicles. GZ-793A-evoked [3H]DA release (10 µM and 100 µM) was included as
a positive control in the experiment (data not shown). Control (CON) represents
[3H]DA release in the absence of reserpine. Data are mean (± S.E.M) [3H]DA
release as a percentage of the control. n = 5 rats.
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Fig. 30. TBZ inhibits METH-evoked [3H]DA release from striatal vesicles.
Data represents the ability of TBZ to inhibit METH-evoked [3H]DA release from
striatal vesicles. Control represents [3H]DA release in the absence of METH and
TBZ. Data are mean (± S.E.M) [3H]DA release as a percentage of the control. n =
4-9 rats/experiment. Inset shows the Schild regression; log of DR−1 is plotted as
a function of log of TBZ concentration.
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Fig. 31. GZ-793A inhibits METH (METH)-evoked [3H]DA release from striatal
vesicles. Data represents the ability of GZ-793A to inhibit METH-evoked [3H]DA
release from striatal vesicles. Control represents [3H]DA release in the absence
of METH and GZ-793A. Data are mean (± S.E.M) [3H]DA release as a
percentage of the control. n = 4-10 rats/experiment. Inset shows the Schild
regression; log of DR−1 is plotted as a function of log of GZ-793A concentration.
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Fig 32. GZ-793A-induced inhibition of METH-evoked DA release is not ratedependent. Data represents the ability of METH to evoke [3H]DA release from
striatal vesicles following 8 min incubation in the absence (closed circle) and
presence of GZ-793A (1 µM; closed square) or following 15 min incubation in the
absence (open circles) and presence of GZ-793A (1 µM; open square). Control
(CON) represents [3H]DA release in the absence of METH and GZ-793A. Data
are mean (± S.E.M) [3H]DA release as a percentage of the control. n = 3 rats.
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Fig 33. GZ-793A interacts with multiple sites on VMAT2. GZ-793A interacts
with the extravesicular [3H]DTBZ binding site (open square) with low affinity, the
extravesicular [3H]DA uptake site (closed circle) with high affinity, and
intravesicular [3H]DA release sites (TBZ- and reserpine-sensitive Hi-affinity site,
closed triangle; TBZ- and reserpine-insensitive Low-affinity site, open triangle).
Also illustrated is the proposed intravesicular site mediating GZ-793A-induced
inhibition of METH-evoked DA release.
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CHAPTER FIVE

Acute and Repeated GZ-793A Does Not Alter DA Content and GZ-793A
Pretreatment Protects Against METH-Induced DA Content Depletion
Portions of this chapter have been submitted for publication in the manuscript:
Siripurapu KB, Horton DB, (co-first authors) Zheng G, Crooks PA, Dwoskin LP.
GZ-793A does not exacerbate methamphetamine-induced dopamine
depletions in striatal tissue and striatal vesicles. Eur J Pharmacol,
submitted, 2011.

I.

Introduction
METH is a highly addictive psychostimulant and currently no

pharmacotherapies have been approved to treat its abuse. METH produces
reward by increasing extracellular DA levels via VMAT2 and DAT interactions (Di
Chiara and Imperato, 1988; Sulzer et al., 2005). Cytosolic DA levels are
increased via inhibition of DA uptake at VMAT2 and by stimulation of vesicular
release (Sulzer et al., 1995; Pifl et al., 1995). Reverse transport through DAT
releases the cytosolic DA into the extracellular space (Fischer and Cho, 1979;
Liang and Rutledge, 1982). Considerable effort has focused on VMAT2 as a
pharmacological target in the discovery of compounds for treatment of METH
abuse (Dwoskin and Crooks, 2002; Crooks et al., 2011; Wimalasena et al.,
2011).
Lobeline, the major alkaloid of Lobelia inflata, interacts with VMAT2 to
inhibit the neurochemical and behavioral effects of METH (Fig. 34; Miller et al.,
2001; Harrod et al., 2001; Dwoskin and Crooks, 2002). However, lobeline is
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nonselective, exhibiting high affinity for nicotinic receptors (Damaj et al., 1997).
Structure-activity relationships revealed that chemical defunctionalization of
lobeline affords lobelane, an analog with decreased water solubility, but
increased potency and selectivity for VMAT2 (Fig. 34; Miller et al., 2004).
Furthermore, lobelane decreased METH-induced DA release from striatal slices
and METH self-administration in rats (Neugebauer et al., 2007; Nickell et al.,
2010). Unfortunately, tolerance developed to the behavioral effects of lobelane
(Neugebauer et al., 2007).
Structural modification of lobelane afforded GZ-793A (Fig. 34), which has
increased water solubility, while retaining potency and selectivity for VMAT2
(Chapter 3, Horton et al., 2011b). GZ-793A inhibits METH-evoked DA release
from striatal slices without altering electrical field stimulation- or nicotine-evoked
DA release, indicating specific inhibition of METH. Also, GZ-793A decreases
METH self-administration and conditioned place preference without altering food
maintained responding (Beckmann et al., 2011). Thus, GZ-793A represents a
new lead in the discovery of novel pharmacotherapeutics to treat METH abuse.
Classical VMAT2 inhibitors (e.g., reserpine, an irreversible VMAT2
inhibitor) deplete striatal DA content (Cleren et al., 2003), suggesting that GZ793A may produce similar effects. METH also depletes striatal DA content,
which serves as an index of dopaminergic neurotoxicity (Krasnova and Cadet,
2009). Furthermore, VMAT2 heterozygous knockout mice exhibit increased
METH-induced neurotoxicity compared to wild-type mice (Fumagalli et al., 1999).
Conversely, reversible VMAT2 inhibitors are neuroprotective against
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dopaminergic toxicity. For example, tetrabenazine and lobeline attenuate
dopaminergic neurotoxicity (Cleren et al., 2003; Eyerman and Yamamoto, 2005).
As such, since GZ-793A interacts with VMAT2, it is imperative to evaluate the
potential of this compound for both exacerbation and/or neuroprotection of
METH-induced dopaminergic neurotoxicity. The outcome of these studies will
provide important insights regarding the further development of GZ-793A as a
lead compound for the treatment of METH abuse.
The hypothesis of this chapter is that VMAT2 inhibition by GZ-793A will
not alter striatal DA content and GZ-793A pretreatment will protect against
METH-induced DA content depletions in striatal tissue and vesicles.
II.

Materials and Methods
IIa.

Animals. Male Sprague-Dawley rats (200-250g, Harlan,

Indianapolis, IN) were housed two per cage with ad libitum access to food and
water in the Division of Laboratory Animal Resources at the University of
Kentucky (Lexington, KY, USA). Experimental protocols involving the animals
were in accord with the 1996 NIH Guide for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal Care and Use Committee
at the University of Kentucky.
IIb.

Chemicals. CaCl2, citric acid, MgCl2, KCl, K2PO4, NaHCO3 and

NaH2PO4 were purchased from Fisher Scientific Co. (Pittsburgh, PA, USA).
Ascorbic acid, ascorbate oxidase, DA, EDTA, EGTA, d-glucose, HEPES, METH,
MgSO4, octane sulphonic acid, potassium tartrate, NaCl and sucrose were
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purchased from Sigma-Aldrich (St. Louis, MO, USA). GZ-793A was synthesized
according to previously reported methods (Chapter 3, Horton et al., 2011b).
IIc.

Experimental Design. To determine the effect of acute GZ-793A

on DA content in striatal tissue and vesicles, GZ-793A (15 mg/kg; s.c) or saline
was administered. The GZ-793A dose was selected based upon behavioral
studies showing efficacy to decrease METH self-administration and conditioned
place preference (Beckmann et al., 2011). To determine the effect of acute GZ793A alone on DA content, GZ-793A or saline was administered s.c. and striata
(8 and 65 mg) were obtained 0.3, 1.3, 8, or 24 hr post-injection for tissue and
vesicular DA content assays, respectively. To determine the interaction of acute
GZ-793A with METH, GZ-793A (15 mg/kg; s.c.) or saline was injected 20 min
prior to METH (0, 5 or 10 mg/kg; i.p.), and 3 days later, striata were obtained for
tissue and vesicular DA content assays. Doses of METH and the time point
following administration were chosen based on previous findings (Xi et al., 2009).
The effect of repeated 7-day pre-treatment with GZ-793A (15 mg/kg, once
daily; s.c) on the acute METH (10 mg/kg; i.p) induced depletion of DA content
was determined. METH was administered 20 min after the last GZ-793A dose on
Day 7. Striata were obtained 3 days subsequently. The effect of GZ-793A (15
mg/kg; s.c) pre-treatment on striatal DA depletion induced by a METH treatment
regimen (7.5 mg/kg x 4, 2-hr injection intervals; i.p.) traditionally used to deplete
DA (Stephans and Yamamoto, 1996; Chapman et al., 2001; Eyerman and
Yamamoto, 2005) was determined. GZ-793A or saline was administered 20 min
prior to each dose of METH. Striata were obtained 7 days after the last
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treatment. Doses of METH and the pre-treatment time point following
administration were chosen based on previous findings (Eyerman and
Yamamoto, 2005). Also, the effect of GZ-793A (15 mg/kg; s.c) post-treatment on
striatal DA depletion induced by METH (7.5 mg/kg x 4 at 2 hr injection intervals;
i.p) was determined. GZ-793A or saline was administered 5 and 7 hr after each
dose of METH. Striata were obtained 7 days after the last treatment. Doses of
METH and the post-treatment time point following administration were chosen
based on previous findings (Eyerman and Yamamoto, 2005).
IId. Tissue and vesicle preparation for DA content assay. Striata from
each rat were used to prepare both tissue (8 mg) and vesicle (65 mg)
preparations for the content assay. Striata were sonicated in 1 ml of 0.1 M
perchloric acid and the suspension centrifuged at 20,000 g for 30 min.
Supernatants (50 µl) were injected into the HPLC with electrochemical detection
to determine tissue DA content.
Striatal vesicle preparations were prepared as previously reported
(Chapter 2, Horton et al., 2011a). Striata were homogenized in 14 ml of ice-cold
0.32 M sucrose solution containing 5 mM NaHCO3 (pH 7.4) with 10 up-and-down
strokes of a Teflon pestle homogenizer (clearance = 0.008”). Homogenates were
centrifuged at 2,000 g for 10 min at 4 °C and resulting supernatants centrifuged
at 10,000 g for 30 min at 4 °C. Pellets were resuspended in 2.0 ml of 0.32 M
sucrose and were transferred to tubes containing 7 ml of milliQ water and
homogenized with 5 up-and-down strokes. Homogenates were transferred to
tubes containing 900 μl of 0.25 M HEPES and 900 μl of 1.0 M potassium tartrate
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solution and centrifuged at 20,000 g for 20 min at 4 ºC. Resulting supernatants
were centrifuged at 55,000 g for 60 min at 4 ºC. Subsequently, 100 μl of 1 mM
MgSO4, 100 μl of 0.25 M HEPES and 100 μl of 1.0 M potassium tartrate were
added to the supernatant and centrifuged at 100,000 g for 45 min at 4 ºC. Final
pellets were resuspended in 1.2 ml of milliQ water. Vesicle suspensions were
sonicated at 4o C for 5 min and centrifuged at 20,000 g for 15 min. Supernatants
(50 µl) were injected into the HPLC with electrochemical detection for
determination of vesicular DA content.
IIe.

DA content determination by HPLC with electrochemical

detection. HPLC-EC determination of DA content was performed by Kiran
Siripurapu, Ph.D.. HPLC with electrochemical detection consisted of a pump and
auto-sampler (508 Beckman Coulter, Inc., Fullerton, CA, USA) and an ODS
ultrasphere C18 reverse-phase column (80 × 4.6 mm, 3-µm ESA Inc.,
Chelmsford, MA, USA). Analytes were detected with a coulometric-II detector
with guard cell (model 5020) maintained at +0.60 V and an analytical cell (model
5011) maintained at potentials E1 = 0.05 V & E2 = +0.32 V (ESA, Inc). The
mobile phase was 0.07 M citrate/0.1 M acetate buffer (pH 4) containing, 175 mg/l
octylsulfonic acid-sodium salt, 650 mg/l of NaCl and 7% methanol. Separations
were performed at room temperature at a flow rate of 1.5 ml/min, and 5-6 min
were required to process each sample. Retention times of DA and
dihydroxyphenylacetic acid (DOPAC) standards were used to identify peaks.
Peak heights were used to quantify detected amounts on the basis of standard
curves. Detection limits for DA and DOPAC were 1 and 2 pg/100 µl, respectively.
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Peak integrations and analyses were performed by using 32 karat software
(Beckman Coulter, Inc.).
IIf.

Data analysis. DA content was expressed as mean ± S.E.M.

ng/mg wet weight for striatal tissue content assays and ng/mg protein for
vesicular content assays. The effect of acute GZ-793A on DA content was
analyzed using a two-way ANOVA with GZ-793A treatment and time as betweensubjects factors.
Both the concentration effect of METH to deplete striatal DA content and
the effect of acute GZ-793A pre-treatment on METH depletion were analyzed
using a two-way ANOVA, with GZ-793A pre-treatment and METH dose as
between-subject factors.
The effect of repeated GZ-793A pre-treatment on depletion of DA content
induced by acute METH treatment was analyzed using a two-way ANOVA
followed by Tukey’s post hoc analysis to determine significant differences
between the treatment groups and respective controls. The effect of GZ-793A
pre-treatment on DA depletion induced by repeated METH was analyzed using a
two-way ANOVA, followed by Tukey’s post hoc analysis to determine differences
between treatment groups and respective controls. The effect of repeated METH
treatment followed by GZ-793A was analyzed using a two-way ANOVA followed
by Tukey’s post hoc analysis to determine differences between treatment groups
and respective controls. Statistical analyses were conducted using SPSS
(version 17.0; SPSS Inc., Chicago, IL, USA) and GraphPad PRISM (version 5.0;
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Graph Pad Software, Inc., San Diego, CA, USA). Statistical significance was
defined as p < 0.05.
III.

Results
IIIa.

GZ-793A does not alter striatal DA content. DA content in

striatal tissue and vesicles 0.3, 1.3, 8 and 24 hr following GZ-793A treatment is
provided in Table 6. Analysis of striatal DA content by two-way ANOVA failed to
reveal a main effect of GZ-793A treatment (F1,56 = 1.45, p > 0.05] or a GZ-793A
treatment x time interaction F3,56 = 0.06, p > 0.05); however a main effect of time
(F3,56 = 10.6, p < 0.05) was observed. Analysis of vesicular DA content by twoway ANOVA also failed to reveal main effects of GZ-793A treatment (F1,56 = 0.04,
p > 0.05) and time (F3,56 = 1.25, p > 0.05), and no GZ-793A treatment x time
interaction (F3,56 = 0.76, p > 0.05).
IIIb.

Acute GZ-793A pre-treatment attenuates the acute METH-

induced decrease in striatal tissue and vesicular DA content. Fig. 35
illustrates the effect of GZ-793A pre-treatment on METH-induced decreases in
striatal tissue and vesicular DA content (top and bottom panel, respectively).
Analysis of DA content in striatal tissue by two-way ANOVA failed to reveal a
main effect of GZ-793A pre-treatment F1,42 = 3.39, p > 0.05) and no GZ-793A x
METH interaction (F2,42 = 1.66, p > 0.05); however, a main effect of METH dose
(F2,42 = 6.96, p < 0.05) was found.
Analysis of vesicular DA content by two-way ANOVA revealed main
effects of GZ-793A pre-treatment (F1,42 = 4.56, p < 0.05) and METH dose F2,42 =
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3.54, p < 0.05) and a GZ-793A x METH interaction (F2,42 = 3.31, p < 0.05).
Further evaluation of the effect of METH in saline pre-treated rats by one-way
ANOVAs revealed a main effect of METH dose (F2,21 = 9.51, p < 0.05). Post hoc
analysis revealed that METH (5 and 10 mg/kg) significantly decreased DA
content in striatal vesicles compared to the respective saline control. Also, oneway ANOVA on the dose effect of METH following GZ-793A pre-treatment did
not reveal a main effect of METH dose (F2,21 = 0.44, p > 0.05). The latter result
demonstrates that GZ-793A pre-treatment attenuated the METH-induced
decrease in DA content in striatal vesicles.
IIIc.

Repeated GZ-793A pre-treatment attenuates the acute METH-

induced decrease in striatal tissue or vesicular DA content. The effect of
repeated GZ-793A pre-treatment on the acute METH (10 mg/kg) induced
decrease in striatal tissue and vesicular DA content is illustrated in Fig. 36 (top
panel and bottom panel, respectively). Analysis of DA content in striatal tissue
following GZ-793A pre-treatment and acute METH by two-way ANOVA revealed
a main effect of METH treatment (F1,35 = 4.29, p < 0.05) and a GZ-793A x METH
interaction (F1,35 = 6.58, p < 0.05); however, a main effect of GZ-793A pretreatment (F1,35 = 0.60, p > 0.05) was not found. Post hoc analysis revealed that
DA content was decreased in the saline + METH group compared to the saline
control group. Also, striatal DA content in both the GZ-793A + saline and the GZ793A + METH groups were not different from the saline control group. Thus,
repeated GZ-793A alone did not decrease striatal DA content and repeated GZ793A attenuated the METH-induced decrease in striatal DA content.
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Analysis of vesicular DA content following GZ-793A pre-treatment and
acute METH treatment by two-way ANOVA revealed a GZ-793A x METH
interaction (F1,36 = 4.87, p < 0.05); however, main effects of GZ-793A pretreatment (F1,36 = 0.54, p > 0.05) and METH treatment (F1,36 = 3.51, p > 0.05)
were not found. Post hoc analysis revealed that vesicular DA content in the
saline + METH group was decreased relative to the saline control group.
Furthermore, vesicular DA content for both the GZ-793A + saline group and the
GZ-793A + METH group was not different from that for the saline control group.
Thus, repeated GZ-793A alone did not alter vesicular DA content and repeated
GZ-793A pre-treatment attenuated the METH-induced decrease in vesicular DA
content.
IIId.

GZ-793A pre-treatment does not exacerbate DA depletion in

striatal tissue or vesicles induced by METH (7.5 mg/kg x 4). The effect of GZ793A pre-treatment on striatal DA depletion induced by METH (7.5 mg/kg x 4, 2hr injection intervals) is provided in Fig. 37 and Table 7. Analysis of DA content in
striatal tissue by two-way ANOVA revealed a main effect of METH treatment
(F1,36 = 14.2, p < 0.05); however, no main effect of GZ-793A pre-treatment (F1,36
= 0.21, p > 0.05) and no GZ-793A x METH interaction (F1,36 = 2.94, p > 0.05) was
observed. Striatal DA content was decreased in both the saline + METH and GZ793A + METH treatment groups compared to the saline control group; and
moreover, the GZ-793A + METH group was not different from the saline + METH
group. Thus, repeated GZ-793A pre-treatment (15 mg/kg x 4) did not alter the
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depletion in striatal DA content induced by a METH regimen traditionally
employed to deplete striatal DA.
Analysis of vesicular DA content by two-way ANOVA failed to reveal main
effects of GZ-793A pre-treatment (F1,36 = 0.86, p > 0.05), METH (F1,36 = 2.15, p >
0.05), and GZ-793A x METH interaction (F1,36 = 1.00, p > 0.05).
IIIe.

GZ-793A post-treatment does not exacerbate depletion of

striatal tissue or vesicular DA content induced by METH (7.5 mg/kg x 4).
The effect of GZ-793A treatment 5 hrs and 7 hrs after METH (7.5 mg/kg x 4, 2-hr
injection intervals) on striatal tissue and vesicular DA content is provided in Fig.
38 and Table 8, respectively. Analysis of DA content in striatal tissue by two-way
ANOVA revealed a main effect of METH (F1,19 = 52.0, p < 0.05), but no main
effect of GZ-793A post-treatment (F1,19 = 0.18, p > 0.05) and no GZ-793A x
METH interaction (F1,19 = 0.32, p >0.05). Striatal DA content was decreased in
both the METH + saline and METH + GZ-793A treatment groups compared to
the saline control group; and moreover, the GZ-793A + METH group was not
different from the saline + METH group. Thus, repeated post-treatment with GZ793A (15 mg/kg) did not alter the depletion in striatal DA content induced by
METH (7.5 mg/kg x 4).
Analysis of vesicular DA content by two-way ANOVA failed to reveal main
effects of GZ-793A pre-treatment (F1,19 = 0.19, p > 0.05), METH treatment (F1,19
= 0.22, p > 0.05) and no GZ-793A x METH interaction effect (F1,19 = 1.25, p >
0.05) was observed.
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IV.

Discussion
In a concentration-dependent manner, GZ-793A potently and selectively

inhibits VMAT2 function and evokes DA release from vesicles (Chapter 3, Horton
et al., 2011a; Chapter 4, Horton et al.,2011c). Despite the ability of GZ-793A to
alter VMAT2 function, the current results show that GZ-793A administered
acutely and repeatedly did not alter striatal DA content across a 24 hr time period
following treatment with a behaviorally relevant dose. Importantly, GZ-793A
inhibits METH-evoked DA release from striatal vesicles and slices (Chapter 3,
Horton et al., 2011b; Chapter 4, Horton et al., 2011c). Moreover, these in vitro
observations translated to the whole animal model, since GZ-793A decreased
METH self-administration (Beckmann et al., 2011). The current results further
show that acute and repeated GZ-793A pre-treatment attenuated the acute
METH-induced decrease in striatal DA content. Pertinent to the development of
GZ-793A as a lead compound for the treatment of METH abuse, GZ-793A did
not exacerbate DA depletion induced by a repeated high dose regimen of METH.
Thus, the ability of GZ-793A to decrease METH self-administration is not
accompanied by an exacerbation of METH-induced dopaminergic neurotoxicity.
These results further advance GZ-793A as a preclinical lead in the development
of pharmacotherapies to treat METH abuse.
GZ-793A is a structural synthetic analog of lobeline, the major alkaloid
from Lobelia inflata. Similar to the current findings with GZ-793A, previous work
showed that lobeline, across a wide dose range, did not alter striatal DA content
during the 24-hr period following its acute or repeated administration (Miller et al.,
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2001). Importantly, both lobeline pre-treatment and post-treatment was shown to
attenuate DA depletion induced by a neurotoxic regimen of METH (Eyerman and
Yamamoto, 2005).
In the current study, acute METH (5 and 10 mg/kg) decreased striatal
tissue and vesicular DA content consistent with previous results (Xi et al., 2009).
Acute and repeated GZ-793A pre-treatment attenuated the DA depletion induced
by acute METH treatment (5 and 10 mg/kg). Recent studies show that GZ-793A
decreases METH-evoked DA release from vesicles via a surmountable allosteric
mechanism (Chapter 4, Horton et al., 2011c), which thereby may have limited the
METH-induced striatal DA depletion. An alternative explanation is that GZ-793A
may interact with DAT to attenuate the METH-induced DA depletion. DAT
inhibitors, including GBR-12909, buproprion and mazindol, attenuate METHinduced depletion of striatal DA content by inhibiting METH-evoked DA release
(Marek et al., 1990; Stephans and Yamamoto, 1994). Similarly, GZ-793A may
interact with DAT to inhibit METH-induced reverse transport (release) of DA and
the METH-induced decrease in striatal DA content. However, GZ-793A is 50-fold
more potent inhibiting VMAT2 function than inhibiting DAT function (Chapter 3,
Horton et al., 2011b). Furthermore, the observation that GZ-793A is not selfadministered in rats (Beckmann et al., 2011), diminishes support for an
interaction with DAT as the underlying mechanism for its ability to attenuate
METH toxicity.
Although GZ-793A attenuated the DA depletion induced by acute METH,
GZ-793A did not alter DA depletion in striatal tissue induced by a neurotoxic
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regimen of METH in contrast with the neuroprotection afforded by lobeline. This
difference in neuroprotection between GZ-793A and lobeline may be due to the
doses chosen to evaluate the interaction with METH. The GZ-793A dose (15
mg/kg) was chosen due to its behavioral relevance, i.e., this dose decreased
METH self-administration in rats (Beckmann et al., 2011). Conversely, a high
dose (10 mg/kg) of lobeline was evaluated for interaction with METH (Eyerman
and Yamamoto, 2005); this high dose was shown to nonspecifically decrease
METH self-administration (Harrod et al., 2001). In this regard, a higher dose of
GZ-793A also may attenuate the dopaminergic depletion induced by the
neurotoxic regimen of METH. Another potential explanation for the difference in
neuroprotection between GZ-793A and lobeline may be that lobeline also acts as
a nicotinic receptor antagonist, whereas GZ-793A does not (Damaj et al., 1997;
Flammia et al., 1999; Miller et al., 2004; Siripirapu et al., 2011). Furthermore,
support for the involvement of nicotinic receptors in lobeline neuroprotection is
the observation that methyllycaconitine, an α7 nicotinic receptor antagonist,
protected against METH-induced dopaminergic neurotoxicity (Northrop et al.,
2011). Thus, the selectivity of GZ-793A for VMAT2 and the lack of interaction
with nicotinic receptors could explain the difference between GZ-793A and its
parent compound to attenuate the dopaminergic neurotoxicity induced by METH.
Although the neurotoxic regimen of METH (7.5 mg/kg x 4) depleted DA in
striatal tissue content, vesicular DA content was not depleted significantly.
Furthermore, although vesicular DA was depleted by ~40% three days following
acute METH (10 mg/kg), striatal vesicles were not depleted significantly seven
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days after the neurotoxic regimen of METH. These results support the concept
that vesicular DA stores are more resilient to depletion induced by METH
compared with striatal tissue DA, and that compensation may have occurred by 7
days to restore vesicular DA levels. The current results are in contrast with a
recent study reporting that vesicular DA was depleted by 50% 7 days following
METH (10 mg/kg x 4) administration (Northrop et al., 2011). Methodological
differences between the studies may be responsible for the contrasting
observation, i.e., different doses of METH employed, and different procedures for
vesicle preparation. Nonetheless, GZ-793A did not potentiate the ability of METH
to deplete vesicular DA content. Furthermore, the METH regimen (7.5 mg/kg x 4)
employed in the current study depleted DA content in the striatal tissue, and this
depletion was not exacerbated by GZ-793A pre-treatment or post-treatment.
Thus, GZ-793A did not protect, but also did not exacerbate, the dopaminergic
neurotoxicity induced by repeated high dose METH.
In summary, results from the current study demonstrate that acute or
repeated GZ-793A alone does not alter DA content in striatal tissue or vesicles.
Furthermore, GZ-793A pre-treatment attenuates the acute METH-induced
decrease in DA content, and importantly, does not exacerbate DA depletion
following repeated high dose METH administration. Thus, behaviorally relevant
doses of GZ-793A did not alter DA content when administered alone, and did not
exacerbate striatal DA depletion induced by METH. In conclusion, GZ-793A
represents an exciting preclinical lead candidate for the treatment of METH
abuse.
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Table 6. Striatal tissue and vesicular DA content at various time points
following saline or GZ-793A (15 mg/kg) treatment.
Tissue DA Content

Vesicular DA Content

(ng/mg tissue)

(ng/mg protein)

Time (hrs)

Saline

GZ-793A

Saline

GZ-793A

0.3

3.03 ± 0.58

2.36 ± 0.49

0.28 ± 0.06

0.32 ± 0.14

1.3

4.65 ± 0.77

4.15 ± 0.61

0.18 ± 0.01

0.14 ± 0.05

8

1.97 ± 0.52

1.75 ± 0.32

0.09 ± 0.003

0.08 ± 0.01

24

5.25 ± 0.59

4.56 ± 0.87

0.07 ± 0.01

0.06 ± 0.01

Data are mean ± S.E.M.; n = 8 rats/treatment
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Table 7. The effect of GZ-793A pretreatment (15 mg/kg) 20 minutes prior to
a traditional regimen of METH administration (7.5 mg/kg x 4; every 2 hrs)
on striatal vesicular DA content.
Vesicular DA Content
Treatment Group

(ng/mg protein)

Saline/Saline

0.11 ± 0.01

GZ-793A/Saline

0.13 ± 0.01

Saline/METH

0.10 ± 0.01

GZ-793A/METH

0.09 ± 0.1

Data are mean ± S.E.M.; n = 10 rats/treatment
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Table 8. The effect of GZ-793A post-treatment (15 mg/kg) 5 and 7 hrs after a
traditional regimen of METH administration (7.5 mg/kg x 4; every 2 hrs) on
striatal vesicular DA content.
Vesicular DA Content
Treatment Group

(ng/mg protein)

Saline/Saline

0.10 ± 0.01

Saline/GZ-793A

0.08 ± 0.01

METH/Saline

0.08 ± 0.01

METH/GZ-793A

0.09 ± 0.01

Data are mean ± S.E.M.; n = 5-6 rats/treatment
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Fig. 34. Chemical structures of lobeline, lobelane, and GZ-793A. Lobeline is
the principle alkaloid found in Lobelia inflata. Lobelane is the defunctionalized,
saturated analog of lobeline. GZ-793A is a 4-methoxyphenyl analog of lobelane
incorporating an N-1,2-diol moiety.
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Fig. 35. Acute GZ-793A pre-treatment attenuates acute methamphetamineinduced decreases in striatal tissue or vesicular dopamine content. Data
are shown as ng/mg tissue and ng/mg protein for tissue (top panel) and vesicles
(bottom panel), respectively and expressed as mean ± S.E.M. *p < 0.05 different
from saline control. n = 8-12 rats/treatment.
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Fig. 36. Repeated GZ-793A pre-treatment attenuates acute
methamphetamine-induced decreases in striatal tissue or vesicular
dopamine content. Data are shown as ng/mg tissue and ng/mg protein for
tissue (top panel) and vesicles (bottom panel), respectively and expressed as
mean ± S.E.M. *p < 0.05 different from saline control. n = 10 rats/treatment.
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Fig. 37. GZ-793A pre-treatment (15 mg/kg) 20 min prior to a traditional
regimen of methamphetamine administration (7.5 mg/kg x 4, 2-hr injection
intervals) does not exacerbate methamphetamine-induced decreases in
striatal tissue dopamine content. Data are shown as ng/mg tissue and
expressed as mean ± S.E.M. *p < 0.05 different from saline control. n = 10
rats/treatment.
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Fig. 38. GZ-793A post-treatment (15 mg/kg) 5 and 7 hrs after a traditional
regimen of methamphetamine administration (7.5 mg/kg x 4, 2-hr injection
intervals) does not exacerbate methamphetamine-induced decreases in
striatal tissue dopamine content. Data are shown as ng/mg tissue for tissue
and expressed as mean ± S.E.M. *p < 0.05 different from saline control. n = 5-6
rats/treatment.
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CHAPTER SIX

Discussion and Conclusions
I. Review
METH is the second most abused illicit drug in the world after marijuana,
with over 25 million METH abusers worldwide (United Nations Office on Drugs
and Crime, 2007; Cadet and Krasnova, 2009; Cruickshank and Dyer, 2009).
METH is the most commonly synthesized illegal drug in the U.S., contributing to
its widespread use (Cadet and Krasnova, 2009). AMPHs were the primary
cause of over 170,000 substance abuse emergency room admissions, with over
80% of these cases involving METH (DASIS, 2008). METH abuse also
represents a significant financial burden, costing the U.S. $23.4 billion in 2005
due to health care, law enforcement, and social welfare costs (Gonzales et al.,
2010). In 2009, the number of people using METH in the past month increased
59% (NSDUH, 2009). Despite increased METH use, there are currently no
pharmacotherapies approved for the treatment of METH abuse. Thus, METH
abuse presents a serious public health concern.
METH elicits its rewarding and stimulant effects by increasing extracellular
DA levels in the brain through an interaction with DAT and VMAT2 (Fischer and
Cho, 1979; Seiden et al., 1993; Pifl et al., 1995; Sulzer et al., 1995; Jones et al.,
1998; Sulzer et al., 2005). Specifically, METH acts as a substrate for DAT,
inhibiting DA uptake into the presynaptic terminal. In the presynaptic terminal,
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METH inhibits DA uptake at VMAT2 and promotes DA release from vesicles,
leading to an increase in cytosolic DA concentrations available for reverse
transport through DAT. Taking into consideration the role DAT plays in the
mechanism of action of METH, numerous studies have been conducted
examining the potential utility of DAT inhibitors such as buproprion and
methylphenidate in the treatment of METH dependence. Unfortunately, results
regarding the effectiveness of these treatments are inconclusive (Newton et al.,
2006; Tiihonen et al., 2007; Vocci and Appel et al., 2007; Gonzales et al., 2009;
Karila et al., 2010). Recent studies have focused on VMAT2 as a therapeutic
target for the development of treatments for METH abuse (Dwoskin and Crooks,
2002; Zheng et al., 2005a; Vocci and Appel et al., 2007; Karila et al., 2010).
Lobeline, the principal alkaloid of Lobelia inflata, inhibits [3H]DTBZ binding
and [3H]DA uptake at VMAT2 (Teng et al., 1997, 1998). In addition to inhibiting
VMAT2 function, lobeline promotes a release of DA from preloaded synaptic
vesicles (Nickell et al., 2011). Similar to METH, lobeline redistributes DA from
vesicles to the cytosol. Unlike METH however, lobeline does not inhibit MAO
and does not reverse DAT (Teng et al., 1997; Dwoskin and Crooks, 2002).
Through the interaction with VMAT2 and redistribution of DA in the presynaptic
terminal, lobeline is hypothesized to limit the DA available for reverse transport
by METH. In support of this hypothesis, lobeline inhibited AMPH-evoked DA
release from striatal slices in the same concentration range that lobeline interacts
with VMAT2. Further, lobeline pretreatment inhibited METH-induced increases in
locomotor activity and METH self-administration in rats (Miller et al., 2001;
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Harrod et al., 2001). Importantly, lobeline is not self-administered in rats and
does not produce conditioned place preference, suggesting limited abuse liability
(Harrod et al., 2003). Recently, lobeline has passed Phase Ib clinical trials,
demonstrating safety in METH users (Jones et al., 2007). Unfortunately, lobeline
exhibits a short half-life and lacks selectivity for VMAT2 over nAChRs.
Structure activity relationships revealed that chemical defunctionalization
of the lobeline molecule (i.e. removal of keto and hydroxyl groups) afforded
analogs, MTD and lobelane which exhibited increased affinity for VMAT2 and
decreased affinity for nAChRs (Miller et al., 2004; Zheng et al., 2005a; Nickell et
al., 2011). In addition to exhibiting increased selectivity for inhibition of VMAT2
function, MTD and lobelane inhibited METH-evoked DA release from striatal
slices (Nickell et al., 2011). To extend these findings, results from the current
research revealed that MTD decreased METH self-administration without altering
food maintained responding. However, MTD inhibited METH self-administration
only at the highest dose tested and tolerance developed to this effect.
Considering the high affinity of MTD for DAT (Ki = 0.10 µM), it is likely that the
MTD-induced attenuation of METH self-administration was a result of high affinity
inhibition of DAT function by MTD. Through inhibiting DAT function, MTD could
act to inhibit METH-induced reverse transport of DA through DAT. Similar to
MTD, lobelane pretreatment decreased METH self-administration in rats, but
tolerance developed to this behavioral effect after repeated treatment
(Neugebauer et al., 2007). In addition, both MTD and lobelane exhibited
decreased water solubility compared to lobeline due to the removal of the keto
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and hydroxyl moieties of the lobeline molecule. Thus, the purpose of this
dissertation research was to identify analogs of MTD and lobelane that exhibited
increased water solubility and VMAT2 selectivity in an effort to develop novel
therapeutics to treat METH abuse.

The first aim of this dissertation was to determine the selectivity of 3,5disubstituted MTD analogs to inhibit VMAT2 function over DAT, SERT, and
nAChRs. Conformationally restricting the MTD molecule by incorporating the
phenylethylene substituents into the piperdine ring afforded analogs with
increased selectivity for VMAT2 compared to the parent analog, MTD. Unlike
MTD, MTD analogs in this series exhibited decreased affinity for DAT,
suggesting a decreased potential for abuse liability compared to MTD. UKMH106, a 2,4-dichlorophenyl MTD analog competitively inhibited VMAT2 function
with over 20-fold selectivity for VMAT2 over DAT, SERT and nAChRs.
Furthermore, UKMH-106 decreased METH-evoked DA release from striatal
slices in a concentration-dependent manner. Interestingly, UKMH-105, a 2,4dichlorophenyl MTD analog and geometrical isomer of UKMH-106, did not inhibit
METH-evoked DA release from striatal slices despite exhibiting equipotency for
inhibition of VMAT2 function compared to UKMH-106. These results suggest that
the site on VMAT2 mediating METH-evoked DA release is less accommodating
to the double bond geometry of MTD analogs compared to the DA uptake site on
VMAT2. Nonetheless, conformationally restricting the MTD molecule afforded
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analogs with increased selectivity for inhibition of VMAT2 function compared to
MTD and UKMH-106 decreased METH-evoked DA release from striatal slices.
The second aim was to determine the selectivity of N-1,2-diol lobelane
analogs to inhibit VMAT2 function over DAT and SERT. Replacement of the Nmethyl moiety with a chiral N-1,2-diol moiety on the piperdine nitrogen of
lobelane afforded analogs with increased water solubility compared to lobelane.
GZ-793A, the 4-methoxyphenyl N-1,2(R)-diol analog, and GZ-794A, the 1naphthalene N-1,2(R)-diol analog, competitively inhibited [3H]DA uptake at
VMAT2 with affinity not different from that exhibited by lobelane. Further, both
analogs inhibited METH-evoked DA release from striatal slices in a
concentration-dependent manner, however GZ-793A exhibited ~35% greater
inhibitory activity compared to GZ-794A. Thus, GZ-793A emerged as the lead
analog of the series, exhibiting over 50-fold selectivity for inhibition of VMAT2
function and inhibiting METH-evoked DA release from striatal slices.
To further identify the cellular mechanism underlying GZ-793A-induced
inhibition of the effects of METH, the third aim determined the ability of GZ-793A
to release DA from vesicles and inhibit METH-evoked DA release from vesicles.
GZ-793A evoked [3H]DA release from synaptic vesicles with high affinity and the
concentration-response curve fit a two-site model of interaction. GZ-793Aevoked DA release at the Hi affinity site was TBZ- and reserpine-sensitive, while
release at the Low affinity site was TBZ- and reserpine-insensitive. GZ-793A
concentrations that interact with the Hi affinity site inhibited METH-evoked [3H]DA
release from striatal synaptic vesicles. Increasing concentrations of GZ-793A
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produced a rightward shift in the METH concentration-response and Schild
regression analysis revealed a slope significantly different from unity, consistent
with a surmountable allosteric mechanism of action. Thus, GZ-793A likely
interacts with at least three distinct sites on VMAT2: 1) the extravesicular DTBZ
binding site (low affinity), 2) the extravesicular DA uptake site (high affinity) and
3) intravesicular DA release sites (high and low affinity).
The fourth aim was to determine the effect of GZ-793A on striatal DA
content and the ability of GZ-793A to protect against METH-induced DA content
depletion. Results from this initial DA neurotoxicity evaluation revealed that
acute or chronic GZ-793A did not alter DA content from striatal tissue or vesicles,
suggesting that the ability of GZ-793A to inhibit the neurochemical and
behavioral effects of METH is not due to a GZ-793A-induced neurotoxicity effect
on DA content. GZ-793A pretreatment (15 mg/kg) prior to acute METH (5 and 10
mg/kg) attenuated METH-induced depletion of DA content. Conversely, GZ793A pretreatment prior to repeated high doses of METH (4 x 10 mg/kg) did not
protect against nor exacerbate METH-induced decreases in DA content. These
preliminary studies suggest that GZ-793A may offer neuroprotective benefits
against acute METH-induced depletions in DA content.
II. Comparisons Between 3,5-Disubstituted MTD analogs and N-1,2-Diol
Lobelane Analogs.
The current research reports on the findings from an iterative drug
discovery approach with the goal of identifiying selective VMAT2 inhibitors to
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inhibit the rewarding effects of METH. This dissertation research focused on two
sets of lobeline analogs, 3,5-disubstituted MTD analogs and N-1,2-diol lobelane
analogs. MTD, the parent of the first series of analogs, exhibited high affinity for
DAT, limiting selectivity for VMAT2. Conformational restriction of the MTD
molecule, as well as various structural changes to the phenyl rings including the
addition of 4-methoxy, 4-methyl, and 2,4-dichloro to the phenyl ring or
replacement of the phenyl rings with thiophene or furan rings, afforded analogs
with 50-1000-fold decreased affinity for DAT compared to MTD. Importantly,
structural modifications did not alter affinity for the DA uptake site on VMAT2,
thereby increasing selectivity for VMAT2 compared to MTD. UKMH-106
emerged as the lead analog of the series exhibiting the highest potency and
selectivity to inhibit VMAT2 function. UKMH-106 decreased METH-evoked DA
release from striatal slices in a concentration-dependent manner. UKMH-106
exhibited poor water solubility however, similar to that of MTD, which limited
further development. Thus, the focus of the research project shifted to identifying
analogs with increased water solubility in addition to VMAT2 selectivity.
Replacement of the N-methyl moiety of lobelane with a chiral N-1,2-diol
moiety on the piperdine nitrogen of lobelane afforded analogs with increased
water solubility compared to lobelane. In addition to the incorportation of the N1,2-diol moiety, various structural modifications to the phenyl rings were
performed including the addition of 2-methoxy, 3-methoxy, 4-methoxy, 3-flouro,
2,4-dichloro, or 3,4-methylenedioxy moieties to both phenyl rings or replacement
of both phenyl rings with naphthalene or biphenyl moieties. While the analogs
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exhibited similar affinity for DAT and SERT compared to lobelane, most analogs
exhibited decreased potency to inhibit VMAT2 function. Exceptions included GZ793A, the 4-methoxyphenyl N-1,2(R)-diol analog, and GZ-794A, the 1naphthalene N-1,2(R)-diol analog, which exhibited potency to inhibit VMAT2
function not different from lobelane. Both GZ-793A and GZ-794A decreased
METH-evoked DA release from striatal slices, however GZ-793A exhibited ~35%
greater inhibitor activity compared to GZ-794A. Further, GZ-793A exhibited 5fold greater selectivity for inhibition of VMAT2 function compared to GZ-794A.
Thus, GZ-793A emerged as the lead analog of the series.
Compared to UKMH-106, GZ-793A exhibited 2.5-fold greater selectivity
for inhibition of VMAT2 function and 35% greater inhibitory activity to inhibit
METH-evoked DA release from striatal slices. Additionally, GZ-793A exhibited
increased water solubility compared to UKMH-106 due to the incorportation of
the N-1,2-diol moiety. Thus, GZ-793A emerged as the lead analog of both series
of analogs and became the focus of the mechanistic vesicular DA release
experiments and DA content studies.
III. Mechanisms Underlying GZ-793A-induced Inhibition of METH-evoked
DA Release from Synaptic Vesicles.
GZ-793A concentrations that interacted with the Hi affinity site on VMAT2
inhibited METH-evoked DA release from striatal synaptic vesicles. Increasing
concentrations of GZ-793A produced a rightward shift in the METH concentration
response without altering maximal DA release suggesting a surmountable
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mechanism of inhibition. Further, Schild regression analysis revealed a slope
significantly different from unity, suggesting an allosteric mechanism. Thus, GZ793A produces a conformational change in the VMAT2 protein which reduces the
affinity of METH for the intravesicular DA release site without altering the efficacy
of METH to release DA. Precendence for surmountable allosteric inhibition is
seen with nicotinic and muscarinic acetylcholine receptor antagonists (Tucek and
Proska, 1995; Kukkonen et al., 2004; Wooters et al., 2011).
One hallmark characteristic of allosteric inhibiton is saturability (Kenakin,
2006). The effect of allosteric inhibitors to shift the concentration-response curve
of the agonist to the right is diminished as the allosteric site is saturated with
increasing concentrations of inhibitor. The current results show that a 5-fold shift
in EC50 was seen between GZ-793A concentrations of 7 and 70 nM, however,
only a 1-2 fold shift was seen between GZ-793A concentrations of 70 nM to 1000
nM. Thus, the effect of GZ-793A to decrease the potency of METH to evoke
vesicular DA release became saturated with increasing concentrations of GZ793A, consistent with allosteric modulation. Further support for an allosteric
inhibition mechanism is given by the finding that the inhibitory effect of GZ-793A
was not rate dependent, as increasing the incubation time did not alter METHevoked DA release in the presence of GZ-793A.
Interpretations of concentration-response curves and Schild regression
analyses used in the classification of antagonists are considerably more
straightforward in binding studies compared to functional data (Kenakin, 1993).
In the current study, agonist response was measured as METH-evoked [3H]DA
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release from synaptic vesicles through an interaction with VMAT2. Considering
the differences between receptors and transporters, the use of receptor-based
models to interpret antagonism derived from experiments measuring transportermediated release is ambiguous. However, studies measuring electrochemical
currents have demonstrated that substrate flux through transporters is
accompanied by ion flow and electrical current, suggesting that transporters
exhibit functions similar to ligand-gated ion channels (Sonders and Amara, 1996;
Galli et al., 1996; Sonders et al., 1997). Thus, precedence exists for the use of
receptor based models in the classification of antagonist mechanisms at
transporters.
Alternatively, VMAT2 could exist in multiple conformations that exhibit
different affinities for METH. GZ-793A could preferentially bind an outward-facing
transporter conformation, which decreases affinity for METH, without altering DA
release. By selectively binding to the outward-facing conformation, GZ-793A
stabilizes the GZ-793A-bound transporter conformation, which would allow for a
shift in the potency of METH to evoke DA release, without altering maximal
response. Evidence for different confirmations of VMAT2 has been shown for the
differential binding of reserpine and TBZ on VMAT2 (Darchen et al., 1989).
An alternative explanation for GZ-793A-induced inhibition of METHevoked DA release is through an interaction with the [3H]DA uptake site. GZ793A exhibits high affinity for the [3H]DA uptake site on VMAT2 (Ki = 29 nM) and
through this interaction, GZ-793A could elicit a conformational change in the
VMAT2 protein which decreases the affinity of the DA release site for METH, but
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does not alter the efficacy of METH to release DA. In addition to allosterically
modulating the DA release site, GZ-793A could be inhibiting METH-evoked DA
release from vesicles through a blockade of VMAT2 function. DAT inhibitors,
such as nomifensine, inhibit METH-evoked DA release though blockade of
reverse transport through DAT (Sulzer et al., 1993, 1995). In a similar manner,
GZ-793A could be interacting with the [3H]DA uptake site to inhibit the uptake of
METH into vesicles, thereby decreasing METH-evoked DA release. METH acts
as a substrate at VMAT2, being taken up into vesicles in a manner similar to DA
(Peter et al., 1994; Erickson et al., 1996). In the facilitated diffusion mechanism
of DA release, the uptake of METH through VMAT2 elicits a conformational
change in VMAT2 that exposes DA binding sites on the inner-facing side of the
transporter and enables the reverse transport of DA into the cytosol (Sulzer et al.,
2005). Thus, GZ-793A could decrease METH-induced reverse transport of DA
through VMAT2 through inhibiting the uptake of METH into vesicles. This
explanation is unlikely, however, as GZ-793A-induced inhibition of the DA uptake
site was consistent with competitive inhibition, while Schild regression analysis
revealed that GZ-793A-induced inhibition of METH-evoked DA release was not
consistent with a competitive inhibition.
GZ-793A-induced inhibition of uptake of METH into vesicles could
presumably decrease METH-induced DA release by the weak base effect as
well. Decreasing accumulation of METH in synaptic vesicles would prevent the
alkanalization of the vesicular lumen, preventing the disruption of the pH gradient
by METH and subsequently, METH-evoked DA release. Even though GZ-793A
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inhibited the active transport of METH through VMAT2, METH can also passively
diffuse across the vesicular membrane. As a lipophilic weak base, high
concentrations of METH diffuse across the vesicular membrane to alkanalize the
vesicular lumen, disrupt the pH gradient and release DA (Peter et al., 1995;
Sulzer et al., 2005). This explanation is supported by the finding that even higher
concentrations of GZ-793A (1µM) that completely inhibit VMAT2 function did not
completely inhibit METH-evoked DA release. Thus, METH-evoked DA release
that is not inhibited by GZ-793A could be occurring non-specifically through a
weak base effect.
An alternative site of interaction for the GZ-793A-induced inhibition of
METH-evoked DA release is the [3H]DTBZ binding site. TBZ inhibited METHevoked DA release from striatal vesicles across a similar concentration range
compared to GZ-793A. However, Schild regression analysis of TBZ-induced
inhibition of METH-evoked DA release was consistent with a competitive
mechanism of inhibition, unlike GZ-793A. Further, GZ-793A and TBZ inhibited
METH-evoked DA release from vesicles in the same concentration range even
though GZ-793A exhibits 600-fold lower affinity for inhibiting [3H]DTBZ binding
compared to TBZ. If GZ-793A-induced inhibition of METH-evoked DA release
was mediated through an interaction with the DTBZ binding site, then TBZ would
be expected to inhibit METH-evoked DA release from vesicles at much lower
concentrations, considering the significant difference in affinity for the [3H]DTBZ
binding site between GZ-793A and TBZ. Moreover, GZ-793A inhibited METHevoked DA release from striatal vesicles at concentrations lower than the
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concentrations that GZ-793A interacts with the [3H]DTBZ binding site. GZ-793A
exhibits low affinity at the [3H]DTBZ binding site (Ki = 8.29 µM), but inhibits
METH-evoked DA release at concentrations around 70 nM. Thus, it is unlikely
that the GZ-793A- and TBZ-induced inhibition of METH-evoked DA release was
through an interaction with the DTBZ binding site on VMAT2.
Interestingly, the in vitro finding that GZ-793A-induced inhibition of METHevoked DA release from striatal synaptic vesicles was surmounted by increasing
concentrations of METH did not translate to the in vivo behavioral model as GZ793A-induced inhibition of METH self-administration in rats was not surmounted
by increasing the dose of METH (Beckmann et al., 2011). The vesicular DA
release studies were performed as a mechanistic approach in vitro allowing us to
use extreme concentrations of METH that are not going to be realized in vivo.
Importantly, however, GZ-793A inhibited METH-evoked DA release from vesicles
at concentrations that are proposed to be realized in vivo.
IV. Mechanisms Underlying GZ-793A-induced Inhibition of METH-evoked
DA Release from Striatal Slices.
GZ-793A inhibits METH-evoked DA release from striatal slices in a
concentration-dependent manner. Consistent with these results, GZ-793A was
found to decrease METH self-administration in rats, without affecting foodmaintained responding. Thus, GZ-793A is inhibiting METH-evoked DA release
to decrease the rewarding effects of METH. One mechanism by which GZ-793A
could inhibit METH-evoked DA release is through the redistribution of DA in the
220

presynaptic terminal. Similar to lobeline, GZ-793A inhibits DA uptake at VMAT2
and evokes DA release from synaptic vesicles, increasing cytosolic DA
concentrations (Chapter 3, Horton et al., 2011b; Chapter 4, Horton et al., 2011c).
In the presence of GZ-793A, cytosolic DA is metabolized into DOPAC since GZ793A is not expected to inhibit MAO as evidenced by the finding that high
concentrations of GZ-793A increased DOPAC release in striatal slices rather
than DA (unpublished observations). Thus, GZ-793A could be interacting with
VMAT2 to increase cytosolic DA for metabolism, thereby limiting DA available for
METH-evoked DA release through DAT.
The observation that GZ-793A does not inhibit MAO activity is based upon
the finding that GZ-793A treatment increases DOPAC concentrations. While this
is an indirect determination of a GZ-793A-MAO interaction, further enzymatic
studies are needed to accurately assess the ability of GZ-793A to inhibit MAO
activity. Furthermore, determination of the drug-drug interaction between METH
and GZ-793A on MAO activity would be beneficial in further elucidating the
underlying mechanism of GZ-793A-induced inhibition of METH’s effects. Unlike
GZ-793A, which is not expected to inhibit MAO, pargyline increases DA content
in striatal tissue and vesicles (Fekete et al., 1979; Buu and Lussier, 1989). Thus,
pargyline is not expected to be a suitable treatment to inhibit the effects of
METH. Furthermore, pargyline would be expected to exacerbate the effect of
METH since pargyline administration would increase DA available for release by
METH. Consistent with this hypothesis, previous research has shown that
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pargyline pretreatment exacerbates METH-induced DA content depletion (Kita et
al., 1995).
In addition to redistributing DA from vesicles and increasing DA available
for metabolism, GZ-793A could be inhibiting the ability of METH to release DA
from vesicles, thereby limiting DA available for METH-induced reverse transport
through DAT. Results from the current study demonstrate that GZ-793A-induced
inhibition of METH-evoked [3H]DA release from synaptic vesicles was consistent
with a surmountable allosteric mechanism as discussed in the section above.
Thus, GZ-793A interacts with VMAT2 to inhibit METH-evoked DA release from
vesicles, resulting in decreased cytosolic DA available for METH-induced reverse
transport through DAT.
In addition to VMAT2, GZ-793A could be interacting with other presynaptic
targets to inhibit METH-evoked DA release from striatal slices. One alternative
explanation could be that GZ-793A is inhibiting METH-evoked DA release
through an interaction with nAChRs. Lobeline acts as an antagonist at both
α4β2* and α7* nAChRs (Briggs and McKenna, 1998; Miller et al., 2000; Dwoskin
and Crooks, 2002). Further, lobeline antagonizes the nAChRs mediating [3H]DA
and [3H]NE release (Gallardo and Leslie, 1998; Miller et al., 2000; Miller et al.,
2005). Chemical defunctionalization of the lobeline molecule afforded analogs,
MTD and lobelane with diminished activity at nAChRs compared to lobeline
(Miller et al., 2004). GZ-793A, a lobelane analog exhibits low affinity for α4β2*
and α7* nAChRs (Ki > 100 µM), as probed by displacement of [3H]NIC and
[3H]MLA binding, respectively (unpublished observations). Further, GZ-793A did
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not alter nicotine-evoked DA release from striatal slices, demonstrating a lack of
interaction with nAChRs mediating DA release. Thus, it is unlikely that GZ-793A
is interacting with nAChRs to inhibit METH-evoked DA release from striatal
slices.
An alternative explanation could be that GZ-793A is interacting with DAT
to inhibit METH-evoked DA release from striatal slices. GZ-793A exhibits affinity
for DAT (Ki = 1.44 µM) within the same concentration range that inhibits METHevoked DA release from striatal slices. Similar to DAT inhibitors such as cocaine
and nomifensine, GZ-793A could decrease METH-evoked DA release through an
inhibition of METH-induced reverse transport through DAT. Unlike DAT
inhibitors, however, GZ-793A does not support self-administration in rats,
suggesting that inhibition of DAT is not the mechanism of action of GZ-793A
(Beckman et al., 2011). In addition, GZ-793A is 50-fold more potent at VMAT2
compared to DAT, providing support for VMAT2 as the pharmacological target.
Thus, it is unlikely that GZ-793A-induced inhibition of METH-evoked DA release
is due to inhibition of DAT.
An alternative explanation for the ability of GZ-793A to inhibit METHevoked DA release could involve a redistribution of VMAT2 containing vesicles in
the presynaptic terminal. VMAT2-containing vesicles are thought to be localized
to two distinct pools, a readily releasable pool located near the active zone of the
synaptic cleft and a non-readily releasable pool located away from the synapse
(Hua et al., 2011). Readily releasable pools are involved in the release of DA
following stimulation, while non-readily releasable pools are unaffected by
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stimulation (Hua et al., 2011). Through a redistribution in VMAT2 containing
vesicles, METH treatment rapidly (within 1 hr) decreases [3H]DA uptake in striatal
vesicles (Brown et al., 2000; Riddle et al., 2002). The effect of GZ-793 on
VMAT2 immunoreactivity and vesicular trafficking is not known. GZ-793A could
redistribute VMAT2-containing vesicles out of the presynaptic terminal thereby
limiting the ability of METH to interact with VMAT2 to increase cytosolic DA
available for reverse transport through DAT. Future studies determining the
effect of GZ-793A and METH on the localization of VMAT2-containing vesicles
within the presynaptic terminal are needed. Studies utilizing western blot
analysis of VMAT2 immunoreactivity following GZ-793A and METH
administration would be beneficial in determining the mechanism underlying GZ793A-induced inhibition of METH-evoked DA release from striatal slices.
V.

Mechanisms underlying the increase in food-maintained responding
following repeated GZ-793A treatment.
While acute and repeated GZ-793A treatment did not decrease food-

maintained responding, repeated GZ-793A treatment significantly increased
food-maintained responding (Beckmann et al., 2011). One mechanism
underlying the orexigenic effects of GZ-793A could be that GZ-793A increases
metabolism to stimulate food intake. GZ-793A could interact with ghrelin
signaling to increase food intake. Ghrelin, a gut peptide hormone, stimulates
energy metabolism and increase food intake (Patterson et al., 2011). Further,
GZ-793A could be interacting with melanocortin (MC3/4) receptors to stimulate
food intake. Previous research has shown that antagonism of the MC3/4
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receptor increased food intake in rats (Hagan et al., 2000). Another potential
explanation for the orexigenic effect of GZ-793A is that GZ-793A could be
increasing food intake through a serotinergic mechanism. The role of the
serotonin system in food intake and appetite has long been established (for
review, Halford et al., 2011). While, GZ-793A inhibits SERT function with
moderate potency (Ki = 9.36 µM; Chapter 3, Horton et al., 2011b), the ability of
GZ-793A to interact with 5-HT receptors is not known. Further studies
determining the ability of GZ-793A to interact with 5-HT receptors would be
beneficial in elucidating the potential mechanisms underlying the orexigenic
effects of GZ-793A.
VI.

Mechanisms underlying the finding that GZ-793A-induced inhibition

of METH-evoked DA release from synaptic vesicles was surmountable
while GZ-793A-induced inhibition of METH self-administration was not
surmounted by increasing doses of METH.
Interestingly, GZ-793A-induced inhibition of METH-evoked DA release
from synaptic vesicles was consistent with an allosteric, surmountable
mechanism of inhibition (Chapter 4, Horton et al., 2011c), while systemic GZ793A pretreatment decreased METH self-administration which was not
surmounted by increasing the METH dose (Beckmann et al., 2011). One
explanation for this is that other mechanisms could be involved in the ability of
GZ-793A to inhibit the effects of METH. The in vitro experiments in this study are
performed in vesicle preparations while the in vivo experiments where conducted
in the whole animal model. In the whole animal model GZ-793A could interact
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with multiple targets to inhibit the effects of METH. While GZ-793A inhibits the
action of METH at VMAT2 in a surmountable manner, GZ-793A could inhibit the
effects of METH through different mechanisms which are not surmounted by
increasing doses of METH in the whole animal. In addition to the abililty of GZ793A to inhibit the effects of METH on VMAT2, other mechanisms by which GZ793A inhibit the effects of METH may be involved.
VII.

Mechanisms Underlying the Finding that GZ-793A Treatment Does

Not Alter Striatal DA Content.
Acute and repeated treatment of a behaviorally active dose of GZ-793A
(15 mg/kg; s.c.) did not alter DA content in striatal tissue and vesicles. Even
though GZ-793A inhibits [3H]DA uptake at VMAT2 with high affinity and promotes
[3H]DA release from striatal vesicles, systemic GZ-793A treatment had no effect
on DA content. One possible explanation for this finding is that GZ-793A could
act as a reversible inhibitor of VMAT2. Unlike GZ-793A, reserpine acts as an
irreversible inhibitor of DA uptake at VMAT2, which cannot be surmounted by
increasing substrate concentrations (Yelin and Schuldiner, 2000). As a result, in
vivo treatment of reserpine corresponds to a long-lasting decrease in DA content
(Yelin and Schuldiner, 2000). Conversely, GZ-793A-induced inhibition of DA
uptake at VMAT2 was surmounted by increasing concentrations of DA. Thus,
unlike reserpine, GZ-793A-induced inhibition of VMAT2 function is short-lasting.
Consistent with this hypothesis, GZ-793A treatment did not alter DA content in
striatal tissue or vesicles 0.3, 1, 8 and 24 hrs following treatment. These results
were similar to results found in DA content studies conducted with lobeline that
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demonstrate that acute or repeated lobeline treatment (1-30 mg/kg, s.c.) did not
alter striatal DA content (Miller et al., 2001).
An alternative explanation for the lack of DA content depletion following
GZ-793A treatment could be the effect of GZ-793A on DA synthesis. GZ-793A
could increase DA synthesis in presynaptic terminals to compensate for a
presumed decrease in synaptic DA content resulting from DA release from
vesicles and inhibition of DA uptake at VMAT2. While an increase in DA content
was not seen following GZ-793A treatment, studies examining the effect of GZ793A on TH activity would be beneficial to determine if GZ-793A is increasing DA
synthesis.
VIII.

Mechanisms Underlying Attenuation of METH-induced Depletion of

Striatal DA Content by GZ-793A Pretreatment.
Acute and repeated GZ-793A pretreatment (15 mg/kg, s.c.) attenuated
METH-induced depletion of striatal DA content. One explanation is that GZ-793A
interacts with VMAT2 to inhibit METH-evoked DA release. GZ-793A interacts
with VMAT2 to inhibit METH-evoked DA release from striatal vesicles decreasing
cytosolic DA concentrations available for METH-induced reverse-transport
through DAT. Thus, GZ-793A inhibits METH-evoked DA release through an
interaction with VMAT2, attenuating METH-induced depletions of DA content.
Another explanation for GZ-793A-induced attenuation of METH-induced
DA depletion could be a redistribution of VMAT2-containing vesicles within the
presynaptic terminal. Recent studies have shown that methylphenidate protects
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DA neurons from METH-induced toxicity (Volz et al., 2008). Methylphenidate
acts primarily to increase extracellular DA concentrations though an inhibition of
DAT (Schweri et al., 1985). In addition, methylphenidate increases VMAT2
immunoreactivity in cytoplasmic fractions in rat synaptosomes (Sandoval et al.,
2002). Through an increase in vesicular trafficking to the cytoplasmic fraction,
methylphenidate increases vesicular DA content to compensate for the DA
depleted by METH. Additionally, methylphenidate augments DA sequestration
through an increase in VMAT2 function in the membrane-associated vesicles to
protect against METH-induced decreases in DA content (Volz et al., 2007, 2008).
In a similar manner, GZ-793A treatment could increase VMAT2 function and
VMAT2 immunoreactivity to attenuate METH-induced DA content depletion.
Additional studies determining the effect of systemic GZ-793A treatment on
changes in VMAT2 function and localization of VMAT2-containing vesicles are
needed.
An alternative explanation is that GZ-793A could be inhibiting DAT to
protect against METH-induced DA content depletion. Through an inhibition of
DAT function, GZ-793A could inhibit the transport of METH into presynaptic
terminals and METH-induced reverse transport of DA through DAT. Precedence
for this mechanism of action is given by Marek and colleagues in demonstrating
that DAT inhibitors, amfonelic acid, mazindol and buproprion protected against
striatal DA content depletions by high doses of METH (100 mg/kg, s.c.; Marek et
al., 1990). Moreover, pretreatment with GBR-12909, a high affinity DAT inhibitor,
protected against striatal DA content depletions following a neurotoxic regimen of
228

METH (Stephans and Yamamoto, 1994). In a similar manner, GZ-793A could
inhibit METH uptake and METH-evoked DA release through DAT to protect
against METH-induced depletions in DA content. Unlike DAT inhibitors,
however, GZ-793A does not support self-administration in rats (Beckmann et al.,
2011), suggesting that DAT is not the pharmacological target involved in the
mechanism of action of GZ-793A.
Another possible explanation for GZ-793A-induced attenuation of METHinduced striatal DA content depletion is that GZ-793A could protect against
METH-induced hyperthermia. METH administration induces hyperthermia,
leading to striatal DA content depletion (Bowyer et al., 1994). GZ-793A could
inhibit the effect of METH to increase body temperature thereby attenuating the
effect of METH to deplete DA content through this mechanism. This explanation
is unlikely however, as the ability of the parent analog, lobeline to attenuate
METH-induced DA content depletion is not due to an effect on METH-induced
hyperthermia (Eyerman and Yamamoto, 2005). Nonetheless, the effect of GZ793A on METH-induced increases in body temperature is unknown and future
studies determining the effect of GZ-793A on METH-induced changes in body
temperature would be beneficial in determining the underlying mechanism of GZ793A-induced attenuation of METH-induced DA content depletion.
IX. Implications
The results from this dissertation research imply that VMAT2 represents a
pharmacological target to prevent the effects of METH in the development of
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treatments for METH abuse. GZ-793A selectively inhibits DA uptake at VMAT2
and promotes a DA release from synaptic vesicles, resulting in a redistribution of
DA from vesicles to the cytosol. In addition, GZ-793A decreases METH-evoked
DA release from synaptic vesicles through an interaction with VMAT2, thereby
reducing cytosolic DA concentrations available for METH-induced reverse
transport through DAT. GZ-793A selectively inhibits METH-evoked DA release
from striatal slices and GZ-793A pretreatment decreases METH selfadministration without altering food-maintained responding in rats (Beckmann et
al., 2011). GZ-793A-induced inhibition of METH self-administration is not
surmounted by increasing the dose of METH and tolerance does not develop
following repeated GZ-793A dosings (Beckmann et al., 2011). Moreover, GZ793A pretreatment prevents the development of METH-induced conditioned
place preference and inhibits METH cue-induced reinstatement (Beckmann et
al., 2011; unpublished observations). Thus, GZ-793A would be expected to
inhibit METH-induced cravings in METH-addicted individuals. In addition to
inhibiting the behavioral effects of METH, GZ-793A does not support selfadministration in rats, suggesting limited abuse potential. Thus, selective
inhibition of VMAT2 by GZ-793A represents a valid target for the development of
pharmacotherapies for METH abuse.
GZ-793A exhibits a different pharmacological profile for interaction of
VMAT2 compared to classic VMAT2 inhibitors, TBZ and reserpine. First, while
GZ-793A, TBZ and reserpine exhibited similar affinity for the DA uptake site on
VMAT2, inhibition by GZ-793A and TBZ is surmountable (Chapter 3, Horton et
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al., 2011b; Nickell et al., 2011), while reserpine-induced inhibition of DA uptake is
not (Rudnick et al., 1990). Second, these compounds interact with the DTBZ
binding site on VMAT2 with different affinities (TBZ > reserpine > GZ-793A).
Third, concentration-response curves for GZ-793A-evoked DA release was
consistent with a two-site model of interaction, while the concentration-response
curves for TBZ and reserpine to release DA fit a one-site model of interaction.
To our knowledge, GZ-793A is the first compound shown to evoke vesicular DA
release through an interaction with a Hi and Low affinity site. Concentrations of
GZ-793A that selectively interacted with the Hi affinity DA release site on VMAT2
inhibited METH-evoked DA release through a surmountable allosteric
mechanism. While GZ-793A and TBZ inhibited METH-evoked DA release
across similar concentration ranges, TBZ-induced inhibition of METH-evoked DA
release is consistent with a competitive mechanism of action, unlike GZ-793A.
Thus, GZ-793A exhibits a different pharmacological profile to interact with
VMAT2 compared to TBZ and reserpine.
Additional results from this research imply that selective inhibition of
VMAT2 function by GZ-793A did not deplete striatal DA content. Acute and
repeated GZ-793A treatment, of a dose that inhibited the behavioral effects of
METH (15 mg/kg), did not alter DA content in striatal tissue or vesicles. These
results suggest that GZ-793A acts differently than reserpine to inhibit VMAT2
function, presumably in a short-acting, reversible manner. Further, results
showed that inhibition of VMAT2 function by GZ-793A did not exacerbate acute
METH-induced depletions of DA content. In fact, acute and repeated GZ-793A
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pretreatment attenuated acute METH-induced DA content depletions. With
respect to multiple high doses of METH, GZ-793A pretreatment did not protect
against nor exacerbate METH-induced striatal DA content depletions. Thus, GZ793A treatment alone did not alter striatal DA content and GZ-793A pretreatment
might offer neuroprotective benefits against the neurotoxic effects of METH.
X.

Limitations
One limitation of the current research was the limited water solubility

exhibited by UKMH-106, GZ-794A, and GZ-796A. In determining the ability of
the forementioned analogs to inhibit METH-evoked DA release from striatal
slices, higher concentrations of analogs were needed to establish a full
concentration-response curve. As such, the Imax of these analogs to inhibit
METH-evoked DA release has been estimated with the highest soluble analog
concentration. The use of other vehicles (such as PEG or DMSO), which would
allow higher concentrations of analogs to be reached which would be beneficial
in determining the ability of these analogs to inhibit METH-evoked DA release.
Another limitation of the current research was that METH exhibited low
potency (EC50 = 18.9 µM) to evoke [3H]DA release from striatal vesicles. Due to
the low potency of METH to release vesicular DA, maximal DA release occurs
close to the highest METH concentrations tested (10 mM). Since higher METH
concentrations cannot be tested, the experiment is limited in the ability to fully
characterize the plateau of maximal DA release. Therefore our estimation of the
Emax is limited in that it is based upon only 1 or 2 data points. Since GZ-793A232

induced inhibition of METH-evoked DA release from vesicles is characterized by
a rightward shift in potency, the Emax of METH-evoked DA release in the
presence of GZ-793A is even more difficult to ascertain than METH alone. Since
the Emax is difficult to determine in the presence of GZ-793A, it is therefore
difficult to determine if the inhibitory effect of GZ-793A is surmounted by
increasing concentrations of METH. Thus, the low potency of METH to release
DA from striatal vesicles limits the ability to classify inhibition as surmountable or
unsurmountable in determining the mechanisms of action of inhibitors.
The current research utilized in vitro models to determine the effect of
lobeline analogs on VMAT2 selectivity and METH-evoked DA release from
striatal vesicles and slices. As such, assumptions are made that the analogs
tested are reaching the pharmacological targets following systemic treatment,
e.g., in striatal synaptosome preparations analogs will have greater access to
plasma membrane transporters compared to striatal slice preparations.
Mechanistic studies such as the vesicular DA release assay are performed in
vitro which allows us to use extreme concentrations that are not going to be
realized in vivo. Further, when considering affinity of analogs for transporters, it is
important to note that these values were obtained via in vitro and ex vivo models
characterized by tissue functioning in buffer and not in fully intact, physiological
systems and conditions.
XI. Future Directions
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One of the main findings of this dissertation is that GZ-793A evokes
[3H]DA release at low concentrations through an interaction with the Hi affinity
site on VMAT2. Support for this tenet arises from the finding that inhibition of
VMAT2 function through known inhibitors TBZ and resepine inhibit GZ-793A
evoked [3H]DA release at the Hi affinity site. GZ-793A evoked DA release at the
Low affinity site on VMAT2 is unaffected by TBZ or reserpine, however.
Presumably, higher concentration of GZ-793A (> 1 µM) evoked [3H]DA release
through a non-specific mechanism such as the weak base effect. To test this
hypothesis, the vesicular pH could be measured to determine if GZ-793A
alkalinized the vesicular lumen leading to a disruption of pH gradients. Recently,
Sulzer and colleagues have developed pH-responsive fluorescent false
neurotransmitters (FFNs) to measure vesicular pH in intact presynaptic terminals
(Lee et al., 2010). These FFNs act as VMAT2 substrates, being taken up into
synaptic vesicles. FFNs contain a built-in ratiometric fluorescent pH sensor
which allows the optical in situ measurement of intravesicular pH. By utilizing
FFNs, the ability of high concentrations of GZ-793A to alter vesicular pH and
non-specifically release vesicular DA from synaptic vesicles could be determined.
In addition to using FFNs to determine the effect of GZ-793A on vesicular
pH, the effect of GZ-793A on METH-induced changes of vesicular pH could also
be determined. METH is known to evoke DA release from vesicles at least in
part through a weak base effect. As a lipophilic weak base, METH gets
protonated inside the vesicle, alkalinizing the interior pH and disrupting the pH
gradient which is responsible for DA transport through VMAT2 (Sulzer et al.,
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2005). By inhibiting the uptake of METH into synaptic vesicles, GZ-793A could
inhibit the ability of METH to alter vesicular pH and thereby release vesicular DA.
Utilizing FFNs, the ability of METH to alter vesicular pH could be measured in the
absence and presence of GZ-793A. While results from these experiments could
be confounded by the ability of high concentrations of METH to passively diffuse
across the vesicular membrane, these results could provide additional
information about METH-evoked DA release through non-specific mechanisms.
While results from the current research suggest that GZ-793A inhibits
METH-evoked DA release primarily through an interaction with VMAT2, the effect
of GZ-793A on DAT and VMAT2 trafficking is unknown. Considering that METH
interacts with DAT and VMAT2 to increase extracellular DA, modulating the
expression and localization of these proteins could be a viable mechanism for
inhibition of the effects of METH. For example, GZ-793A could downregulate
DAT surface expression through a trafficking-mediated mechanism, thereby
decreasing the availability of one of the pharmacological targets of METH.
Further, GZ-793A could increase VMAT2 function through an increase in
trafficking of VMAT2-containing vesicles in the cytosol to inhibit the effects of
METH and protect against METH-induced neurotoxicity, similar to the
neuroprotective mechanism of methylphenidate (Volz et al., 2008). Thus the
ability of GZ-793A to modulate DAT and VMAT2 function through trafficking
would be beneficial in elucidating the mechanism of GZ-793A-induced inhibition
of the effects of METH.

235

Considering the finding that METH administration increases body
temperature leading to striatal DA content depletion, one potential mechanism
underlying GZ-793A-induced attenuation of METH-induced striatal DA content
depletion is the effect of GZ-793A on body temperature. GZ-793A could be
inhibiting the effect of METH to deplete DA content by protecting against METHinduced increases in body temperature. As such, additional studies determining
the effect of GZ-793A pretreatment on METH-induced changes in body
temperature would be beneficial in further elucidating the underlying mechanism
of GZ-793A-induced attenuation of METH-induced striatal DA content depletion.
XII.

Final Comments
The results from this dissertation research report on the findings from an

iterative drug discovery approach with the aim of developing VMAT2 selective
lobeline analogs as treatments for METH abuse. The current results
demonstrate that the lead analog, GZ-793A inhibits the neurochemical effects of
METH through a selective interaction with VMAT2. This research shows that
GZ-793A potently and selectively inhibits DA uptake at VMAT2 and promotes a
release of DA from vesicles to redistribute DA from vesicles into the cytosol.
Further, GZ-793A inhibits METH-evoked DA release from synaptic vesicles
decreasing the cytosolic DA available for METH-induced reverse transport
through DAT. Despite potent and selective inhibition of VMAT2 function, acute
and repeated GZ-793A treatment does not alter striatal DA content. Importantly,
GZ-793A pretreatment protects against acute METH-induced DA content
depletions. Thus, results from this dissertation demonstrate that GZ-793A
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represents an exciting preclinical lead in the development of novel
pharmacotherapies to treat METH abuse.

Copyright © David B. Horton 2012
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LIST OF ABBREVIATIONS

U.S., United States; DA, dopamine; DAT, dopamine transporter; METH,
methamphetamine; AMPH, amphetamine; VMAT2, vesicular monoamine
transporter-2; nAChRs, nicotinic acetylcholine receptors; MTD, meso-transdiene;
CNS, central nervous system; NAc, nucleus accumbens; TH, tyrosine
hydroxylase; L-DOPA, L-dihydroxylphenylalanine; LDVC, large dense core
vesicles; SSV, small synaptic vesicles; TMD, transmembrane domain; cAMP,
cyclic adensosine monophosphate; COMT, catechol-O-methyl transferase; MAO,
monoamine oxidase; DOPAC, dihydroxyphenylacetic acid; MPP+, 1-methyl-4phenylpyridinium; NET, norepinephrine transporter; VTA, ventral tegmental area;
SERT, serotonin transporter; KO, knock-out; WT, wild-type; PKC, protein kinase
C; PKA, protein kinase A; 5-HT, serotonin; NE, norepinephrine; E, epinephrine;
TBZ, tetrabenazine; AMPT, α-methyl-p-tyrosine; BBB, blood-brain barrier; CBT,
cognitive behavioral therapy; CM, contingency management; MPD,
methylphenidate; ADHD, attention deficit hyperactivity disorder; SSRIs, selective
serotonin reuptake inhibitors; GABA, gamma-aminobutyric acid; ACh,
acetylcholine; MLA, methyllycaconitine; DTBZ, dihydrotetrabenazine; diol,
dihydroxypropyl; SAR, structure-activity relationships; EDTA, disodium
ethylenediamine tetraacetate; EGTA, ethylene glycol tetraacetate; GBR 12909,
1-(2-(bis-(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine; GBR
12935, 1-(2-(diphenylmethoxy)ethyl)-4-(3-phenylpropyl)piperazine;WIN 35,428,
[3H](–)-2-β-carbomethoxy-3-β-(4-fluorophenyl)tropane-1,5-napthalenedisulfonate;
HEPES, N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid]; MgSO4,
magnesium sulfate; PEI, polyethyleneimine; Ro-4-1284, (2R,3S,11bS)-2-ethyl-3isobutyl-9,10-dimethoxy-2,2,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2ol; 6-OHDA, 6-hydroxydopamine; CaCl2, calcium chloride; MgCl2, magnesium
chloride; KCl, potassium chloride; K2PO4, potassium phosphate; NaHCO3,
sodium bicarbonate; NaH2PO4, sodium phosphate; UKMH-101, (3Z,5E)-3,5dibenzylidene-1-methylpiperidine; UKMH-102, (3Z,5Z)-3,5-dibenzylidene-1methylpiperidine; UKMH-103, [(3Z,5E)-1-methyl-3,5-bis((E)-3phenylallylidene)piperidine; UKMH-104, (3Z,5Z)-1-methyl-3,5-bis((E)-3phenylallylidene)piperidine; UKMH-105, (3Z,5E)-3,5-bis(2,4dichlorobenzylidene)-1-methylpiperidine; UKMH-106, (3Z,5Z)-3,5-bis(2,4dichlorobenzylidene)-1-methylpiperidine; UKMH-107, (3Z,5Z)-3,5-bis(4methoxybenzylidene)-1-methylpiperidine; UKMH-108, (3Z,5Z)-1-methyl-3,5bis(4-methylbenzylidene)-piperidine; UKMH-109, (3Z,5Z)-1-methyl-3,5bis(thiophen-2-ylmethylene)piperidine; UKMH-110, (3Z,5Z)-1-methyl-3,5bis(thiophen-3-ylmethylene)piperidine; UKMH-111, (3Z,5Z)-3,5-bis(furan-2ylmethylene)-1-methylpiperidine; UKMH-112, (3Z,5Z)-3,5-bis(furan-3ylmethylene)-1-methylpiperidine GZ-252C, para-methoxyphenyl lobelane; GZ745A, (R)-3-(2,6-cis-diphenethylpiperidin-1-yl)propane-1,2-diol; GZ-745B, (S)-3(2,6-cis-diphenethylpiperidin-1-yl)propane-1,2-diol; GZ-790A, (R)-3-[2,6-cis-di(3methoxyphenethyl)piperidin-1-yl]propane-1,2-diol; GZ-790B, (S)-3-[2,6-cis-di(3methoxyphenethyl)piperidin-1-yl]propane-1,2-diol; GZ-791A, (R)-3-[2,6-cis-di(3238

fluorophenethyl)piperidin-1-yl]propane-1,2-diol; GZ-791B, (S)-3-[2,6-cis-di(3fluorophenethyl)piperidin-1-yl]propane-1,2-diol; GZ- 792A, (R)-3-[2,6-cis-di(2methoxyphenethyl)piperidin-1-yl]propane-1,2-diol; GZ-792B, (S)-3-[2,6-cis-di(2methoxyphenethyl)piperidin-1-yl]propane-1,2-diol; GZ-793A, (R)-3-[2,6-cis-di(4methoxyphenethyl)piperidin-1-yl]propane-1,2-diol; GZ-793B, (S)-3-[2,6-cis-di(4methoxyphenethyl)piperidin-1-yl]propane-1,2- diol; GZ-794A, (R)-3-[2,6-cis-di(1naphthylethyl)piperidin-1-yl]propane-1,2-diol; GZ-794B, (S)-3-[2,6-cis-di(1naphthylethyl)piperidin-1-yl]propane-1,2-diol; GZ- 795A, (R)-3-[2,6-cis-di(2,4dichlorophenethyl)piperidin-1-yl]propane-1,2-diol; GZ-795B, (S)-3-[2,6-cis-di(2,4dichlorophenethyl)piperidin-1-yl]propane-1,2-diol; GZ-796A, (R)-3-[2,6-cis-di(4biphenylethyl)piperidin-1-yl]propane-1,2-diol; GZ-796B, (S)-3-[2,6-cis-di(4biphenylethyl)piperidin-1-yl]propane-1,2-diol; GZ-797A, (R)-3-[2,6-cis-di(3,4methylenedioxyphenethyl)piperidin-1-yl]propane-1,2-diol; GZ-797B, (S)-3-[2,6cis-di(3,4-methylenedioxyphenethyl)piperidin-1-yl]propane-1,2-diol; UKCP-110,
cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride; GZ-250C, 2,6-bis(2-(3,4methylenedioxyphenyl)ethyl)-1-methylpiperidine hydrochloride; GZ-252C, paramethoxyphenyl lobelane or 2,6-bis(2-(4-methoxyphenyl)ethyl)-1-methylpiperidine
hydrochloride; GZ-260C, 2,6-bis(2-(2,4-dichlorophenyl)ethyl)-1-methylpiperidine
hydrochloride; GZ-261C, 2,6-bis(2-(3-methoxyphenyl)ethyl)-1-methylpiperidine
hydrochloride; GZ-272C, 2,6-bis(2-(biphenyl-4-yl)ethyl)-1-methylpiperidine
hydrochloride; GZ-273C, 2,6-bis(2-(2-methoxyphenyl)ethyl)-1-methylpiperidine
hydrochloride; GZ-275C, 2,6-bis(2-(3-fluorophenyl)ethyl)-1-methylpiperidine
hydrochloride
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